

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

## ANNEX U.K.

### INTRODUCTION Information to be submitted, its generation and its presentation

1. The information submitted shall meet the following requirements.
  - 1.1. The information shall be sufficient to evaluate the foreseeable risks, whether immediate or delayed, which the active substance may entail for humans, including vulnerable groups, animals and the environment and contain at least the information and results of the studies referred to in this Annex.
  - 1.2. Any information on potentially harmful effects of the active substance, its metabolites and impurities on human and animal health or on groundwater shall be included.
  - 1.3. Any information on potentially unacceptable effects of the active substance, its metabolites and impurities on the environment, on plants and plant products shall be included.
  - 1.4. The information shall include all relevant data from the scientific peer reviewed open literature on the active substance, metabolites and breakdown or reaction products and plant protection products containing the active substance and dealing with side-effects on health, the environment and non-target species. A summary of this data shall be provided.
  - 1.5. The information shall include a full and unbiased report of the studies conducted as well as a full description of them. Such information shall not be required, where one of the following conditions is fulfilled: U.K.
    - (a) it is not necessary owing to the nature of the product or its proposed uses, or it is not scientifically necessary;
    - (b) it is technically not possible to supply.

In such a case a justification shall be provided.

- 1.6. The simultaneous use of the active substance as a biocide or in veterinary medicine shall be reported. U.K.

If the applicant for the active substance in the plant protection product is identical to the one responsible for the notification of the active substance as a biocide or as a veterinary medicine, a summary of all relevant data submitted for approval of the biocide or the veterinary medicine, shall be submitted. This summary shall include toxicological reference values and MRL proposals, taking into account any possible cumulative exposure due to different uses of the same substance based on scientific methods accepted by the European competent authorities, together with a summary of the residues and toxicology data and information on the use of the product.

If the applicant for the active substance in the plant protection product is not identical to the one responsible for the notification of the active substance as a biocide or in veterinary medicine, a summary of all available data shall be submitted.

- 1.7. Where relevant, the information shall be generated using test methods, which are included in the list referred to in point 6. In the absence of suitable internationally or nationally validated test guidelines, test guidelines accepted by the European competent authority shall be used. Any deviations shall be described and justified.
- 1.8. The information shall include a full description of the test methods used.

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

- 1.9. The information shall include a list of endpoints for the active substance.
- 1.10. Where relevant, the information shall be generated in accordance with Directive 2010/63/EU of the European Parliament and of the Council<sup>(1)</sup>.
- 1.11. The information on the active substance, taken together with the information concerning one or more plant protection products containing the active substance and together, if appropriate, with the information concerning safeners and synergists and other components of the plant protection product, shall be sufficient to: **U.K.**
- (a) permit an assessment of the risks for humans, associated with handling and use of plant protection products containing the active substance;
  - (b) permit an assessment of the risks for human and animal health, arising from residues of the active substance and its metabolites, impurities, breakdown and reaction products remaining in water, air, food and feed;
  - (c) predict the distribution, fate and behaviour in the environment of the active substance and metabolites, breakdown and reaction products, where they are of toxicological or environmental significance, as well as the time courses involved;
  - (d) permit an assessment of the impact on non-target species (flora and fauna), including the impact on their behaviour, which are likely to be exposed to the active substance, its metabolites, breakdown and reaction products, where they are of toxicological or environmental significance. Impact can result from single, prolonged or repeated exposure and can be direct or indirect, reversible or irreversible;
  - (e) evaluate the impact on biodiversity and the ecosystem;
  - (f) identify non-target species and populations for which hazards arise because of potential exposure;
  - (g) permit an evaluation of short and long-term risks for non-target species, populations, communities and processes;
  - (h) classify the active substance as to hazard in accordance with Regulation (EC) No 1272/2008 of the European Parliament and of the Council<sup>(2)</sup>;
  - (i) specify the pictograms, the signal words, and relevant hazard and precautionary statements for the protection of man, non-target species and the environment, which are to be used for labelling purposes;
  - (j) establish, where relevant, an acceptable daily intake (ADI) level for humans;
  - (k) establish acceptable operator exposure levels (AOEL);
  - (l) establish, where relevant, an acute reference dose, (ARfD) for humans;
  - (m) identify relevant first aid measures as well as appropriate diagnostic and therapeutic measures to be followed in the event of poisoning in humans;
  - (n) establish the isomeric composition and the possible metabolic conversion of the isomers, when relevant;
  - (o) establish residues definitions appropriate for risk assessment;
  - (p) establish residues definitions appropriate for monitoring and enforcement purposes;

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

- (q) permit a risk assessment of consumer exposure, including, where relevant, a cumulative risk assessment deriving from exposure to more than one active substance;
  - (r) permit an estimation of the exposure to operators, workers, residents and bystanders including, where relevant, the cumulative exposure to more than one active substance;
  - (s) establish maximum residue levels and concentration/dilution factors in accordance with Regulation (EC) No 396/2005 of the European Parliament and of the Council<sup>(3)</sup>;
  - (t) permit an evaluation to be made as to the nature and extent of the risks for man, animals (species normally fed and kept by humans or food producing animals) and of the risks for other non-target vertebrate species;
  - (u) identify measures necessary to minimise contamination of the environment and impact on non-target species;
  - (v) decide whether or not the active substance has to be considered as persistent organic pollutant (POP), persistent, bio accumulative and toxic (PBT) or very persistent and very bio accumulative (vPvB) in accordance with the criteria laid down in Annex II to Regulation (EC) No 1107/2009;
  - (w) decide whether or not the active substance has to be considered as a candidate for substitution in accordance with the criteria laid down in Annex II to Regulation (EC) No 1107/2009;
  - (x) decide whether or not the active substance has to be considered as a low-risk active substance in accordance with the criteria laid down in Annex II to Regulation (EC) No 1107/2009;
  - (y) decide whether, or not, the active substance is to be approved;
  - (z) specify conditions or restrictions to be associated with any approval.
- 1.12. Where relevant, tests shall be designed and data analysed using appropriate statistical methods.
- 1.13. Exposure calculations shall refer to scientific methods accepted by the European Food Safety Authority, (the Authority), when available. Additional methods, when used, shall be justified.
- 1.14. For each section of the data requirements, a summary of all data, information and evaluation made shall be submitted. This shall include a detailed and critical assessment according to the provisions of Article 4 of Regulation (EC) No 1107/2009.
2. The requirements set out in this Regulation shall represent the minimum data to be submitted. Additional requirements at national level may be necessary in specific circumstances, that is to say specific scenarios, patterns of use other than those taken into account for approval. Careful attention shall be given to environmental, climatic and agronomic conditions when tests are set up and approved by the competent authorities.
3. **Good laboratory practice (GLP) U.K.**
- 3.1. Tests and analyses shall be conducted in accordance with the principles laid down in Directive 2004/10/EC of the European Parliament and of the Council<sup>(4)</sup> where testing is done to obtain data on the properties or safety with respect to human or animal health or the environment.

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) [View outstanding changes](#)

---

- 3.2. By way of derogation from point 3.1: **U.K.**
- 3.2.1. For active substances consisting of micro-organisms or viruses, tests and analyses done to obtain data on the properties and safety with respect to other aspects than human health, may be conducted by official or officially recognised testing facilities or organisations which satisfy at least the requirements under points 3.2 and 3.3 of the introduction of the Annex to Commission Regulation (EU) No 284/2013<sup>(5)</sup>.
- 3.2.2. For tests and analyses made to obtain data for minor crops required under points 6.3 and 6.5.2 of Part A:
- the field phase may have been conducted by official or officially recognised testing facilities or organisations which satisfy at least the requirements as laid down in points 3.2 and 3.3 of the introduction of the Annex to Regulation (EU) No 284/2013;
  - the analytical phase, if not done in accordance with the GLP requirements, shall be conducted by laboratories accredited for the relevant method in accordance with the European standard EN ISO/IEC 17025 ‘General requirements for the competence of testing and calibration laboratories’.
- 3.2.3. Studies conducted before the application of this Regulation, although not fully compliant with GLP requirements or with current test methods, may be integrated into the assessment, when accepted by the competent authorities as scientifically valid, thereby removing the need for repeating animal tests, especially for carcinogenicity and reprotoxicity studies. This derogation applies to studies on all vertebrate species.
4. **Test material** **U.K.**
- 4.1. A detailed description (specification) of the material used shall be provided. Where tests are done using the active substance, the material used shall comply with the specification that will be used in the manufacture of plant protection products to be authorised, except where radio-labelled material or the purified active substance is used.
- 4.2. Where studies are conducted using an active substance produced in the laboratory or in a pilot plant production system, the studies shall be repeated using the active substance as manufactured, unless the applicant shows that the test material used is essentially the same, for the purposes of toxicological, ecotoxicological, environmental and residue testing and assessment. In cases of uncertainty, bridging studies shall be submitted to serve as a basis for a decision as to the possible need for repetition of the studies.
- 4.3. Where studies are conducted using an active substance of different purity or which contains different impurities or different levels of impurities to the technical specification or where the active substance is a mixture of components, the significance of the differences shall be addressed either by data or scientific case. In cases of uncertainty, appropriate studies using the active substance as manufactured for commercial production shall be submitted to serve as a basis for a decision.
- 4.4. In the case of studies in which dosing extends over a period (for example repeated dose studies), dosing shall be done using a single batch of active substance if stability permits. Whenever a study implies the use of different doses, the relationship between dose and adverse effect shall be reported.
- 4.5. When tests shall be conducted using purified active substance ( $\geq 980$  g/kg) of stated specification, the purity of such test material shall be as high as can be achieved using the best available technology and shall be reported. A justification shall be provided in

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

cases where the degree of purity achieved is less than 980 g/kg. Such justification shall demonstrate that all technically feasible and reasonable possibilities for the production of the purified active substance have been exhausted.

- 4.6. Where radio-labelled test material is used, radio-labels shall be positioned at sites (one or more as necessary), to facilitate elucidation of metabolic and transformation pathways and to facilitate investigation of the distribution of the active substance and of its metabolites, reaction and breakdown products.
5. **Tests on vertebrate animals** U.K.
  - 5.1. Tests on vertebrate animals shall be undertaken only where no other validated methods are available. Alternative methods to be considered shall include *in vitro* methods and *in silico* methods. Reduction and refinement methods for *in vivo* testing shall also be encouraged to keep the number of animals used in testing to a minimum.
  - 5.2. The principles of replacement, reduction and refinement of the use of animals shall be taken into account in the design of the test methods, in particular when appropriate validated methods become available to replace, reduce or refine animal testing.
  - 5.3. Tests involving the deliberate administration of the active substance or the plant protection product to humans and non-human primates shall not be performed for the purpose of this Regulation.
  - 5.4. For ethical reasons, study designs shall be carefully considered, taking into account the scope for reduction, refinement and replacement of animal tests. For example, by including one or more additional dose groups or time points for blood sampling in one study, it may be possible to avoid the need for another study.
6. For purposes of information and of harmonisation the list of test methods and guidance documents relevant to the implementation of this Regulation shall be published in the *Official Journal of the European Union*. This list shall be regularly updated.

## PART A U.K.

### CHEMICAL ACTIVE SUBSTANCES

#### SECTION 1 U.K.

##### *Identity of the active substance*

The information provided shall be sufficient to precisely identify each active substance and define it in terms of its specification and nature.

##### 1.1. **Applicant** U.K.

The name and address of the applicant shall be provided, as well as the name, position, telephone, e-mail address and telefax number of a contact point.

##### 1.2. **Producer** U.K.

The name and address of the producer of the active substance shall be provided, as well as the name and address of each manufacturing plant in which the active substance is manufactured. A contact point (name, telephone, e-mail address and telefax number) shall be provided. Where following approval of the active substances, there are changes in the location or number of

---

*Changes to legislation: There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes*

---

producers, the information required shall again be notified to the Commission, the Authority and the Member States.

**1.3. Common name proposed or ISO-accepted, and synonyms** U.K.

The International Organization for Standardization (ISO) common name, or proposed ISO common name and where relevant, other proposed or accepted common names (synonyms), including the name (title) of the nomenclature authority concerned, shall be provided.

**1.4. Chemical name (IUPAC and CA nomenclature)** U.K.

The chemical name as given in Part III of Annex VI to Regulation (EC) No 1272/2008, or, if not included in that Regulation, in accordance with both the International Union of Pure and Applied Chemistry (IUPAC) and Chemical Abstracts (CA) nomenclature, shall be provided, where applicable.

**1.5. Producer's development code numbers** U.K.

Code numbers used to identify the active substance, and where available, formulations containing the active substance, during development work, shall be reported. For each code number reported, the material to which it relates, the period for which it was used, and the Member States or other countries in which it was used and is being used, shall be stated.

**1.6. CAS, EC and CIPAC numbers** U.K.

Chemical Abstracts Service (CAS), European Commission (EC) and Collaborative International Pesticides Analytical Council (CIPAC) numbers, where they exist, shall be reported.

**1.7. Molecular and structural formula, molar mass** U.K.

The molecular formula, molar mass and structural formula of the active substance, and where relevant, the structural formula of each isomer present in the active substance, shall be provided.

For plant extracts, a different approach may be taken if adequately justified.

**1.8. Method of manufacture (synthesis pathway) of the active substance** U.K.

The method of manufacture, in terms of the identity (name, CAS number, structural formula) and purity of the starting materials and whether they are commercially available, the chemical pathways involved, and the identity of impurities present in the final product, shall be provided, for each manufacturing plant. Detailed information shall be given as to the origin of those impurities. Each impurity shall be categorised as resulting from side reactions, impurities in the starting material, remaining reaction intermediates or starting materials. Their toxicological, ecotoxicological and environmental relevance shall be addressed. This information shall also include impurities that are not detected but that could theoretically be formed. Generally process engineering information is not required.

Where the required information is provided for a pilot plant production system, that information shall again be provided once industrial scale production methods and procedures have stabilised. Where available, industrial scale data shall be provided before approval under Regulation (EC) No 1107/2009. Where data on industrial scale production are not available, a justification shall be provided.

**1.9. Specification of purity of the active substance in g/kg** U.K.

The minimum content in g/kg of pure active substance in the manufactured material used for production of plant protection products, shall be reported. A justification shall be provided for

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

the minimum content proposed in the specification; this shall include a statistical analysis of the data on at least five representative batches, as referred to in point 1.11. Additional supporting data may be provided to further justify the technical specification.

Where the required information is provided for a pilot plant production system, that information shall again be provided once industrial scale production methods and procedures have stabilised. Where available, industrial scale data shall be provided before approval under Regulation (EC) No 1107/2009. Where data on industrial scale production are not available, a justification shall be provided.

If the active substance is manufactured as technical concentrate (TK), the minimum and maximum content of the pure active substance shall be given, along with its content in the theoretical dry weight material.

If the active substance is a mixture of isomers, the ratio or the ratio range of the content of isomers shall be provided. The relative biological activity of each isomer, both in terms of efficacy and toxicity, shall be reported.

For plant extracts, a different approach may be taken if adequately justified.

#### 1.10. **Identity and content of additives (such as stabilisers) and impurities** U.K.

The minimum and maximum content in g/kg of each additive shall be provided.

The maximum content in g/kg of each further component other than additives shall also be provided.

If the active substance is manufactured as technical concentrate (TK), the maximum content of each impurity shall be given, along with their content in the theoretical dry weight material.

Isomers that are not part of the ISO common name are considered as impurities.

Where the information provided does not fully identify a component (for example condensates), detailed information on the composition shall be provided for each such component.

Where the required information is provided for a pilot plant production system, that information shall again be provided once industrial scale production methods and procedures have stabilised. Where available, industrial scale data shall be provided before approval under Regulation (EC) No 1107/2009. Where data on industrial scale production are not available, a justification shall be provided.

For plant extracts, a different approach may be taken if adequately justified.

##### 1.10.1. *Additives* U.K.

The trade name of components added to the active substance, prior to manufacture of the plant protection product, to preserve stability and facilitate ease of handling, hereinafter 'additives', shall also be provided. The following information shall, where relevant, be provided for such additives:

- (a) chemical name in accordance with IUPAC and CA nomenclature;
- (b) ISO common name or proposed common name if available;
- (c) CAS number, EC number;
- (d) molecular and structural formula;
- (e) molar mass;

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

(f) minimum and maximum content in g/kg; and

(g) function (for example stabiliser).

#### 1.10.2. Significant impurities **U.K.**

Impurities present in quantities of 1 g/kg or more shall be considered as significant. For significant impurities the following information, where relevant, shall be provided:

(a) chemical name in accordance with IUPAC and CA nomenclature;

(b) ISO common name or proposed common name, if available;

(c) CAS number, EC number;

(d) molecular and structural formula;

(e) molar mass; and

(f) maximum content in g/kg.

Information on how the structural identity of the impurities was determined shall be given.

#### 1.10.3. Relevant impurities **U.K.**

Impurities that are particularly undesirable because of their toxicological, ecotoxicological or environmental properties, shall be considered as relevant. For relevant impurities the following information, where relevant, shall be provided:

(a) chemical name in accordance with IUPAC and CA nomenclature;

(b) ISO common name or proposed common name if available;

(c) CAS number, EC number;

(d) molecular and structural formula;

(e) molar mass; and

(f) maximum content in g/kg.

Information on how the structural identity of the impurities was determined shall be reported.

#### 1.11. Analytical profile of batches **U.K.**

At least five representative batches from recent and current industrial scale production of the active substance shall be analysed for content of pure active substance, impurities, additives and each further component other than additives, as appropriate. All of the representative batches shall be within the last five years of manufacture. Where data from the last five years of production are not available, a justification shall be provided. The analytical results reported shall include quantitative data, in terms of g/kg content, for all components present in quantities of 1 g/kg or more and typically should account for at least 980 g/kg of the material analysed. For plant extracts and semiochemicals (such as pheromones), justified exemptions can be made. The statistical basis for the content proposed in the technical specification shall be explained (for example: maximum level found in practice, average plus three standard deviations of levels found in practice, etc.). Supporting data may be provided to further justify the technical specification. The actual content of components which are particularly undesirable because of their toxicological, ecotoxicological or environmental properties shall be determined and reported even if present in quantities below 1 g/kg. Data reported shall include the results of the



---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

analysis of individual samples and a summary of that data, to show the minimum, maximum and mean content of each relevant component.

Where an active substance is produced in different plants the information set out in the first paragraph shall be provided for each of the plants separately.

In addition, where relevant, samples of the active substance produced at laboratory scale or in pilot production systems, shall be analysed, if such material was used in generating toxicological or ecotoxicological data. If this data is not available a justification shall be provided.

Where the information provided relates to a pilot plant production system, the information required shall again be provided once industrial scale production methods and procedures have stabilised. Where available, industrial scale data shall be provided before approval under Regulation (EC) No 1107/2009. Where data on industrial scale production are not available, a justification shall be provided.

## SECTION 2 U.K.

### *Physical and chemical properties of the active substance*

#### 2.1. Melting point and boiling point U.K.

The melting point or where appropriate the freezing or solidification point of purified active substance shall be determined and reported. Measurements shall be taken up to 360 °C.

The boiling point of purified active substance shall be determined and reported. Measurements shall be taken up to 360 °C.

Where melting point or boiling point cannot be determined because of decomposition or sublimation, the temperature at which decomposition or sublimation occurs shall be reported.

#### 2.2. Vapour pressure, volatility U.K.

The vapour pressure of purified active substance at 20 °C or 25 °C shall be reported. Where vapour pressure is less than  $10^{-5}$  Pa at 20 °C the vapour pressure at 20 °C or 25 °C shall be estimated by a vapour pressure curve with measurements at higher temperatures.

In the case of active substances which are solids or liquids, volatility (Henry's law constant) of purified active substance shall be determined or calculated from its water solubility and vapour pressure and be reported (in  $\text{Pa} \times \text{m}^3 \times \text{mol}^{-1}$ ).

#### 2.3. Appearance (physical state, colour) U.K.

A description of both the colour, if any, and the physical state of both the active substance as manufactured and purified active substance, shall be provided.

#### 2.4. Spectra (UV/VIS, IR, NMR, MS), molar extinction at relevant wavelengths, optical purity U.K.

The following spectra, including a table of signal characteristics needed for interpretation, shall be determined and reported: ultraviolet/visible (UV/VIS), infrared (IR), nuclear magnetic resonance (NMR) and mass spectra (MS) of purified active substance.

Molar extinction at relevant wavelengths shall be determined and reported ( $\epsilon$  in  $\text{L} \times \text{mol}^{-1} \times \text{cm}^{-1}$ ). Relevant wavelengths include all maxima in the UV/visible absorption spectrum, as well as the wavelength range of 290-700 nm.

---

*Changes to legislation:* There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

In the case of active substances which are resolved optical isomers, the optical purity shall be measured and reported.

Where necessary for the identification of the impurities considered to be of toxicological, ecotoxicological or environmental significance, the UV/visible absorption spectra, IR, NMR and MS spectra, shall be determined and reported.

#### 2.5. Solubility in water U.K.

The water solubility of purified active substances under atmospheric pressure shall be determined and a value reported for 20 °C. These water solubility determinations shall be made in the neutral range (that is to say in distilled water in equilibrium with atmospheric carbon dioxide). If the pKa is between 2 and 12, water solubility shall also be determined in the acidic range (pH 4 to 5) and in the alkaline range (pH 9 to 10). Where the stability of the active substance in aqueous media is such that water solubility cannot be determined, a justification based on test data shall be provided.

#### 2.6. Solubility in organic solvents U.K.

The solubility of the active substances as manufactured or purified active substance in the following organic solvents at 15 to 25 °C shall be determined and reported if less than 250 g/L; the temperature applied shall be specified. Results shall be reported as g/L.

- (a) Aliphatic hydrocarbon: preferably heptane
- (b) Aromatic hydrocarbon: preferably toluene
- (c) Halogenated hydrocarbon: preferably dichloromethane
- (d) Alcohol: preferably methanol or isopropyl alcohol
- (e) Ketone: preferably acetone
- (f) Ester: preferably ethyl acetate.

If for a particular active substance, one or more of those solvents is unsuitable (for example reacts with test material), alternative solvents may be used instead. In such cases, choices of solvents shall be justified in terms of their structure and polarity.

#### 2.7. Partition coefficient n-octanol/water U.K.

The n-octanol/water partition coefficient ( $K_{ow}$  or  $\log P_{ow}$ ) of purified active substance and of all components of the residue definition for risk assessment shall be determined and reported for 20 °C or 25 °C. The effect of pH (4 to 10) shall be investigated when the active substance has a pKa value between 2 and 12.

#### 2.8. Dissociation in water U.K.

Where dissociation in water occurs, the dissociation constants (pKa values) of the purified active substance shall be determined and reported for 20 °C. The identity of the dissociated species formed, based on theoretical considerations, shall be reported. If the active substance is a salt the pKa value of the non-dissociated form of the active substance shall be given.

#### 2.9. Flammability and self-heating U.K.

The flammability and self-heating of active substances as manufactured shall be determined and reported. A theoretical estimation based on structure shall be accepted if it meets the criteria set out in Appendix 6 of the United Nations' Recommendations on the Transport of Dangerous

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

Goods Manual of Tests and Criteria<sup>(6)</sup>. In justified cases, data for purified active substance may be used.

2.10. **Flash point** U.K.

The flash point of active substances as manufactured with a melting point below 40 °C shall be determined and reported. In justified cases, data for purified active substance may be used.

2.11. **Explosive properties** U.K.

The explosive properties of active substances as manufactured shall be determined and reported. A theoretical estimation based on structure shall be accepted if it meets the criteria set out in Appendix 6 of the United Nations 'Recommendations on the Transport of Dangerous Goods, Manual of Tests and Criteria'. In justified cases, data for purified active substance may be used.

2.12. **Surface tension** U.K.

The surface tension of purified active substance shall be determined and reported.

2.13. **Oxidising properties** U.K.

The oxidising properties of active substances as manufactured, shall be determined and reported. A theoretical estimation based on structure shall be accepted if it meets the criteria set out in Appendix 6 of the United Nations 'Recommendations on the Transport of Dangerous Goods Manual of Tests and Criteria'. In justified cases data for purified active substance may be used.

2.14. **Other studies** U.K.

Supplementary studies necessary for the classification of the active substance by hazard shall be carried out in accordance with Regulation (EC) No 1272/2008.

**SECTION 3** U.K.

***Further information on the active substance***

3.1. **Use of the active substance** U.K.

The information provided shall describe the intended purposes for which plant protection products containing the active substance are used, or are to be used and the dose and manner of their use or proposed use.

3.2. **Function** U.K.

The function shall be specified from among the following:

- (a) acaricide;
- (b) bactericide;
- (c) fungicide;
- (d) herbicide;
- (e) insecticide;
- (f) molluscicide;
- (g) nematocidal;

---

*Changes to legislation: There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes*

---

- (h) plant growth regulator;
- (i) repellent;
- (j) rodenticide;
- (k) semio-chemical;
- (l) talpicide;
- (m) viricide;
- (n) other (shall be specified by the applicant).

### 3.3. **Effects on harmful organisms** U.K.

The nature of the effects on harmful organisms shall be stated:

- (a) contact action;
- (b) stomach action;
- (c) inhalation action;
- (d) fungitoxic action;
- (e) fungistatic action;
- (f) desiccant;
- (g) reproduction inhibitor;
- (h) other (shall be specified by the applicant).

It shall be stated whether or not the active substance is translocated in plants and where relevant whether such translocation is apoplastic, symplastic or both.

### 3.4. **Field of use envisaged** U.K.

The fields of use, existing and proposed, for plant protection products containing the active substance shall be specified from among the following:

- (a) field use, such as agriculture, horticulture, forestry and viticulture;
- (b) protected crops;
- (c) amenity;
- (d) weed control on non-cultivated areas;
- (e) home gardening;
- (f) house plants;
- (g) plant products storage practice;
- (h) other (shall be specified by applicant).

### 3.5. **Harmful organisms controlled and crops or products protected or treated** U.K.

Details of existing use and the intended use in terms of crops, groups of crops, plants, or plant products treated and where relevant protected shall be provided.

---

*Changes to legislation: There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes*

---

Where relevant, details of harmful organisms against which protection is afforded shall be provided.

Where relevant, effects achieved, such as sprout suppression, retardation of ripening, reduction in stem length, enhanced fertilisation shall be reported.

### 3.6. **Mode of action** U.K.

To the extent that it has been elucidated, a statement shall be provided as to the mode of action of the active substance in terms, where relevant, of the biochemical and physiological mechanisms and biochemical pathways involved. Where available, the results of relevant experimental studies shall be reported.

Where it is known that to exert its intended effect, the active substance has to be converted to a metabolite or breakdown product following application or use of plant protection products containing it, the following information shall be provided for active metabolite or breakdown products:

- (a) chemical name in accordance with IUPAC and CA nomenclature;
- (b) ISO common name or proposed common name;
- (c) CAS-number EC number;
- (d) molecular and structural formula; and
- (e) molar mass.

The information referred to in points (a) to (e) shall be cross referenced to and drawing on information provided under Sections 5 to 8, where relevant.

Available information relating to the formation of active metabolites and breakdown products shall be provided. Such information shall include:

- the processes, mechanisms and reactions involved,
- kinetic and other data concerning the rate of conversion and if known the rate limiting step,
- environmental and other factors effecting the rate and extent of conversion.

### 3.7. **Information on the occurrence or possible occurrence of the development of resistance and appropriate management strategies** U.K.

Where available, information on the occurrence or possible occurrence of the development of resistance or cross-resistance shall be provided.

Appropriate risk management strategies shall be addressed for national/regional areas.

### 3.8. **Methods and precautions concerning handling, storage, transport or fire** U.K.

A safety data sheet pursuant to Article 31 of Regulation (EC) No 1907/2006 of the European Parliament and of the Council<sup>(7)</sup> shall be provided for all active substances.

The studies, data and information submitted, together with other relevant studies, data and information, shall both specify and justify the methods and precautions to be followed in the event of fire. The possible products of combustion in the event of fire shall be estimated, based on the chemical structure and the chemical and physical properties of the active substance.

### 3.9. **Procedures for destruction or decontamination** U.K.

---

*Changes to legislation:* There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

In many cases the preferred or sole means to safely dispose of active substances, contaminated materials, or contaminated packaging is through controlled incineration in a licensed incinerator. Such incineration shall be carried out in accordance with the criteria set out in Council Directive 94/67/EC<sup>(8)</sup>.

Other methods to dispose of the active substance, contaminated packaging and contaminated materials, where proposed, shall be fully described. Data shall be provided for such methods, to establish their effectiveness and safety.

### 3.10. **Emergency measures in case of an accident** U.K.

Procedures for the decontamination of water and soil in case of an accident shall be provided.

The studies, data and information submitted, together with other relevant studies, data and information, shall demonstrate the suitability of measures proposed for use in emergency situations.

## SECTION 4 U.K.

### *Analytical methods*

#### **Introduction**

The provisions of this Section cover analytical methods used for the generation of pre-approval data and required for post-approval control and monitoring purposes.

Descriptions of methods shall be provided and include details of equipment, materials and conditions used.

On request, the following shall be provided:

- (a) analytical standards of the purified active substance;
- (b) samples of the active substance as manufactured;
- (c) analytical standards of relevant metabolites and all other components included in all monitoring residue definitions;
- (d) samples of reference substances for the relevant impurities.

Where possible, the standards referred to in points (a) and (c) shall be made commercially available and, on request, the distributing company shall be named.

### 4.1. **Methods used for the generation of pre-approval data** U.K.

#### 4.1.1. *Methods for the analysis of the active substance as manufactured* U.K.

Methods shall be provided, with a full description, for the determination of:

- (a) pure active substance in the active substance as manufactured and specified in the dossier submitted in support of approval under Regulation (EC) No 1107/2009;
- (b) significant and relevant impurities and additives (such as stabilisers) in the active substance as manufactured.

The applicability of existing CIPAC methods shall be assessed and reported. In case of use of a CIPAC method, further validation data shall not be required, but example chromatograms shall be submitted, where available.

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

The specificity of the methods shall be determined and reported. In addition, the extent of interference by other substances present in the active substance as manufactured (such as impurities or additives), shall be determined.

The linearity of methods shall be determined and reported. The calibration range shall extend (by at least 20 %) beyond the highest and lowest nominal content of the analyte in relevant analytical solutions. Either duplicate determinations at three or more concentrations or single determinations at five or more concentrations shall be made. The equation of the calibration line and the correlation coefficient shall be reported and a typical calibration plot shall be submitted. In cases where a non-linear response is used, this shall be justified by the applicant.

The precision (repeatability) of the methods shall be determined and reported. A minimum of five replicate sample determinations shall be made and the mean, the relative standard deviation and the number of determinations shall be reported.

For the determination of the active substance content, an assessment of accuracy of the method shall be made by an assessment of the interference and precision.

As regards additives and significant and relevant impurities:

- the accuracy of the methods shall be determined on at least two representative samples at levels appropriate to the batch data and material specification. The mean and the relative standard deviation of the recoveries shall be reported,
- the experimental determination of the limit of quantification (LOQ) shall not be required. However, it shall be demonstrated that the methods are sufficiently precise to analyse significant impurities at levels appropriate to the material specification and relevant impurities at a concentration equivalent to at least 20 % less than the specification limit.

#### 4.1.2. *Methods for risk assessment* U.K.

Methods shall be submitted, with a full description, for the determination of non-isotope-labelled residues in all areas of the dossier, as set out in detail in the following points:

- (a) in soil, water, sediment, air and any additional matrices used in support of environmental fate studies;
- (b) in soil, water and any additional matrices used in support of efficacy studies;
- (c) in feed, body fluids and tissues, air and any additional matrices used in support of toxicology studies;
- (d) in body fluids, air and any additional matrices used in support of operator, worker, resident and bystander exposure studies;
- (e) in or on plants, plant products, processed food commodities, food of plant and animal origin, feed and any additional matrices used in support of residues studies;
- (f) in soil, water, sediment, feed and any additional matrices used in support of ecotoxicology studies;
- (g) in water, buffer solutions, organic solvents and any additional matrices used in the physical and chemical properties tests.

The specificity of the methods shall be determined and reported. Validated confirmatory methods shall be submitted if appropriate.

---

*Changes to legislation:* There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

The linearity, recovery and precision (repeatability) of methods shall be determined and reported.

Data shall be generated at the LOQ and either the likely residue levels or ten times the LOQ. Where relevant, the LOQ shall be determined and reported for each analyte.

#### 4.2. **Methods for post-approval control and monitoring purposes** U.K.

Methods, with a full description, shall be submitted for:

- (a) the determination of all components included in the monitoring residue definition as submitted in accordance with the provisions of point 6.7.1 in order to enable Member States to determine compliance with established maximum residue levels (MRLs); they shall cover residues in or on food and feed of plant and animal origin;
- (b) the determination of all components included for monitoring purposes in the residue definitions for soil and water as submitted in accordance with the provisions of point 7.4.2;
- (c) the analysis in air of the active substance and relevant breakdown products formed during or after application, unless the applicant shows that exposure of operators, workers, residents or bystanders is negligible;
- (d) the analysis in body fluids and tissues for active substances and relevant metabolites.

As far as practicable these methods shall employ the simplest approach, involve the minimum cost, and require commonly available equipment.

The specificity of the methods shall be determined and reported. It shall enable all components included in the monitoring residue definition to be determined. Validated confirmatory methods shall be submitted if appropriate.

The linearity, recovery and precision (repeatability) of methods shall be determined and reported.

Data shall be generated at the LOQ and either the likely residue levels or ten times the LOQ. The LOQ shall be determined and reported for each component included in the monitoring residue definition.

For residues in or on food and feed of plant and animal origin and residues in drinking water, the reproducibility of the method shall be determined by means of an independent laboratory validation (ILV) and reported.

## SECTION 5 U.K.

### *Toxicological and metabolism studies*

#### **Introduction**

1. The relevance of generating toxicity data in animal models with dissimilar metabolic profiles to those found in humans shall be addressed, if such metabolic information is available, and taken into consideration for study design and risk assessment.
2. All potentially adverse effects found during toxicological investigations (including effects on organs/systems such as the immune system, the nervous system, or the endocrine system) shall be reported. Additional studies may be necessary to



---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

investigate the mechanisms underlying effects that could be critical to hazard identification or risk assessment. U.K.

All available biological data and information relevant to the assessment of the toxicological profile of the active substance tested, including modelling, shall be reported.

3. Where available, historical control data shall be provided routinely. The data submitted shall be for endpoints that could represent critical adverse effects, and shall be strain-specific and from the laboratory which carried out the index study. They shall cover a five-year period, centred as closely as possible on the date of the index study.
4. When preparing a study plan, available data on the test substance, such as its physico-chemical properties (such as volatility), purity, reactivity (such as rate of hydrolysis, electrophilicity) and structure-activity relationships of chemical analogues, shall be taken into account.
5. For all studies actual achieved dose in mg/kg body weight, as well as in other convenient units (such as mg/L inhalation, mg/cm<sup>2</sup> dermal), shall be reported.
6. The analytical methods to be used in toxicity studies shall be specific for the entity to be measured and shall be adequately validated. The LOQ shall be adequate for the measurement of the range of concentration anticipated to occur in the generation of the toxicokinetic data.
7. Where, as a result of metabolism or other processes in or on treated plants, in livestock, in soil, in ground water, open air, or as a result of processing of treated products, the terminal residue to which humans will be exposed contains a substance which is not the active substance itself and is not identified as a significant metabolite in mammals, toxicity studies shall, where technically possible, be carried out on that substance unless it can be demonstrated that human exposure to that substance does not constitute a relevant risk to health. U.K.

Toxicokinetic and metabolism studies relating to metabolites and breakdown products shall only be required if toxicity findings of the metabolite cannot be evaluated by the available results relating to the active substance.

8. The oral route shall always be used if it is practical. In cases where exposure of humans is mainly by the gas phase, it can be more appropriate to perform some of the studies via inhalation.
9. For dose selection, toxicokinetic data such as saturation of absorption measured by systemic availability of substance and/or metabolites shall be taken into consideration.
- 5.1. **Studies on absorption, distribution, metabolism and excretion in mammals** U.K.

Information on blood and tissues concentration of the active substance and relevant metabolites, for example around the time to reach the maximum plasma concentration ( $T_{max}$ ), shall be generated in short and long-term studies on relevant species to enhance the value of the toxicological data generated in terms of understanding the toxicity studies.

The main objective of the toxicokinetic data is to describe the systemic exposure achieved in animals and its relationship to the dose levels and the time course of the toxicity studies.

Other objectives are:

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

- (a) to relate the achieved exposure in toxicity studies to toxicological findings and contribute to the assessment of the relevance of these findings to human health, with a particular regard to vulnerable groups;
  - (b) to support the design of a toxicity study (choice of species, treatment regimen, selection of dose levels) with respect to kinetics and metabolism;
  - (c) to provide information which, in relation to the findings of toxicity studies, contributes to the design of supplementary toxicity studies as outlined in point 5.8.2;
  - (d) to compare the metabolism of rats with the metabolism in livestock as outlined in point 6.2.4.
- 5.1.1. *Absorption, distribution, metabolism and excretion after exposure by oral route* **U.K.**

Limited data restricted to one *in vivo* test species (normally rat) may be all that is required as regards absorption, distribution, metabolism and excretion after exposure by oral route. These data can provide information useful in the design and interpretation of subsequent toxicity tests. However, it shall be remembered that information on interspecies differences is crucial in extrapolation of animal data to humans and information on metabolism following administration via other routes may be useful in human risk assessments.

It is not possible to specify detailed data requirements in all areas, since the exact requirements will depend upon the results obtained for each particular test substance.

The studies shall provide sufficient information about the kinetics of the active substance and its metabolites in relevant species after being exposed to the following:

- (a) a single oral dose (low and high dose levels);
- (b) an intravenous dose preferably or, if available, a single oral dose with assessment of biliary excretion (low dose level); and
- (c) a repeated dose.

A key parameter is systemic bioavailability (F), obtained by comparison of the area under the curve (AUC) after oral and intravenous dosing.

When intravenous dosing is not feasible a justification shall be provided.

The design of the kinetic studies required shall include:

- (a) an evaluation of the rate and extent of oral absorption including maximum plasma concentration ( $C_{\max}$ ), AUC,  $T_{\max}$  and other appropriate parameters, such as bioavailability;
- (b) the potential for bioaccumulation;
- (c) plasma half-lives;
- (d) the distribution in major organs and tissues;
- (e) information on the distribution in blood cells;
- (f) the chemical structure and the quantification of metabolites in biological fluids and tissues;
- (g) the different metabolic pathways;

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

- (h) the route and time course of excretion of active substance and metabolites;
- (i) investigations whether and to what extent enterohepatic circulation takes place.

Comparative *in vitro* metabolism studies shall be performed on animal species to be used in pivotal studies and on human material (microsomes or intact cell systems) in order to determine the relevance of the toxicological animal data and to guide in the interpretation of findings and in further definition of the testing strategy.

An explanation shall be given or further tests shall be carried out where a metabolite is detected *in vitro* in human material and not in the tested animal species.

#### 5.1.2. Absorption, distribution, metabolism and excretion after exposure by other routes **U.K.**

Data on absorption, distribution, metabolism and excretion (ADME) following exposure by the dermal route shall be provided where toxicity following dermal exposure is of concern compared to that following oral exposure. Before investigating ADME *in vivo* following dermal exposure, an *in vitro* dermal penetration study shall be conducted to assess the likely magnitude and rate of dermal bioavailability.

Absorption, distribution, metabolism and excretion after exposure by the dermal route shall be considered on the basis of the above information, unless the active substance causes skin irritation that would compromise the outcome of the study.

Dermal absorption estimation from data generated in these studies on the active substance shall be critically assessed for relevance to humans. Dermal absorption measurement of the plant protection product is specifically considered under point 7.3 of Part A of the Annex to Regulation (EU) No 284/2013.

For volatile active substances (vapour pressure > 10<sup>-2</sup> Pascal) absorption, distribution, metabolism and excretion after exposure by inhalation may be useful in human risk assessments.

#### 5.2. Acute toxicity **U.K.**

The studies, data and information to be provided and evaluated shall be sufficient to permit the identification of effects following a single exposure to the active substance, and in particular to establish, or indicate:

- (a) the toxicity of the active substance;
- (b) the time course and characteristics of the effects with full details of behavioural changes, clinical signs, where evident, and possible gross pathological findings at post-mortem;
- (c) the possible need to consider establishing acute reference doses (such as ARfD, aAOEL<sup>(9)</sup>);
- (d) where possible mode of toxic action;
- (e) the relative hazard associated with the different routes of exposure.

While the emphasis shall be on estimating the toxicity ranges involved, the information generated shall also permit the active substance to be classified in accordance with Regulation (EC) No 1272/2008. The information generated through acute toxicity testing is of particular value in assessing hazards likely to arise in accident situations.

##### 5.2.1. Oral **U.K.**

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

### *Circumstances in which required*

The acute oral toxicity of the active substance shall always be reported.

#### 5.2.2. *Dermal* U.K.

##### *Circumstances in which required*

The acute dermal toxicity of the active substance shall be reported unless waiving is scientifically justified (for example where oral LD<sub>50</sub><sup>(10)</sup> is greater than 2 000 mg/kg). Both local and systemic effects shall be investigated.

Findings of severe skin irritation (Grade 4 erythema or oedema) in the dermal study shall be used instead of performing a specific irritation study.

#### 5.2.3. *Inhalation* U.K.

##### *Circumstances in which required*

The acute inhalation toxicity of the active substance shall be reported where any of the following apply:

- the active substance has a vapour pressure  $> 1 \times 10^{-2}$  Pa at 20 °C;
- the active substance is a powder containing a significant proportion of particles of a diameter  $< 50 \mu\text{m}$  ( $> 1\%$  on weight basis);
- the active substance is included in products that are powders or are applied by spraying.

The head/nose only exposure shall be used, unless whole body exposure can be justified.

#### 5.2.4. *Skin irritation* U.K.

The results of the study shall provide information on the potential for skin irritancy of the active substance including, where relevant, the potential reversibility of the effects observed.

Before undertaking *in vivo* studies for corrosion/irritation of the active substance, a weight-of-evidence analysis shall be performed on the existing relevant data. Where insufficient data are available, they can be developed through application of sequential testing.

The testing strategy shall follow a tiered approach:

- (1) the assessment of dermal corrosivity using a validated *in vitro* test method;
- (2) the assessment of dermal irritation using a validated *in vitro* test method (such as human reconstituted skin models);
- (3) an initial *in vivo* dermal irritation study using one animal, and where no adverse effects are noted;
- (4) confirmatory testing using one or two additional animals.

##### *Circumstances in which required*

The skin irritancy study of the active substance shall always be provided. Where available, a dermal toxicity study shown not to produce irritation of the skin at the limit test dose level of 2 000 mg/kg body weight shall be used to waive the need for any dermal irritation studies.

#### 5.2.5. *Eye irritation* U.K.

The results of the study shall provide the potential of eye irritancy of the active substance including, where relevant, the potential reversibility of the effects observed.

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

Before undertaking *in vivo* studies for eye corrosion/irritation of the active substance, a weight-of-evidence analysis shall be performed on the existing relevant data. Where available data are considered insufficient, further data may be developed through application of sequential testing.

The testing strategy shall follow a tiered approach:

- (1) the use of an *in vitro* dermal irritation/corrosion test to predict eye irritation/corrosion;
- (2) the performance of a validated or accepted *in vitro* eye irritation study to identify severe eye irritants/corrosives (such as Bovine Corneal Opacity and Permeability (BCOP) assay, Isolated Chicken Eye (ICE) assay, Isolated Rabbit Eye (IRE) assay, Hen's Egg Test - Chorio-Allantoic Membrane assay (HET-CAM)), and where negative results are obtained, the assessment of eye irritation using an *in vitro* test method for identification of non-irritants or irritants, and where not available;
- (3) an initial *in vivo* eye irritation study using one animal, and where no adverse effects are noted;
- (4) confirmatory testing using one or two additional animals.

*Circumstances in which required*

The eye irritancy of the active substance shall always be tested, except where it is likely that severe effects on the eyes may be produced based on criteria listed in the test methods.

#### 5.2.6. Skin sensitisation **U.K.**

The study shall provide sufficient information to assess the potential of the active substance to provoke skin sensitisation reactions.

*Circumstances in which required*

The study shall always be carried out, except where the active substance is a known sensitiser. The local lymph node assay (LLNA) shall be used, including where appropriate the reduced variant of the assay. In case the LLNA cannot be conducted, a justification shall be provided and the Guinea Pig Maximisation Test shall be performed. Where a guinea pig assay (Maximisation or Buehler), meeting OECD guidelines and providing a clear result, is available, further testing shall not be carried out for animal welfare reasons.

Since an active substance identified as a skin sensitiser can potentially induce hypersensitivity reaction, potential respiratory sensitisation should be taken into account when appropriate tests are available or when there are indications of respiratory sensitisation effects.

#### 5.2.7. Phototoxicity **U.K.**

The study shall provide information on the potential of certain active substances to induce cytotoxicity in combination with light, for example active substances that are phototoxic *in vivo* after systemic exposure and distribution to the skin, as well as active substances that act as photoirritants after dermal application. A positive result shall be taken into account when considering potential human exposure.

*Circumstances in which required*

The *in vitro* study shall be required where the active substance absorbs electromagnetic radiation in the range 290-700 nm and is liable to reach the eyes or light-exposed areas of skin, either by direct contact or through systemic distribution.

If the Ultraviolet/visible molar extinction/absorption coefficient of the active substance is less than  $10 \text{ L} \times \text{mol}^{-1} \times \text{cm}^{-1}$ , no toxicity testing is required.

#### 5.3. Short-term toxicity **U.K.**

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

Short-term toxicity studies shall be designed to provide information as to the amount of the active substance that can be tolerated without adverse effects under the conditions of the study and to elucidate health hazards occurring at higher dose levels. Such studies provide useful data on the risks for those handling and using plant protection products containing the active substance, among other possible exposed groups. In particular, short-term studies provide an essential insight into possible repeated actions of the active substance and the risks to humans who may be exposed. In addition short-term studies provide information useful in the design of chronic toxicity studies.

The studies, data and information to be provided and evaluated, shall be sufficient to permit the identification of effects following repeated exposure to the active substance, and in particular to further establish, or indicate:

- (a) the relationship between dose and adverse effects;
- (b) toxicity of the active substance including where possible the No Observed Adverse Effect Level (NOAEL);
- (c) target organs, where relevant (including immune, nervous and endocrine systems);
- (d) the time course and characteristics of adverse effects with full details of behavioural changes and possible pathological findings at post-mortem;
- (e) specific adverse effects and pathological changes produced;
- (f) where relevant the persistence and reversibility of certain adverse effects observed, following discontinuation of dosing;
- (g) where possible, the mode of toxic action;
- (h) the relative hazard associated with the different routes of exposure;
- (i) relevant critical endpoints at appropriate time points for setting reference values, where necessary.

Toxicokinetic data (that is to say blood concentration) shall be included in short term studies. In order to avoid increased animal use, the data may be derived in range finding studies.

If nervous system, immune system or endocrine system are specific targets in short term studies at dose levels not producing marked toxicity, supplementary studies, including functional testing, shall be carried out (see point 5.8.2).

#### 5.3.1. Oral 28-day study **U.K.** *Circumstances in which required*

Where available, 28-day studies shall be reported.

#### 5.3.2. Oral 90-day study **U.K.** *Circumstances in which required*

The short-term oral toxicity of the active substance to rodents (90-day), usually the rat, a different rodent species shall be justified, and non rodents (90-day toxicity study in dogs), shall always be reported.

In the 90-day study, potential neurotoxic and immunotoxic effects, genotoxicity by way of micronuclei formation and effects potentially related to changes in the hormonal system shall be carefully addressed.

#### 5.3.3. Other routes **U.K.**

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

### *Circumstances in which required*

For human risk assessment additional dermal studies shall be considered on a case by case basis, unless the active substance is a severe irritant.

For volatile active substances (vapour pressure  $>10^{-2}$  Pascal) expert judgement (for example based on route-specific kinetic data) shall be required to decide whether the short term studies have to be performed by inhalation exposure.

#### 5.4. Genotoxicity testing **U.K.**

The aim of genotoxicity testing shall be to:

- predict genotoxic potential,
- identify genotoxic carcinogens at an early stage,
- elucidate the mechanism of action of some carcinogens.

Appropriate dose levels, depending on the test requirements, shall be used in either *in vitro* or *in vivo* assays. A tiered approach shall be adopted, with selection of higher tier tests being dependent upon interpretation of results at each stage.

Special testing requirements in relation to photomutagenicity may be indicated by the structure of a molecule. If the Ultraviolet/visible molar extinction/absorption coefficient of the active substance and its major metabolites is less than  $1\ 000\ \text{L} \times \text{mol}^{-1} \times \text{cm}^{-1}$ , photomutagenicity testing is not required.

##### 5.4.1. In vitro studies **U.K.**

#### *Circumstances in which required*

The following *in vitro* mutagenicity tests shall be performed: bacterial assay for gene mutation, combined test for structural and numerical chromosome aberrations in mammalian cells and test for gene mutation in mammalian cells.

However, if gene mutation and clastogenicity/aneuploidy are detected in a battery of tests consisting of Ames and *in vitro* micronucleus (IVM), no further *in vitro* testing needs to be conducted.

If there are indications of micronucleus formation in an *in vitro* micronucleus assay further testing with appropriate staining procedures shall be conducted to clarify if there is an aneugenic or clastogenic response. Further investigation of the aneugenic response may be considered to determine whether there is sufficient evidence for a threshold mechanism and threshold concentration for the aneugenic response (particularly for non-disjunction).

Active substances which display highly bacteriostatic properties as demonstrated in a range finding test shall be tested in two different *in vitro* mammalian cell tests for gene mutation. Non performance of the Ames test shall be justified.

For active substances bearing structural alerts that have given negative results in the standard test battery, additional testing may be required if the standard tests have not been optimised for these alerts. The choice of additional study or study plan modifications depends on the chemical nature, the known reactivity and the metabolism data on the structurally alerting active substance.

##### 5.4.2. In vivo studies in somatic cells **U.K.**

#### *Circumstances in which required*

If all the results of the *in vitro* studies are negative, at least one *in vivo* study shall be done with demonstration of exposure to the test tissue (such as cell toxicity or toxicokinetic data),

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

unless valid *in vivo* micronucleus data are generated within a repeat dose study and the *in vivo* micronucleus test is the appropriate test to be conducted to address this information requirement.

A negative result in the first *in vivo* test in somatic cells shall provide sufficient reassurance for active substances that are negative in the three *in vitro* tests.

For active substances for which an equivocal or a positive test result is obtained in any *in vitro* test, the nature of additional testing needed shall be considered on a case-by-case basis taking into account all relevant information using the same endpoint as in the *in vitro* test.

If the *in vitro* mammalian chromosome aberration test or the *in vitro* micronucleus test is positive for clastogenicity, an *in vivo* test for clastogenicity using somatic cells such as metaphase analysis in rodent bone marrow or micronucleus test in rodents shall be conducted.

If the *in vitro* micronucleus test for numerical chromosome aberrations on mammalian cells is positive or the *in vitro* mammalian chromosome test is positive for numerical chromosome changes, an *in vivo* micronucleus test shall be conducted. In case of positive result in the *in vivo* micronucleus assay, appropriate staining procedure such as fluorescence in-situ hybridisation (FISH) shall be used to identify aneuploid and/or clastogenic response.

If either of the *in vitro* gene mutation tests is positive, an *in vivo* test to investigate the induction of gene mutation shall be conducted, such as the Transgenic Rodent Somatic and Germ Cell Gene Mutation Assay.

When conducting *in vivo* genotoxicity studies, only relevant exposure routes and methods (*such as* admixture to diet, drinking water, skin application, inhalation and gavage) shall be used. There shall be convincing evidence that the relevant tissue will be reached by the chosen exposure route and application method. Other exposure techniques (*such as* intraperitoneal or subcutaneous injection) that are likely to result in abnormal kinetics, distribution and metabolism shall be justified.

Consideration shall be given to conducting an *in vivo* test as part of one of the short-term toxicity studies described under point 5.3.

#### 5.4.3. *In vivo studies in germ cells* U.K. *Circumstances in which required*

The necessity for conducting these tests shall be considered on a case by case basis, taking into account information regarding toxicokinetics, use and anticipated exposure.

For most of the active substances recognised as *in vivo* somatic cell mutagens no further genotoxicity testing shall be necessary since they will be considered to be potential genotoxic carcinogens and potential germ cell mutagens.

However, in some specific cases germ cells studies may be undertaken to demonstrate whether a somatic cell mutagen is or is not a germ cell mutagen.

The type of mutation produced in earlier studies namely gene, numerical chromosome or structural chromosome changes, shall be considered when selecting the appropriate assay.

A study for the presence of DNA adducts in gonad cells may also be considered.

#### 5.5. **Long-term toxicity and carcinogenicity** U.K.

The results of the long-term studies conducted and reported, taken together with other relevant data and information on the active substance, shall be sufficient to permit the identification of effects, following repeated exposure to the active substance, and in particular shall be sufficient to:



---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

- identify adverse effects resulting from long-term exposure to the active substance,
- identify target organs, where relevant,
- establish the dose-response relationship,
- establish the NOAEL and, if necessary, other appropriate reference points.

Correspondingly, the results of the carcinogenicity studies taken together with other relevant data and information on the active substance, shall be sufficient to permit the evaluation of hazards for humans, following repeated exposure to the active substance, and in particular shall be sufficient:

- (a) to identify carcinogenic effects resulting from long-term exposure to the active substance;
- (b) to establish the species, sex, and organ specificity of tumours induced;
- (c) to establish the dose-response relationship;
- (d) where possible, to identify the maximum dose eliciting no carcinogenic effect;
- (e) where possible, to determine the mode of action and human relevance of any identified carcinogenic response.

*Circumstances in which required*

The long-term toxicity and carcinogenicity of all active substances shall be determined. If in exceptional circumstances it is claimed that such testing is unnecessary, that claim shall be fully justified.

*Test conditions*

A long-term oral toxicity study and a long-term carcinogenicity study (two years) of the active substance shall be conducted using rat as test species; where possible these studies shall be combined.

A second carcinogenicity study of the active substance shall be conducted using mouse as test species, unless it can be scientifically justified that this is not necessary. In such cases, scientifically validated alternative carcinogenicity models may be used instead of a second carcinogenicity study.

If comparative metabolism data indicate that either rat or mouse is an inappropriate model for human cancer risk assessment, an alternative species shall be considered.

Experimental data, including the elucidation of the possible mode of action involved and relevance to humans, shall be provided where the mode of action for carcinogenicity is considered to be non-genotoxic.

Where submitted, historical control data shall be from the same species and strain, maintained under similar conditions in the same laboratory and shall be from contemporaneous studies. Additional historical control data from other laboratories may be reported separately as supplementary information.

The information on historical control data provided shall include:

- (a) identification of species and strain, name of the supplier, and specific colony identification, if the supplier has more than one geographical location;
- (b) name of the laboratory and the dates when the study was performed;
- (c) description of the general conditions under which animals were maintained, including the type or brand of diet and, where possible, the amount consumed;

---

*Changes to legislation:* There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

- (d) approximate age, in days, and weight of the control animals at the beginning of the study and at the time of killing or death;
- (e) description of the control group mortality pattern observed during or at the end of the study, and other pertinent observations (such as diseases, infections);
- (f) name of the laboratory and the examining scientists responsible for gathering and interpreting the pathological data from the study;
- (g) a statement of the nature of the tumours that may have been combined to produce any of the incidence data.

The historical control data shall be presented on a study by study basis giving absolute values plus percentage and relative or transformed values where these are helpful in the evaluation. If combined or summary data are submitted, these shall contain information on the range of values, the mean, median and, if applicable, standard deviation.

The doses tested, including the highest dose tested, shall be selected on the basis of the results of short-term testing and where available at the time of planning the studies concerned, on the basis of metabolism and toxicokinetic data. Dose selection should consider toxicokinetic data such as saturation of absorption measured by systemic availability of active substance and/or metabolites.

Doses, causing excessive toxicity shall not be considered relevant to evaluations to be made. Determination of blood concentration of the active substance (for example around  $T_{max}$ ) shall be considered in long-term studies.

In the collection of data and compilation of reports, incidence of benign and malignant tumours shall not be combined. Dissimilar, un-associated tumours, whether benign or malignant, occurring in the same organ, shall not be combined for reporting purposes.

In the interests of avoiding confusion, conventional histopathological terminology commonly used when the study is conducted such as that published by the International Agency for Research on Cancer shall be used in the nomenclature and reporting of tumours. The system used shall be identified.

Biological material selected for histopathological examination shall include material selected to provide further information on lesions identified during gross pathological examination. Where relevant to the elucidation of mechanism of action and available, special histological (staining) techniques, histochemical techniques and electron microscopic examinations, might be of value, and when conducted, shall be reported.

#### 5.6. Reproductive toxicity **U.K.**

Possible effects on reproductive physiology and the development of progeny shall be investigated and reported concerning the following aspects:

- Impairment of male and female reproductive functions or capacity, for example from effects on oestrus cycle, sexual behaviour, any aspect of spermatogenesis or oogenesis, or hormonal activity or physiological response which would interfere with the capacity to fertilise, fertilisation itself or development of the fertilised ovum up to and including implantation.
- Harmful effects on the progeny, for example any effect interfering with normal development, both before and after birth. This includes morphological malformations such as anogenital distance, nipple retention, and functional disturbances (such as reproductive and neurological effects).

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

Effects accentuated over generations shall be reported.

The active substance and its relevant metabolites shall be measured in milk as a second tier investigation where relevant effects are observed in the offspring or are expected (for example from a range-finding study).

Potential neurotoxic, immunotoxic effects and effects potentially related to changes in the hormonal system shall be carefully addressed and reported.

Investigations shall take account of all available and relevant data, including the results of general toxicity studies if relevant parameters (such as semen analysis, oestrous cyclicity, reproductive organ histopathology) are included, as well as knowledge concerning structural analogues to the active substance.

While the standard reference point for treatment responses shall be concurrent control data, historical control data may be helpful in the interpretation of particular reproductive studies. Where submitted, historical control data shall be from the same species and strain, maintained under similar conditions in the same laboratory and shall be from contemporaneous studies.

The information on historical control data provided shall include:

- (a) identification of species and strain, name of the supplier, and specific colony identification, if the supplier has more than one geographical location;
- (b) name of the laboratory and the dates when the study was performed;
- (c) description of the general conditions under which animals were maintained, including the type or brand of diet and, where possible, the amount consumed;
- (d) approximate age, in days, and weight of the control animals at the beginning of the study and at the time of killing or death;
- (e) description of the control group mortality pattern observed during or at the end of the study, and other pertinent observations (such as diseases, infections);
- (f) name of the laboratory and the examining scientists responsible for gathering and interpreting the pathological data from the study.

The historical control data shall be presented on a study by study basis giving absolute values plus percentage and relative or transformed values where these are helpful in the evaluation. If combined or summary data are submitted, these shall contain information on the range of values, the mean, median and, if applicable, standard deviation.

In order to provide useful information in the design and interpretation of developmental toxicity studies, information on blood concentration of the active substance in parents and foetus/offspring may be included in higher tier studies and reported.

#### 5.6.1. *Generational studies* **U.K.**

The generational studies reported, taken together with other relevant data and information on the active substance, shall be sufficient to permit the identification of effects for reproduction, following repeated exposure to the active substance, and in particular shall be sufficient:

- (a) to identify direct and indirect effects on reproduction resulting from exposure to the active substance;
- (b) to identify any non-reproductive adverse effects occurring at lower doses than in short-term and chronic toxicity testing;

---

*Changes to legislation:* There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

- (c) to establish the NOAELs for parental toxicity, reproductive outcome and pup development.

*Circumstances in which required*

A reproduction toxicity study in rats over at least two generations shall be reported.

The OECD extended one-generation reproductive toxicity study may be considered as an alternative approach to the multi-generation study.

Where necessary for a better interpretation of the effects on reproduction and as far as this information is not yet available, supplementary studies may be required to provide information on the affected gender and the possible mechanisms.

5.6.2. *Developmental toxicity studies* **U.K.**

The developmental toxicity studies reported, taken together with other relevant data and information on the active substance, shall be sufficient to permit the assessment of effects on embryonic and foetal development, following repeated exposure to the active substance, and in particular shall be sufficient:

- (a) to identify direct and indirect effects on embryonic and foetal development resulting from exposure to the active substance;
- (b) to identify any maternal toxicity;
- (c) to establish the relationship between observed responses and dose in both dam and offspring;
- (d) to establish NOAELs for maternal toxicity and pup development;
- (e) to provide additional information on adverse effects in pregnant as compared with non-pregnant females;
- (f) to provide additional information on any enhancement of general toxic effects of pregnant animals.

*Circumstances in which required*

Developmental toxicity studies shall always be carried out.

*Test conditions*

Developmental toxicity shall be determined for rat and rabbit by the oral route; the rat study shall not be conducted if developmental toxicity has been adequately assessed as part of an extended one-generation reproductive toxicity study.

Additional routes may be useful in human risk assessment. Malformations and variations shall be reported separately and combined in such a way that all relevant changes which are observed to occur in characteristic patterns in individual foetuses or those that can be considered to represent different grades of severity of the same type of change are reported in a concise manner.

Diagnostic criteria for malformations and variations shall be given in the report. The glossary of terminology under development by the International Federation of Teratology Societies shall be considered where possible.

When indicated by observations in other studies or the mode of action of the test substance, supplementary studies or information may be required to provide information on the postnatal manifestation of effects such as developmental neurotoxicity.

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

## 5.7. Neurotoxicity studies U.K.

### 5.7.1. Neurotoxicity studies in rodents U.K.

Neurotoxicity studies in rodents shall provide sufficient data to evaluate the potential neurotoxicity of the active substance (neurobehavioural and neuropathological effects) after single and repeated exposure.

#### *Circumstances in which required*

Such studies shall be performed for active substances with structures that are similar or related to those capable of inducing neurotoxicity, and for active substances which induce specific indications of potential neurotoxicity, neurological signs or neuropathological lesions in toxicity studies at dose levels not associated with marked general toxicity. Performance of such studies shall also be considered for substances with a neurotoxic mode of pesticidal action.

Consideration shall be given to including neurotoxicity investigations in routine toxicology studies.

### 5.7.2. Delayed polyneuropathy studies U.K.

Delayed polyneuropathy studies shall provide sufficient data to evaluate if the active substance may provoke delayed polyneuropathy after acute and repeated exposure. A repeated exposure study may be waived unless there are indications that the compound accumulates and significant inhibition of neuropathy target esterase or clinical/histopathological signs of delayed polyneuropathy occur at around the hen LD<sub>50</sub> as determined in the single dose test.

#### *Circumstances in which required*

These studies shall be performed for active substances of similar or related structures to those capable of inducing delayed polyneuropathy such as organophosphorus compounds.

## 5.8. Other toxicological studies U.K.

### 5.8.1. Toxicity studies of metabolites U.K.

Supplementary studies, where they relate to substances other than the active substance, are not a routine requirement. Decisions as to the need for supplementary studies shall be made on a case by case basis.

Where as a result of metabolism or other processes, metabolites from plants or in animal products, soil, groundwater, open air differ from those in animals used for the toxicology studies or are detected in low proportions in animals, further testing shall be carried out on a case by case basis, taking into account the amount of metabolite and the chemical structure of the metabolite compared to the parent.

### 5.8.2. Supplementary studies on the active substance U.K.

Supplementary studies shall be carried out where they are necessary to further clarify observed effects taking into account the results of the available toxicological and metabolism studies and the most important exposure routes. Such studies may include:

- (a) studies on absorption, distribution, excretion and metabolism, in a second species;
- (b) studies on the immunotoxicological potential;
- (c) a targeted single dose study to derive appropriate acute reference values (ARfD, aAOEL);
- (d) studies on other routes of administration;

---

*Changes to legislation:* There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

(e) studies on the carcinogenic potential;

(f) studies on mixture effects.

Studies required shall be designed on an individual basis, in the light of the particular parameters to be investigated and the objectives to be achieved.

#### 5.8.3. *Endocrine disrupting properties* U.K.

If there is evidence that the active substance may have endocrine disrupting properties, additional information or specific studies shall be required:

- to elucidate the mode/mechanism of action,
- to provide sufficient evidence for relevant adverse effects.

Studies required shall be designed on an individual basis and taking into account Union or internationally agreed guidelines, in the light of the particular parameters to be investigated and the objectives to be achieved.

#### 5.9. **Medical data** U.K.

Where available and without prejudice to Article 10 of Council Directive 98/24/EC<sup>(1)</sup>, practical data and information relevant to the recognition of the symptoms of poisoning and on the effectiveness of first aid and therapeutic measures shall be submitted. Such data and information shall include reports of any studies investigating antidote pharmacology or safety pharmacology. Where relevant, the effectiveness of potential antagonists to poisoning shall be investigated and reported.

Data and information relevant to the effects of human exposure, where available, shall be used to confirm the validity of extrapolations made and conclusions reached with respect to target organs, dose-response relationships, and the reversibility of adverse effects. Such data may be generated following accidental, occupational exposure or incidents of intentional self-poisoning, and shall be reported if available.

##### 5.9.1. *Medical surveillance on manufacturing plant personnel and monitoring studies* U.K.

Reports of occupational health surveillance programs and of monitoring studies shall be submitted, supported with detailed information on the design of the programme, the number of exposed persons included in the programme, the nature of their exposure to the active substance, and their exposure to other potentially hazardous agents. Such reports shall, where feasible, include data relevant to the mechanism of action of the active substance. These reports shall, where available, include data from persons exposed in manufacturing plants, or during or after application of the active substance (for example from monitoring studies in operators, workers, residents, bystanders or victims of accidents). Available information on adverse health effects including allergenic responses in workers and others exposed to the active substance, shall be provided, and include where relevant details of any incident. The information provided shall, where available, include details of frequency, level and duration of exposure, symptoms observed and other relevant clinical information.

##### 5.9.2. *Data collected on humans* U.K.

Where available, reports from studies with humans, such as tests on toxicokinetics and metabolism, or tests on skin irritation or skin sensitisation, shall be submitted.

In general, the reference values shall be based on animal studies, but if appropriate scientifically valid and ethically generated human data are available and show that humans are more sensitive and lead to lower regulatory limit values, these data shall take precedence over animal data.

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

### 5.9.3. *Direct observations* U.K.

Available reports from the open literature, relating to clinical cases and poisoning incidents, where they are from refereed journals or official reports, shall be submitted together with reports of any follow-up studies undertaken. Such reports shall, where available, contain complete descriptions of the nature, level and duration of exposure, as well as the clinical symptoms observed, first aid and therapeutic measures applied and measurements and observations made.

Where supported with the necessary level of detail, such documentation shall be used to confirm the validity of extrapolations from animal data to man and to identify unexpected adverse effects which are specific to humans.

### 5.9.4. *Epidemiological studies* U.K.

Relevant epidemiological studies shall be submitted, where available.

### 5.9.5. *Diagnosis of poisoning (determination of active substance, metabolites), specific signs of poisoning, clinical tests* U.K.

Where available, detailed description of the clinical signs and symptoms of poisoning, including the early signs and symptoms and full details of clinical tests useful for diagnostic purposes shall be provided including full details of the time courses involved relevant to the ingestion, dermal exposure or inhalation of varying amounts of the active substance.

### 5.9.6. *Proposed treatment: first aid measures, antidotes, medical treatment* U.K.

First aid measures to be used in the event of poisoning (actual and suspected) and in the event of contamination of eyes shall be provided. Therapeutic regimes for use in the event of poisoning or contamination of eyes, including where available the use of antidotes, shall be described in full. Information based on practical experience, where it exists and is available, in other cases on theoretical grounds, as to the effectiveness of alternative treatment regimes, where relevant, shall be provided. Contraindications associated with particular regimes, particularly those relating to 'general medical problems' and conditions, shall be described.

### 5.9.7. *Expected effects of poisoning* U.K.

Where known, the expected effects and the duration of these effects following poisoning shall be described. That description shall include the impact of:

- the type, level and duration of exposure, or ingestion, and
- varying time periods between exposure, or ingestion, and commencement of treatment.

## SECTION 6 U.K.

### *Residues in or on treated products, food and feed*

#### 6.1. **Storage stability of residues** U.K.

Studies concerning storage stability of residues shall investigate the stability of residues in plants, plant products and products of animal origin during storage prior to analysis.

##### *Circumstances in which required*

Provided that samples are frozen within 24 hours after sampling and unless a compound is otherwise known to be volatile or labile, stability data shall not be required for samples extracted and analysed within 30 days from sampling (six months in the case of radio-labelled material).

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

The stability of extracts shall be investigated if extracts are not analysed immediately.

*Test conditions*

Studies with non-radio-labelled active substances shall be carried out with representative substrates. They may be either performed on samples from treated crops or animals with incurred residues or by fortification experiments. In the latter case, aliquots of prepared control samples shall be spiked with a known amount of chemical before storage under normal storage conditions.

The studies shall address stability of individual components of the residue definition relevant to risk assessment, which may require spiking different samples with different analytes. In case of different analytical targets (for example targeting either single compounds or a common moiety) more than one set of storage stability data may be needed.

The duration of the stability studies shall be suitable to address the length over which the samples or extracts have been stored in the corresponding studies.

Detailed information with respect to the sample preparation and storage conditions (temperature and duration) of samples and extracts shall be submitted. Where the degradation during storage is significant (more than 30%) a change in the storage conditions or not storing the samples prior to analysis shall be considered. All studies where unsatisfactory storage conditions were used shall be repeated.

Storage stability data using sample extracts shall also be required unless samples are analysed within 24 hours of extraction.

Results shall be presented as absolute values in mg/kg and not adjusted by recovery, as well as percentage of nominal spike value.

## 6.2. Metabolism, distribution and expression of residues U.K.

Data on metabolism representative for existing or intended good agricultural practices (GAPs) shall be provided, together with a schematic diagram of the metabolic pathways in plants and animals with a brief explanation of the distribution and chemical reactions involved. These studies shall be conducted with one or more radio-labelled forms of the active substance and, where relevant, stereoisomer forms of the active substance and its metabolites. For plant extracts, a different approach may be taken if adequately justified.

For plants, the objectives of these studies shall be:

- (a) to provide an estimate of total terminal residues in the relevant portion of crops at harvest following treatment as proposed;
- (b) to identify the major components of the total terminal residue;
- (c) to indicate the distribution of residues between relevant crops parts;
- (d) to quantify the major components of the residue and to show the efficiency of extraction procedures for these components;
- (e) to characterise and quantify conjugated and bound residues;
- (f) to indicate the components to be analysed for in residue quantification studies (crop residue studies).

For food producing animals, the objectives of these studies shall be:

- (a) to provide an estimate of total terminal residues in edible animal products;



---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

- (b) to identify the major components of the total terminal residue in edible animal products;
- (c) to indicate the distribution of residues between relevant edible animal products;
- (d) to provide evidence whether or not a residue should be classified as fat soluble;
- (e) to quantify the total residue in certain animal products (milk or eggs) and excreta;
- (f) to quantify the major components of the residue and to show the efficiency of extraction procedures for these components;
- (g) to characterise and quantify conjugated and bound residues;
- (h) to indicate the components to be analysed for in residue quantification studies (livestock feeding studies);
- (i) to generate data from which a decision on the need for feeding studies on food producing animals can be made.

The results of the metabolism study conducted with poultry, normally laying hens, shall be extrapolated to all food producing poultry whereas the results of the metabolism study conducted with ruminants, normally lactating goats and, where necessary, with pigs, shall be extrapolated to all food producing mammals.

Metabolites not found in the ADME studies or that cannot be explained as intermediates, but identified in metabolism/transformation studies (plant, food producing animals, processing and rotational crops) shall be considered relevant for the consumer risk assessment, unless it can be demonstrated by scientific evidence (such as structure-activity relationship, toxicological bridging studies) that, also in view of their concentration, they cause no potential risks to the consumer.

#### 6.2.1. *Plants* U.K. *Circumstances in which required*

Studies on plants shall be performed unless no part of the plants or plant products will be used as food or feed material or unless a 'zero' residue situation applies (such as bait applications).

##### *Test conditions*

The intended method of application (such as seed treatment, soil/foliar spraying, dipping, fogging) and the properties of the active substance (such as systemic properties or volatility) shall be taken into account when planning metabolism studies. Metabolism studies have to involve crops from different categories of crops in which plant protection products containing the active substance in question would be used. For this purpose crops shall be considered as falling into one of the following categories:

- (a) fruit (code F);
- (b) root crops (code R);
- (c) leafy crops (code L);
- (d) cereal/grass crops (code C/G);
- (e) pulses and oilseeds (code P/O);
- (f) miscellaneous.

The category 'miscellaneous' shall only be used on a case by case basis.

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

A metabolism study shall be submitted for each type of crop group for which use is proposed. In order to extrapolate results from metabolism studies with an active substance to all crop groups, metabolism studies on a minimum of three representative crops (from the different crop groups except 'miscellaneous') shall be conducted. If the results of these three studies indicate a comparable metabolic route (qualitatively and to a lesser extent quantitatively), then additional studies shall not be needed. If the results from the available studies from three of these categories indicate that the route of degradation is not similar in all three categories, studies from the remaining categories except 'miscellaneous' shall be provided.

If authorisation is sought for one crop group only, metabolism studies in one crop from that crop group shall be sufficient as long as the crop is truly representative of the crop group and the metabolic pathway is elucidated.

The studies shall reflect the intended use pattern of the active ingredient such as foliar, soil/seed or post-harvest treatments. If, for instance, three studies have been conducted using foliar application and at a later date soil application (such as seed treatment, granular or soil drench) is proposed, then at least one additional study reflecting soil application shall be conducted. The applicant shall discuss with the national competent authorities the possible replacement of a foliar study with a post-harvest study.

An evaluation of the results from different studies shall be submitted on:

- (a) the site of uptake (for example via leaves or roots);
- (b) the formation of metabolites and breakdown products;
- (c) the distribution of residues between relevant parts of the crop at harvest (with particular emphasis on food and feed);
- (d) the metabolic pathways.

If studies show that the active substance or relevant metabolites or breakdown products are not taken up by the crop, a rationale shall be given.

#### 6.2.2. Poultry U.K.

##### *Circumstances in which required*

Metabolism studies on poultry shall be provided where the plant protection product is to be used in crops whose parts or products, also after processing, are fed to poultry and where the intake is expected to exceed 0,004 mg/kg bw/day<sup>(12)</sup>.

##### *Test conditions*

Studies shall be carried out in laying hens.

Dose rates shall be at least equivalent to the likely maximum daily exposure resulting from all intended uses.

If the identification of metabolites cannot be carried out with dose rates of 10 mg/kg feed (dry matter), higher doses may be used.

If no feeding studies are carried out, plateau levels in eggs shall be demonstrated in the metabolism study taking into account that plateau levels usually occur no later than 14 days from the beginning of dosing in laying poultry.

#### 6.2.3. Lactating ruminants U.K.

##### *Circumstances in which required*

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

Metabolism studies on lactating ruminants shall be provided where the plant protection product is to be used in crops whose parts or products, also after processing, are fed to ruminants and where the intake is expected to exceed 0,004 mg/kg bw/day.

*Test conditions*

Studies shall be carried out in lactating goats, where available, or in lactating cows as an alternative.

Dose rates shall at least be equivalent to the likely maximum daily exposure resulting from all intended uses.

If the identification of main metabolites cannot be carried out with dose rates of 10 mg/kg feed (dry matter), higher doses may be used.

If no feeding studies are carried out, plateau levels in milk shall be demonstrated in the metabolism study taking into account that plateau levels usually occur five to seven days after the beginning of dosing in lactating ruminants.

6.2.4. *Pigs* **U.K.**

*Circumstances in which required*

Metabolism studies on pigs shall be provided where the plant protection product is used in crops whose parts or products, also after processing, are fed to pigs and where it becomes apparent that metabolic pathways differ significantly in the rat as compared to ruminants and where the intake is expected to exceed 0,004 mg/kg bw/day.

*Test conditions*

Studies shall be carried out in pigs.

Dose rates shall at least be equivalent to the likely maximum daily exposure resulting from all intended uses.

If the identification of metabolites cannot be carried out with dose rates of 10 mg/kg feed (dry matter), higher doses may be used.

The duration of this study shall be the same as for lactating ruminants.

6.2.5. *Fish* **U.K.**

*Circumstances in which required*

Metabolism studies on fish may be required where the plant protection product is used in crops whose parts or products, also after processing, are fed to fish and where residues in feed may occur from the intended applications.

Results from studies provided for under point 8.2.2.3 may be used if it can be demonstrated with scientific evidence that the results of these studies may be assumed to be equivalent. Special consideration shall be given to the different routes of ingestion.

6.3. **Magnitude of residue trials in plants** **U.K.**

The objectives of magnitude of residue trials in plants shall be the following:

- to quantify the highest likely residue levels of all components of the different residue definitions in treated crops, at harvest or outloading from store, in accordance with the proposed GAP, and
- to determine, where appropriate, the decline rate of plant protection product residues in plants.

*Circumstances in which required*

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

These studies shall always be performed where the plant protection product is to be applied to plants or plant products that are used as food or feed or where residues from soil or other substrates can be taken up by such plants except where extrapolation from adequate data on another crop is possible.

When planning residue trials, it shall be borne in mind that information on the residues in ripe or unripe crops may be of interest with respect to the risk assessment in other areas like ecotoxicology or worker safety.

#### *Test conditions*

Supervised residue trials shall correspond to the proposed critical GAP. The test conditions (such as maximum number of proposed applications, shortest interval between applications, maximum application rate and concentration, most critical safety intervals<sup>(13)</sup> with regard to exposure) shall be defined to identify the highest residues which may reasonably arise and shall be representative of the realistic conditions at the critical GAP in which the active substance is to be used.

When establishing a supervised residue trial programme, factors such as main growing areas and the range of conditions, likely to be encountered in the main growing areas concerned shall be considered.

Differences in agricultural production methods (for example outdoor versus indoor uses), seasons of production and types of formulations shall be taken into account.

For the evaluation of residue behaviour and the setting of maximum residue levels (MRLs) according to Regulation (EC) No 396/2005, the Union shall be divided into two zones, a Northern European and a Southern European zone. For the purpose of use in greenhouses, as post-harvest treatment and for treatment of empty storage rooms, one residue zone shall apply.

The number of trials necessary is difficult to determine before the evaluation of their results. Assuming all other variables having an impact on the residue levels are comparable, the minimum number of trials shall vary for each residue zone between a minimum of 4 trials for a minor crop and a minimum of 8 trials for a major crop.

However, if the GAP is the same in both residue zones, 6 trials equally distributed in the representative growing zones are normally sufficient for a minor crop.

The number of studies to be performed may be reduced if residue trials show that the residue levels in plants or plant products are lower than the LOQ. The number of trials shall not be below the minimum of three per zone for minor crops and four per zone for major crops.

In cases where a 'zero' residue situation is predicted from representative plant metabolism studies, three trials shall be performed for commodities significant in diet. No trials shall be required for commodities insignificant in diet. A 'zero' residue situation shall be predicted where no detectable residues occur in studies with exaggerated application rates compared to the envisaged ones.

Provided that conditions are comparable and that trials are widely spread over different zones, it shall be sufficient to carry out trials over one growing season.

Part of the trials may be replaced by trials performed outside the Union, provided that they correspond to the critical GAP and that the production conditions (such as cultural practices, climatic conditions) are comparable.

Trials showing the residue behaviour in post-harvest treatments shall be carried out at different locations with different cultivars. A set of trials shall be carried out for each application method and storage condition, unless the worst case residue situation can be clearly identified.

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

Where a plant protection product has both a field use and an indoor use with the same GAP, a full data package shall be submitted for both situations, unless it is already accepted that one use is the critical GAP.

It shall be checked on a case-by-case basis, taking into account plant morphology and application conditions, whether extrapolation from the crop used for the metabolism study to other crops belonging to the same crop group is possible.

Where a significant part of the consumable commodity is present at the time of application, half of the supervised residue trials reported shall include data to show the effect of time on the level of residue present (residue decline studies), unless the consumable part is not exposed during application of the plant protection product under the proposed conditions of use. For crops harvested after blossom (such as fruits or fruiting vegetables) a significant part of the consumable crop is present from full blossom (BBCH 65) onwards. In case of most crops from which leafy parts are harvested (for example lettuce), this condition is satisfied if 6 true leaves, leaf pairs or whorls are unfolded (BBCH 16).

In case of an active substance for which an ARfD has been derived, the distribution of residues among single units may be investigated through variability studies. If a sufficient number of results is available, the default variability factor may be replaced by a specific factor derived from these studies.

#### 6.4. Feeding studies **U.K.**

The objective of feeding studies shall be to determine residues in products of animal origin which result from residues in feed.

The results from a feeding study conducted with laying hens shall be extrapolated to all food producing poultry. The results from a feeding study with lactating cows and, where necessary, with pigs shall be extrapolated to all food producing mammals.

##### *Circumstances in which required*

Feeding studies shall be provided where metabolism studies indicate that residues at levels of above 0,01 mg/kg may occur in edible animal tissue, milk, eggs or fish, taking into account the residue levels in potential feeding stuffs, obtained at the 1 × dose rate, calculated on the dry weight basis.

Feeding studies shall not be required where intake is below 0,004 mg/kg bw/day, except in cases where the residue, that is to say the active substance, its metabolites or breakdown products, as defined in the residue definition for risk assessment, tends to accumulate.

##### 6.4.1. Poultry **U.K.**

Poultry feeding studies shall be carried out in laying hens. For each treatment regime chosen a minimum of nine chickens should be treated.

In general, the feed shall be administered in three dosages (first dose = expected residue level). The animals shall be dosed for a minimum of 28 days or until plateau level is reached in eggs.

##### 6.4.2. Ruminants **U.K.**

Ruminant feeding studies shall be carried out in lactating cows. For each treatment regime chosen, a minimum of three dairy cows shall be treated.

In general, the feed shall be administered in three dosages (first dose = expected residue level). The animals shall be dosed for a minimum of 28 days or until plateau level is reached in milk.

##### 6.4.3. Pigs **U.K.**

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

Where it appears from the metabolism studies that metabolic pathways differ significantly in pigs as compared to ruminants, a pig feeding study may be conducted. For each treatment regime chosen a minimum of three pigs shall be treated.

In general, the feed shall be administered in three dosages (first dose = expected residue level). The animals shall be dosed for at least the same time as ruminants.

#### 6.4.4. Fish **U.K.**

A fish feeding study may be required where residues at levels above 0,01 mg/kg may be reasonably expected in edible tissues, based on the findings of the fish metabolism study and the estimated maximum residues which might occur in fish feed. Particular attention should be laid on lipophilic substances with an intrinsic tendency for accumulation.

#### 6.5. Effects of processing **U.K.**

##### 6.5.1. Nature of the residue **U.K.**

The objective of studies on the nature of the residue shall be to establish whether or not breakdown or reaction products arise from residues in the raw agricultural commodity during processing, which may require a separate risk assessment.

##### *Circumstances in which required*

Studies on the nature of residues in processing shall be provided where residues in products of plant or animal origin subject to processing may occur at a level of or higher than 0,01 mg/kg (based on the residue definition for risk assessment for the raw commodity). No studies shall, however, be required in the following cases:

- substances with a water solubility < 0,01 mg/L;
- only simple physical operations, not involving a change in temperature of the commodity are carried out, such as washing, trimming or pressing; or
- the distribution of residues between pulp and inedible peel is the only effect of processing.

##### *Test conditions*

Depending upon the expected level and chemical nature of the residue in the product of plant or animal origin, a set of representative hydrolysis situations simulating the relevant processing operations shall be investigated, where appropriate. Consideration shall also be given to the effects of processes other than hydrolysis and the potential for the formation of toxicologically significant breakdown products.

The studies shall be conducted with one or more radio-labelled forms of the relevant substance.

##### 6.5.2. Distribution of the residue in inedible peel and pulp **U.K.**

The objectives of studies concerning distribution of the residue in inedible peel and pulp shall be:

- to determine the quantitative distribution of residues between inedible peel and pulp,
- to estimate peeling factors, and
- to allow a more realistic estimation of dietary intake of residues.

##### *Circumstances in which required*

These studies shall be provided for plant products where the peel is either inedible (such as melons, bananas) or is very rarely entirely eaten by consumers (such as citrus fruit).

##### *Test conditions*

These studies shall be performed as part of supervised residue trials, the number of results reported depending on the number of residue trials conducted. Special attention shall be paid to

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

possible contamination of the pulp. Precautionary measures shall be taken in order to quantify a realistic highest residue level.

### 6.5.3. Magnitude of residues in processed commodities U.K.

The main objectives of studies concerning magnitude of residues in processed commodities shall be:

- to determine the quantitative distribution of residues in the various processed commodities used as food or feed,
- to estimate processing factors, and
- to allow a more realistic estimation of dietary intake of residues.

#### *Circumstances in which required*

The following points shall be taken into consideration when deciding whether it is necessary to carry out processing studies:

- (a) the dietary burden of a processed product in the human (such as apples) or animal diet (such as apple pomace);
- (b) the level of residue in the plant or plant product to be processed (normally  $\geq 0,1$  mg/kg);
- (c) the physical and chemical properties of the active substance and its relevant metabolites (such as fat-solubility in case of oil seed processing); and
- (d) the possibility that breakdown products of toxicological significance may occur after processing of the plant or plant product.

If the level of residues is less than 0,1 mg/kg, processing studies shall be carried out if the contribution of the commodity under consideration to the theoretical maximum daily intake (TMDI) is  $\geq 10$  % of the ADI or if the estimated daily intake is  $\geq 10$  % of the ARfD for any European consumer group diet.

Processing studies shall not be required if plants or plant products are exclusively used raw (unprocessed) for food and feed purposes.

In some cases, a simple calculation shall be sufficient to determine the processing factor such as concentration from dehydration or dilution factors, as long as the process under consideration is not expected to have an influence on the nature of residues.

#### *Industrial processing*

If the properties of the active substance, the impurity or the metabolite, as appropriate, indicate that it might concentrate in a given processed fraction, then a processing study shall be necessary even in situations where the residue in the plant or plant product to be processed is lower than 0,1 mg/kg. In such cases, exaggerated application rates up to  $5 \times$  or shortened PHIs shall be applied where necessary to achieve a quantifiable residue in the plant or plant product to be processed. A processing study shall not be required if exaggerated application rates (up to  $5 \times$ ) fail to yield a quantifiable residue in the plant or plant product to be processed. Phytotoxicity shall be considered when contemplating exaggerated rate treatments.

#### *Domestic processing*

For domestic or home transformation processes and minor industrial ones, when no residues are found at or above 0,1 mg/kg in the raw agricultural commodity at recommended GAP from supervised field trials conducted at the maximum label rate and minimum PHI, no processing studies shall be required.

#### *Test conditions*

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

Processing studies shall represent domestic preparations (for example cooked vegetables) or commercial industrial processes (for example production of apple juice). Processing studies shall be carried out at least on a representative crop of a crop group, where use is envisaged. The choice of the crop and of the process shall be justified and explained.

The technology used in processing studies shall correspond as closely as possible to the actual conditions that are normally used. For each crop to be investigated two studies per process shall be carried out to determine concentration and dilution factors in processed commodities. If more than one processing method is in use, the one which is expected to give the highest residues in the processed product for human consumption shall be chosen. The results shall be extrapolated to all crops within a crop group undergoing the same process.

When the results (processing factor) of the two studies differ in the main processed products by more than 50 %, further studies shall be provided to derive a consistent processing factor.

Additional studies shall be carried out if, when using processing factors derived by extrapolation, the estimate of the dietary intake exceeds the ADI or ARfD. Those studies shall be carried out on major processes and commodities which contribute most to the ADI/ARfD exceedance.

#### 6.6. Residues in rotational crops **U.K.**

Studies concerning residues in rotational crops shall be performed to allow the determination of the nature and extent of potential residue accumulation in rotational crops from soil uptake and of the magnitude of residues in rotational crops under realistic field conditions.

Rotational crop studies shall not be required for uses of plant protection products in permanent crops (such as citrus and pome fruits crop group), semi-permanent crops (such as asparagus, pineapples) or fungi, where rotations on the same substrate are not part of the normal agricultural practices.

##### 6.6.1. Metabolism in rotational crops **U.K.**

The objectives of metabolism studies in rotational crops shall be:

- (a) to provide an estimate of the total terminal residues in the relevant portion of crops at harvest of rotational crops following treatment of the preceding crop as proposed;
- (b) to identify the major components of the total terminal residue;
- (c) to indicate the distribution of residues between relevant crop parts;
- (d) to quantify the major components of the residue;
- (e) to indicate additional components to be analysed for in residue quantification studies (field crop rotation studies);
- (f) to decide on restrictions in crop rotation; and
- (g) to decide on the necessity of field residue trials in rotational crops (limited field studies).

##### *Circumstances in which required*

Metabolism studies in rotational crops shall be provided if the parent compound or soil metabolites are persistent in soil or significant concentrations of metabolites in soil occur.

Rotational crop metabolism studies shall not be required if worst case conditions can be appropriately represented by other available studies in treated crops in accordance with point



---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

6.2.1, where the plant protection product was applied directly to the soil (for example as a pre-planting or pre-emergence application).

*Test conditions*

Metabolism studies shall at least involve three crops from three different groups of crops: root and tuber vegetables, leafy vegetables and cereals. Data from further crop groups may be relevant for MRL setting. These crops shall be planted into soil treated at the recommended maximum total application rate for the preceding crops after an appropriate plant-back interval that mimics crop failure early in the vegetation of the crop, crop rotation in the same vegetation period or year and crop rotation in the next vegetation period or year.

6.6.2. *Magnitude of residues in rotational crops* U.K.

The objectives of studies on residues in rotational crops shall be:

- (a) to permit an evaluation of the magnitude of residues in rotational crops;
- (b) to decide on restrictions in crop rotation;
- (c) to provide information for assessing the overall significance of the residues for dietary risk assessment; and
- (d) to decide on the necessity of MRLs for rotational crops.

*Circumstances in which required*

If the metabolism studies indicate that residues of the active substance or of relevant metabolites or breakdown products either from plant or soil metabolism may occur ( $> 0,01$  mg/kg), limited field studies and, if necessary, field trials shall be carried out.

Studies shall not be required in the following cases:

- no metabolism studies on rotational crops are to be performed, or
- metabolism studies on rotational crops show that no residues of concern are to be expected in rotational crops.

*Test conditions*

A tiered approach shall be adopted to fulfil the above mentioned objectives. In the first tier, limited field studies at two sites in major growing areas shall be conducted. The plant protection product for which authorisation is sought or a very similar formulation shall be used.

No further studies shall be required where, based on the result from the first tier studies, no detectable residues ( $< 0,01$  mg/kg) in rotational crops are to be expected or if in metabolism studies no residues requiring risk assessment are observed.

For the second tier, additional data shall be submitted to enable appropriate evaluation of dietary risks and establishment of MRLs. These studies shall cover the common crop rotation practice. They shall be performed taking into account the requirements under point 6.3. Trials shall be conducted as closely as possible to agricultural practice on representative crops from major crop groups. At least four trials per crop shall be conducted across the Union in one year. These trials shall be performed in the main production areas across the Union at the highest application rate for the preceding crops. If annual applications of persistent active substances result in higher plateau concentrations in soil than a single application, the plateau concentration shall be taken into account. The necessary residue trials data shall be set up in consultation with the national competent authorities in the Member States.

6.7. **Proposed residue definitions and maximum residue levels** U.K.

6.7.1. *Proposed residue definitions* U.K.

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

The following elements shall be considered when judging which compounds are to be included in the residue definition:

- the toxicological significance of the compounds,
- the amounts likely to be present, and
- the analytical methods proposed for post-approval control and monitoring purposes.

Two different residue definitions may be needed: one for enforcement purposes, based on the marker concept, and one for risk assessment purposes, taking into account toxicologically relevant compounds.

Analytical work in residue trials and feeding studies shall cover all the components of the residue definition for risk assessment.

6.7.2. *Proposed maximum residue levels (MRLs) and justification of the acceptability of the levels proposed* U.K.

A maximum residue level shall be provided for all products of plant and animal origin covered by Regulation (EC) No 396/2005. In all other cases of products of plant and animal origin used as food or feed and in case of tobacco and medical herbs, a guideline level, that is to say a level derived on the same principles used for MRL setting, shall be provided.

For processed products processing factors shall be provided, unless no processing studies are required.

Furthermore, supervised trials median residue (STMR) and highest residue (HR) values shall be derived and, in cases where processing factors are proposed, STMR-P and HR-P values.

In exceptional cases, when the conditions laid down in Article 16(1) to Regulation (EC) No 396/2005 are met, MRLs may be proposed on the basis of monitoring data. In such cases the proposal shall cover the 95<sup>th</sup> percentile of the data population at the 95 % confidence level.

6.7.3. *Proposed maximum residue levels (MRLs) and justification of the acceptability of the levels proposed for imported products (import tolerance)* U.K.

Point 6.7.2 shall apply to MRLs proposed for imported products (import tolerances).

6.8. **Proposed safety intervals** U.K.

Safety intervals (that is to say pre-harvest intervals for envisaged uses, or withholding periods or storage periods, in the case of post-harvest uses) shall be set taking into account the pest to be controlled and the results from the residue trial data. These intervals shall last at least one day.

6.9. **Estimation of the potential and actual exposure through diet and other sources** U.K.

When estimating the exposure it shall be born in mind that the risk assessment has to take into account the residue definition established for risk assessment.

Where relevant, the possible presence of pesticide residues arising from sources other than current plant protection uses of active substances (for example use of active substances resulting in common metabolites, use as biocide or veterinary drug), and their aggregate exposure shall be taken into account. In addition, the cumulative exposure to more than one active substance shall, where relevant, be considered.

6.10. **Other studies** U.K.

6.10.1. *Residue level in pollen and bee products* U.K.

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

The objective of these studies shall be to determine the residue in pollen and bee products for human consumption resulting from residues taken up by honeybees from crops at blossom.

The type and conditions of the studies to be performed shall be discussed with the national competent authorities.

## SECTION 7 U.K.

### *Fate and behaviour in the environment*

#### 7.1. Fate and behaviour in soil U.K.

All relevant information on the type and the properties of the soil used in the studies, including pH, organic carbon content, particle size distribution and water holding capacity shall be reported.

The microbial biomass of soils used for laboratory degradation studies shall be determined immediately before the commencement and at the end of the study.

The soils used for degradation, adsorption and desorption or mobility studies shall be representative of the range of agricultural soils typical of the various regions of the Union where use exists or is anticipated.

The soils shall fulfil the following conditions:

- they shall cover a range of organic carbon content, particle size distribution and pH<sub>(preferably CaCl<sub>2</sub>)</sub> values, and
- where on the basis of other information, degradation or mobility are expected to be pH dependent, for example solubility and hydrolysis rate (see points 2.7 and 2.8), they shall cover approximately the following pH<sub>(preferably CaCl<sub>2</sub>)</sub> ranges: 5 to 6, 6 to 7 and 7 to 8.

Soils used shall, wherever possible, be freshly sampled. If use of stored soils is unavoidable, storage shall be carried out for a limited time (at the most three months) under defined and reported conditions, which are adequate to maintain soil microbial viability. Soils stored for longer periods of time may only be used for adsorption/desorption studies.

A soil having extreme characteristics with respect to parameters such as particle size distribution, organic carbon content and pH shall not be used.

Field studies shall be carried out in conditions as close to normal agricultural practice as possible on a range of soils and climatic conditions representative of the areas of use. Weather conditions shall be reported in cases where field studies are conducted.

#### 7.1.1. Route of degradation in soil U.K.

The data and information provided, together with other relevant data and information, shall be sufficient to:

- (a) identify, if possible, the relative importance of the types of processes involved (balance between chemical and biological degradation);
- (b) identify the individual components present which at any time account for more than 10 % of the amount of active substance added, including, if possible, non-extractable residues;

---

*Changes to legislation:* There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

- (c) identify, if possible, the individual components which in at least two sequential measurements, account for more than 5 % of the amount of active substance added;
- (d) identify, if possible, the individual components (> 5 %) for which at the end of the study the maximum of formation is not yet reached;
- (e) identify or characterise, if possible, other individual components present;
- (f) establish the relative proportions of the components present (mass balance); and
- (g) permit the soil residue of concern to which non-target species are or may be exposed, to be defined.

For the purposes of this Section non-extractable residues means chemical species originating from active substances contained in plant protection products used in accordance with good agricultural practice that cannot be extracted by methods which do not significantly change the chemical nature of these residues or the nature of the soil matrix. These non-extractable residues are not considered to include fragments through metabolic pathways leading to natural products.

#### 7.1.1.1. *Aerobic degradation* U.K. *Circumstances in which required*

The pathway or pathways of aerobic degradation shall be reported except where the nature and manner of use of plant protection products containing the active substance precludes soil contamination, such as indoor uses on stored products or brush applied wound healing treatments for trees.

##### *Test conditions*

Studies on the degradation pathway or pathways shall be reported for at least one soil. Oxygen levels shall be maintained at levels that do not restrict micro-organisms ability to metabolise aerobically. If there is reason to believe that the route of degradation is dependent on one or more properties of the soil, such as pH or clay content, the route of degradation shall be reported for at least one additional soil for which dependent properties are different.

Results obtained shall be presented in the form of schematic drawings showing the pathways involved, and in the form of balance sheets which show the distribution of radio-label as a function of time, as between:

- (a) active substance;
- (b) CO<sub>2</sub>;
- (c) volatile compounds other than CO<sub>2</sub>;
- (d) individual identified transformation products referred to in point 7.1.1;
- (e) extractable substances not identified; and
- (f) non-extractable residues in soil.

The investigation of degradation pathways shall include all possible steps to characterise and quantify non-extractable residues formed after 100 days when exceeding 70 % of the applied dose of the active substance. The techniques and methodologies applied shall be selected on a case-by-case basis. A justification shall be provided where the compounds involved are not characterised.

The duration of the study shall be at least 120 days, except where after a shorter period the levels of non-extractable residues and CO<sub>2</sub> are such that they can be extrapolated in a reliable way to

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

100 days. It shall be longer where this is necessary to establish the degradation pathway of the active substance and its metabolites, breakdown or reaction products.

7.1.1.2. *Anaerobic degradation* U.K.  
*Circumstances in which required*

An anaerobic degradation study shall be submitted unless the applicant shows that exposure of the plant protection products containing the active substance to anaerobic conditions is unlikely to occur for the intended uses.

*Test conditions*

Point 7.1.1.1 shall apply as regards test conditions except oxygen levels which shall be minimised as to ensure that micro-organisms metabolise anaerobically.

7.1.1.3. *Soil photolysis* U.K.  
*Circumstances in which required*

A soil photolysis study shall be submitted unless the applicant shows that deposition of the active substance on the soil surface is unlikely to occur or that photolysis is not expected to contribute significantly to the degradation of the active substance in soil for example due to low light absorbance of the active substance.

7.1.2. *Rate of degradation in soil* U.K.

7.1.2.1. *Laboratory studies* U.K.

Laboratory studies on soil degradation shall provide best possible estimates of the time required for degradation of 50 % and 90 % (DegT<sub>50</sub><sub>lab</sub> and DegT<sub>90</sub><sub>lab</sub>) of the active substance, its metabolites, breakdown and reaction products under laboratory conditions.

7.1.2.1.1. *Aerobic degradation of the active substance* U.K.  
*Circumstances in which required*

The rate of degradation in soil shall be reported, except where the nature and manner of use of plant protection products containing the active substance preclude soil contamination such as indoor uses on stored products or brush applied wound healing treatments for trees.

*Test conditions*

Studies on the rate of aerobic degradation of the active substance shall be reported for three soils in addition to the one required under point 7.1.1.1. Reliable DegT<sub>50</sub> and 90 values shall be available for a minimum of four different soils.

The duration of the study shall be at least 120 days. It shall be longer where this is necessary to establish the kinetic formation fractions of the metabolites, breakdown or reaction products. If more than 90 % of the active substance is degraded before the period of 120 days expires, the test duration may be shorter.

In order to assess the influence of temperature on degradation, a calculation with an adequate Q<sub>10</sub> factor or an adequate number of additional studies at a range of temperatures shall be performed.

7.1.2.1.2. *Aerobic degradation of metabolites, breakdown and reaction products* U.K.  
*Circumstances in which required*

Aerobic degradation (DegT<sub>50</sub> and 90 values) from a minimum of three different soils shall be provided for metabolites, breakdown and reaction products which occur in soil if one of the following conditions is fulfilled:

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

- (a) they account for more than 10 % of the amount of active substance added at any time during the studies;
- (b) they account for more than 5 % of the amount of active substance added in at least two sequential measurements;
- (c) the maximum of formation is not reached at the end of the study but accounts for at least 5 % of the active substance at the final measurement;
- (d) all metabolites found in lysimeter studies at annual average concentrations exceed 0.1 µg/L in the leachate.

Studies shall not be required where three DegT50 and 90 values can be reliably determined from the results of the degradation studies where the active substance is applied as test substance.

Test conditions

Test conditions shall be those indicated in Section 7.1.2.1.1 except the test substance applied will be the metabolite, breakdown or reaction product. Studies on metabolites, breakdown and reaction products shall be provided where these are necessary to obtain reliable DegT50 and 90 values for at least three different soils.

#### 7.1.2.1.3. Anaerobic degradation of the active substance U.K.

Circumstances in which required

The rate of anaerobic degradation of the active substance shall be reported where an anaerobic study has to be performed in accordance with point 7.1.1.2.

Test conditions

Anaerobic DegT50 and 90 values for the active substance are needed for the test conditions outlined in point 7.1.1.2.

#### 7.1.2.1.4. Anaerobic degradation of metabolites, breakdown and reaction products U.K.

Circumstances in which required

Anaerobic degradation studies shall be provided for metabolites, breakdown and reaction products which occur in soil if they fulfil one of the following conditions:

- (a) at any time during the studies account for more than 10 % of the amount of active substance added;
- (b) in at least two sequential measurements account for more than 5 % of the amount of active substance added, if feasible;
- (c) at the end of the study the maximum of formation is not yet reached but accounts for at least 5 % of the active substance at the final measurement, if feasible.

The applicant may deviate from such requirement by showing that DegT50 values for metabolites, breakdown and reaction products can be reliably determined from the results of the anaerobic degradation studies with the active substance.

Test conditions

Studies on metabolites, breakdown and reaction products shall be provided for one soil for the test conditions outlined at point 7.1.1.2.

#### 7.1.2.2. Field studies U.K.

##### 7.1.2.2.1. Soil dissipation studies U.K.

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

The soil dissipation studies shall provide estimates of the time required for dissipation of 50 % and 90 % ( $\text{DisT50}_{\text{field}}$  and  $\text{DisT90}_{\text{field}}$ ) and, if possible, of the time required for degradation of 50 % and 90 % ( $\text{DegT50}_{\text{field}}$  and  $\text{DegT90}_{\text{field}}$ ), of the active substance under field conditions. Where relevant, information on metabolites, breakdown and reaction products shall be provided. Circumstances in which required

Such studies shall be conducted for the active substance, its metabolites, breakdown and reaction products if one of the following conditions is fulfilled:

- (a)  $\text{DegT50}_{\text{lab}}$  for active substance,  $\text{DegT50}_{\text{lab}}$  or  $\text{DisT50}_{\text{lab}}$  for metabolites, breakdown and reaction products, in one or more soils determined at 20 °C and at a moisture content of the soil related to a pF value of 2 (suction pressure) is greater than 60 days; or
- (b)  $\text{DegT90}_{\text{lab}}$  for active substance,  $\text{DegT90}_{\text{lab}}$  or  $\text{DisT90}_{\text{lab}}$  for metabolites, breakdown and reaction products, in one or more soils determined at 20 °C and at a moisture content of the soil related to a pF value of 2 (suction pressure) is greater than 200 days.

However, where plant protection products containing the active substance are intended for use in cold climatic conditions, the studies shall be conducted if one of the following conditions is fulfilled:

- (a)  $\text{DegT50}_{\text{lab}}$  for active substance,  $\text{DegT50}_{\text{lab}}$  or  $\text{DisT50}_{\text{lab}}$  for metabolites, breakdown and reaction products, determined at 10 °C and at a moisture content of the soil related to a pF value of 2 (suction pressure) is greater than 90 days; or
- (b)  $\text{DegT90}_{\text{lab}}$  for active substance,  $\text{DegT90}_{\text{lab}}$  or  $\text{DisT90}_{\text{lab}}$  for metabolites, breakdown and reaction products, in one or more soils, determined at 10 °C and at a moisture content of the soil related to a pF value of 2 (suction pressure) is greater than 300 days.

If during field studies metabolites, breakdown and reaction products which are present in laboratory studies are below the lowest technically feasible LOQ, which shall not exceed an equivalent of 5 % (molar basis) of the nominal concentration of active ingredient applied, no additional information on the fate and behaviour of these compounds shall be provided. In those cases, a scientifically valid justification for any discrepancy between laboratory and field appearance of metabolites shall be provided.

Test conditions

Individual studies on a range of representative soils (normally at least four different types at different geographical locations) shall be continued until at least 90% of the amount applied has dissipated from the soil or been transformed to substances that are not the subject of the investigation.

#### 7.1.2.2.2. Soil accumulation studies **U.K.**

Soil accumulation studies shall provide sufficient information to evaluate the possibility of accumulation of residues of the active substance and of metabolites, breakdown and reaction products. The soil accumulation studies shall provide estimates of the time required for dissipation of 50 % and 90 % ( $\text{DisT50}_{\text{field}}$  and  $\text{DisT90}_{\text{field}}$ ) and, if possible, shall provide estimates of the time required for degradation of 50 % and 90 % ( $\text{DegT50}_{\text{field}}$  and  $\text{DegT90}_{\text{field}}$ ), of the active substance under field conditions.

Circumstances in which required

Where on the basis of soil dissipation studies it is established that  $\text{DisT90}_{\text{field}}$ , in one or more soils, is greater than one year and where repeated application is envisaged, whether in the same growing season or in succeeding years, the possibility of accumulation of residues in soil and

---

*Changes to legislation:* There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

the level at which a plateau concentration is achieved shall be investigated except where reliable information can be provided by a model calculation or another appropriate assessment.

Test conditions

Long-term field studies shall be performed on at least two relevant soils at different geographical locations and involve multiple applications.

In absence of guidance being included in the list referred to under point 6 of the introduction, the type and conditions of the study to be performed shall be discussed with the national competent authorities.

### 7.1.3. Adsorption and desorption in soil U.K.

#### 7.1.3.1. Adsorption and desorption U.K.

The information provided, together with other relevant data, shall be sufficient to establish the adsorption coefficient of the active substance and of its metabolites, breakdown and reaction products.

##### 7.1.3.1.1. Adsorption and desorption of the active substance U.K.

Circumstances in which required

Studies on adsorption and desorption of the active substance shall be provided, except where the nature and manner of use of plant protection products containing the active substance preclude soil contamination such as indoor uses on stored products or brush applied wound healing treatments for trees.

Test conditions

Studies on the active substance shall be reported for at least four soils.

Where the batch equilibrium method cannot be applied due to fast degradation, methods such as studies with short equilibration times, QSPR (Quantitative Structure Property Relationship) or the HPLC (High-Performance Liquid Chromatography) method shall be considered as possible alternatives. Where the batch equilibrium method cannot be applied due to weak adsorption, column leaching studies (see point 7.1.4.1) shall be considered as an alternative.

##### 7.1.3.1.2. Adsorption and desorption of metabolites, breakdown and reaction products U.K.

Circumstances in which required

Studies on adsorption and desorption shall be provided for all metabolites, breakdown and reaction products, for which in soil degradation studies one of the following conditions is fulfilled:

- (a) they account for more than 10 % of the amount of active substance added, at any time during the studies;
- (b) they account for more than 5 % of the amount of active substance added in at least two sequential measurements;
- (c) the maximum of formation is not reached at the end of the study but accounts for at least 5 % of the active substance at the final measurement;
- (d) all metabolites found in lysimeter studies at annual average concentrations exceeding 0,1 µg/L in the leachate.

Test conditions

Studies on metabolites, breakdown and reaction products shall be provided for at least three soils.



---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) [View outstanding changes](#)

---

Where the batch equilibrium method cannot be applied due to fast degradation, methods such as studies with short equilibration times, QSPR or the HPLC method shall be considered as an alternative. Where the batch equilibrium method cannot be applied due to weak adsorption, column leaching studies (see point 7.1.4.1) shall be considered as an alternative.

#### 7.1.3.2. *Aged sorption* U.K.

As a higher tier option, information on aged sorption may be provided.

*Circumstances in which required*

The need to carry out a study on aged sorption shall be discussed with the national competent authorities.

*Test conditions*

In absence of guidance being included in the list referred to under point 6 of the introduction, the type and conditions of the study to be performed shall be discussed with the national competent authorities. The influence on the rate of degradation shall also be considered. Aged sorption data shall be compatible with the model in which those values will be used.

#### 7.1.4. *Mobility in soil* U.K.

##### 7.1.4.1. *Column leaching studies* U.K.

###### 7.1.4.1.1. *Column leaching of the active substance* U.K.

Column leaching studies shall provide sufficient data to evaluate the mobility and leaching potential of the active substance.

*Circumstances in which required*

Studies in at least four soils shall be carried out where in the adsorption and desorption studies provided for under point 7.1.2 it is not possible to obtain reliable adsorption coefficient values due to weak adsorption (such as  $K_{oc} < 25$  L/Kg).

###### 7.1.4.1.2. *Column leaching of metabolites, breakdown and reaction products* U.K.

The test shall provide sufficient data to evaluate the mobility and leaching potential of metabolites, breakdown and reaction products.

*Circumstances in which required*

Studies in at least three soils shall be carried out where in the adsorption and desorption studies provided for under point 7.1.2 it is not possible to obtain reliable adsorption coefficient values due to weak adsorption (such as  $K_{oc} < 25$  L/Kg).

#### 7.1.4.2. *Lysimeter studies* U.K.

Lysimeter studies shall be performed, where necessary, to provide information on:

- the mobility in soil,
- the potential for leaching to ground water,
- the potential distribution in soil.

*Circumstances in which required*

The decision whether lysimeter studies are to be carried out, as an experimental outdoor study in the framework of a tiered leaching assessment scheme shall take into account the results of degradation and other mobility studies and the predicted environmental concentrations in groundwater ( $PEC_{GW}$ ), calculated in accordance with the provisions of Section 9 of Part A of the Annex to Regulation (EU) No 284/2013. The type and conditions of the study to be performed shall be discussed with the national competent authorities.

---

*Changes to legislation:* There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) [View outstanding changes](#)

---

### *Test conditions*

Studies shall cover the realistic worst case situation, and the duration necessary for observation of potential leaching, taking into account the soil type, climatic conditions, the application rate and the frequency and period of application.

Water percolating from soil columns shall be analysed at suitable intervals, while residues in plant material shall be determined at harvest. Residues in the soil profile in at least five layers shall be determined on termination of experimental work. Intermediate sampling shall be avoided, since removal of plants (except for harvesting in accordance with normal agricultural practice) and soil influence the leaching process.

Precipitation, soil and air temperatures shall be recorded at regular intervals, at least on a weekly base.

The depth of the lysimeters shall be at least 100 cm. The soil cores shall be undisturbed. Soil temperatures shall be similar to those pertaining in the field. Where necessary, supplementary irrigation shall be provided to ensure optimal plant growth and to ensure that the quantity of percolation water is similar to that in the regions for which authorisation is sought. When during the study the soil has to be disturbed for agricultural reasons it shall not be disturbed deeper than 25 cm.

#### 7.1.4.3. *Field leaching studies* U.K.

Field leaching studies shall be performed, where necessary, to provide information on:

- the mobility in soil,
- the potential for leaching to ground water,
- the potential distribution in soil.

#### *Circumstances in which required*

The decision whether field leaching studies are to be carried out, as an experimental outdoor study in the framework of a tiered leaching assessment scheme shall take into account the results of degradation and other mobility studies and the predicted environmental concentrations in groundwater (PEC<sub>GW</sub>), calculated in accordance with the provisions of Section 9 of Part A of the Annex to Regulation (EU) No 284/2013. The type and conditions of the study to be performed shall be discussed with the national competent authorities.

### *Test conditions*

Studies shall cover the realistic worst case situation, taking into account the soil type, climatic conditions, the application rate and the frequency and period of application.

Water shall be analysed at suitable intervals. Residues in the soil profile in at least five layers shall be determined on termination of experimental work. Intermediate sampling of plant and soil material shall be avoided (except for harvesting in accordance with normal agricultural practice), since removal of plants and soil influence the leaching process.

Precipitation, soil and air temperatures shall be recorded at regular intervals (at least on a weekly base).

Information on the groundwater table in the experimental fields shall be submitted. Depending on the experimental design, a detailed hydrological characterisation of the test field shall be carried out. If soil cracking is observed during the study this shall be fully described.

Attention shall be given to the number and the location of water collection devices. The placement of these devices in the soil shall not result in preferential flow paths.

## 7.2. **Fate and behaviour in water and sediment** U.K.

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) [View outstanding changes](#)

---

The information provided, taken together with that provided for one or more plant protection products containing the active substance, and other relevant information, shall be sufficient to establish or permit estimation of:

- (a) persistence in water systems (bottom sediment and water, including suspended particles);
- (b) the extent to which water and sediment organisms are at risk;
- (c) potential for contamination of surface water and groundwater.

7.2.1. *Route and rate of degradation in aquatic systems (chemical and photochemical degradation)* **U.K.**

The data and information provided, together with other relevant data and information, shall be sufficient to:

- (a) identify the relative importance of the types of processes involved (balance between chemical and biological degradation);
- (b) where possible, identify the individual components present;
- (c) establish the relative proportions of the components present and their distribution as between water, including suspended particles, and sediment; and
- (d) permit the residue of concern to which non-target species are or may be exposed, to be defined.

7.2.1.1. *Hydrolytic degradation* **U.K.**  
*Circumstances in which required*

The hydrolysis rate of purified active substances shall be determined and reported at 20 °C or 25 °C. Studies on hydrolytic degradation shall also be performed for degradation and reaction products which account at any time for more than 10 % of the amount of active substance added in the hydrolysis study, unless sufficient information on their degradation is available from the test performed with the active substance. No additional hydrolysis information on degradates shall be required if they are considered to be stable in water.

*Test conditions*

The hydrolysis rate for pH 4, 7 and 9 under sterile conditions in the absence of light shall be determined and reported at 20 °C or 25 °C. For active substances that are stable or have a low rate of hydrolysis at 20-25 °C, the rate shall be determined at 50 °C, or another temperature above 50 °C. If degradation is observed at 50 °C or above, the degradation rate at at least three other temperatures shall be determined and an Arrhenius plot shall be constructed to permit an estimate to be made of hydrolysis rate at 20 °C and 25 °C. The identity of hydrolysis products formed and the rate constants observed, shall be reported. The estimated DegT50 values shall be reported for 20 °C or 25 °C.

7.2.1.2. *Direct photochemical degradation* **U.K.**  
*Circumstances in which required*

For compounds with a molar (decadic) absorption coefficient ( $\epsilon$ )  $> 10 \text{ L} \times \text{mol}^{-1} \times \text{cm}^{-1}$  at a wavelength ( $\lambda$ )  $\geq 295 \text{ nm}$  direct phototransformation of purified active substances shall be determined and reported unless the applicant shows that contamination of surface water will not occur.

Studies on direct photochemical degradation shall also be performed for metabolites, breakdown and reaction products which account at any time for more than 10 % of the amount of active

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

substance added in the photolysis study, unless sufficient information on their degradation is available from the test performed with the active substance.

No additional photolysis information on degradates shall be required if they are considered to be stable under photolytic conditions.

#### *Test conditions*

The direct phototransformation in purified, (for example distilled) buffered water using artificial light under sterile conditions, if necessary using a solubiliser, shall be determined and reported. In the first theoretical step a maximum possible photolysis rate shall be estimated based on the molar extinction coefficient of the active substance. If photolysis is considered to be a potentially significant degradation pathway, photolysis experiments for range finding shall be carried out (tier 2). Determination of quantum yield and direct photolysis route/rate (tiers 3 and 4) shall be carried out for active substances where tier 2 indicates significant photolysis. The identity of breakdown products formed which exceed 10 % of the applied test substance at any time during the study, a mass balance to account for at least 90 % of the applied radioactivity, as well as photochemical half-life (DT50) shall be reported.

#### 7.2.1.3. *Indirect photochemical degradation* U.K.

##### *Circumstances in which required*

Studies on indirect photochemical degradation may be submitted where there are indications from other available data that route and rate of degradation in the water phase can be significantly influenced by indirect photodegradation.

##### *Test conditions*

Studies shall be performed in an aqueous system containing organic (humic substances) and inorganic (salts) compounds in a composition that is typical for natural surface waters.

#### 7.2.2. *Route and rate of biological degradation in aquatic systems* U.K.

##### 7.2.2.1. *'Ready biodegradability'* U.K.

##### *Circumstances in which required*

The 'ready biodegradability' test shall be performed. If no such test is provided, the active substance shall by default be considered not 'readily biodegradable'.

##### 7.2.2.2. *Aerobic mineralisation in surface water* U.K.

The data and information provided, together with other relevant data and information, shall be sufficient to:

- (a) identify individual components present, which at any time account for more than 10 % of the amount of active substance added, including, where possible, non-extractable residues;
- (b) identify individual components present, which account for more than 5 % of the amount of active substance added in at least two sequential measurements, where possible;
- (c) identify individual components (> 5 %) for which at the end of the study the maximum of formation is not yet reached, where possible;
- (d) identify or characterise, where possible, other individual components;
- (e) establish, where relevant, the relative proportions of the components (mass balance); and

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

- (f) permit, where relevant, the sediment residue of concern and to which non-target species are or may be exposed, to be defined.

*Circumstances in which required*

Studies on aerobic mineralisation in surface water shall be provided unless the applicant shows that contamination of open water (freshwater, estuarine and marine) will not occur.

*Test conditions*

The rate of degradation and the pathway or pathways shall be reported either for a 'pelagic' test system or for a 'suspended sediment' system. Where relevant, additional test systems, which differ with respect to organic carbon content, texture or pH shall be used.

Results obtained shall be presented in the form of schematic drawings showing the pathways involved, and in the form of balance sheets which show the distribution of radio-label in water and, where relevant, sediment as a function of time, as between:

- (a) active substance;
- (b) CO<sub>2</sub>;
- (c) volatile compounds other than CO<sub>2</sub>; and
- (d) individual identified transformation products.

The duration of the study shall not exceed 60 days unless the semi-continuous procedure with periodical renewal of the test suspension is applied. However, the period for the batch test may be extended to a maximum of 90 days, if the degradation of the test substance has started within the first 60 days.

7.2.2.3. *Water/sediment study* **U.K.**

The information provided, together with other relevant information, shall be sufficient to:

- (a) identify individual components present which at any time account for more than 10 % of the amount of active substance added, including, where possible, non-extractable residues;
- (b) identify individual components present which account for more than 5 % of the amount of active substance added in at least two sequential measurements, where possible;
- (c) identify individual components (> 5 %) for which at the end of the study the maximum of formation is not yet reached, where possible;
- (d) identify or characterise, where possible, also other individual components present;
- (e) establish the relative proportions of the components (mass balance); and
- (f) define the sediment residue of concern, to which non-target species are or may be exposed.

Where a reference is made to non-extractable residues these shall be defined as chemical species originating from active substances used in accordance with good agricultural practice that cannot be extracted by methods which do not significantly change the chemical nature of these residues or the nature of the sediment matrix. These non-extractable residues are not considered to include fragments through metabolic pathways leading to natural products.

*Circumstances in which required*

The water/sediment study shall be reported unless the applicant shows that contamination of surface water will not occur.

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

### *Test conditions*

The degradation pathway or pathways shall be reported for two water/sediment systems. The two sediments selected shall differ with respect to organic carbon content and texture, and where relevant, with respect to pH.

Results obtained shall be presented in the form of schematic drawings showing the pathways involved, and in the form of balance sheets which show the distribution of radio-label in water and sediment as a function of time, as between:

- (a) active substance;
- (b) CO<sub>2</sub>;
- (c) volatile compounds other than CO<sub>2</sub>;
- (d) individual identified transformation products;
- (e) extractable substances not identified; and
- (f) non-extractable residues in sediment.

The duration of the study shall be at least 100 days. It shall be longer where this is necessary to establish the degradation pathway and water/sediment distribution pattern of the active substance and its metabolites, breakdown and reaction products. If more than 90 % of the active substance is degraded before the period of 100 days expires, the test duration may be shorter.

The degradation pattern of potentially relevant metabolites occurring within the water/sediment study shall be established either by extension of the study for the active substance, or by conducting a separate study for potentially relevant metabolites.

#### *7.2.2.4. Irradiated water/sediment study* U.K.

The same general provisions as provided under point 7.2.2.3 apply.

##### *Circumstances in which required*

If photochemical degradation is of importance a water/sediment study under influence of a light/dark regime may additionally be provided.

##### *Test conditions*

The type and conditions of the study to be performed shall be discussed with the national competent authorities.

#### *7.2.3. Degradation in the saturated zone* U.K.

The type and conditions of the study to be performed shall be discussed with the national competent authorities.

### **7.3. Fate and behaviour in air** U.K.

#### *7.3.1. Route and rate of degradation in air* U.K.

The vapour pressure of purified active substance, as provided under point 2.2, shall be reported. An estimate of the half-life in the upper atmosphere of the active substance and any volatile metabolites, breakdown and reaction products, formed in soil or natural water systems, shall be calculated and reported.

Estimates of active substance upper atmospheric half-lives, based on monitoring data shall also be calculated, when monitoring data that enable this to be done, are available.

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

### 7.3.2. *Transport via air* U.K.

The type and conditions of the study to be performed shall be discussed with the national competent authorities.

#### *Circumstances in which required*

If the trigger for volatilisation,  $V_p = 10^{-5}$  Pa (plant) or  $10^{-4}$  Pa (soil) at a temperature of 20 °C, is exceeded and (drift) mitigation measures are required, data from confined experiments may be reported.

If needed, experiments to determine deposition following volatilisation may be provided.

The national competent authorities shall be consulted to decide whether this information is necessary.

### 7.3.3. *Local and global effects* U.K.

For substances that are applied in high amounts, the following effects shall be considered:

- global warming potential (GWP);
- ozone depleting potential (ODP);
- photochemical ozone creation potential (POCP);
- accumulation in the troposphere;
- acidification potential (AP);
- eutrophication potential (EP).

## 7.4. **Definition of the residue** U.K.

### 7.4.1. *Definition of the residue for risk assessment* U.K.

The residue definition relevant for risk assessment for each compartment shall be defined to include all components (active substance, metabolites, breakdown and reaction products) that were identified in accordance with the criteria referred to in this Section.

The chemical composition of residues occurring in soil, groundwater, surface water (freshwater, estuarine and marine), sediment and air, resulting from use, or proposed use, of a plant protection product containing the active substance, shall be taken into account.

### 7.4.2. *Definition of the residue for monitoring* U.K.

Considering the results of toxicological and ecotoxicological testing, the residue for monitoring shall be defined to include those components from the definition of the residue for risk assessment, which are considered relevant when assessing the results in those tests.

## 7.5. **Monitoring data** U.K.

Available monitoring data concerning fate and behaviour of the active substance and relevant metabolites, breakdown and reaction products in soil, groundwater, surface water, sediment and air shall be reported.

## SECTION 8 U.K.

### *Ecotoxicological studies*

#### **Introduction**

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

1. All available biological data and information which is relevant to the assessment of the ecotoxicological profile of the active substance shall be reported. This shall include all potentially adverse effects found during routine ecotoxicological investigations. Where required by the national competent authorities, additional studies, necessary to investigate the probable mechanisms involved and to assess the significance of these effects, shall be carried out and reported on.
2. The ecotoxicological assessment shall be based on the risk that the proposed active substance used in a plant protection product poses to non-target organisms. In carrying out a risk assessment, toxicity shall be compared with exposure. The general term for the output from such a comparison is 'risk quotient' or RQ. It shall be noted that RQ can be expressed in several ways, for example, toxicity:exposure ratio (TER) and as a hazard quotient (HQ). The applicant shall take into account the information from Sections 2, 5, 6, 7 and 8.
3. It may be necessary to conduct separate studies for metabolites, breakdown or reaction products derived from the active substance where non-target organisms may be exposed and where their effects cannot be evaluated by the available results relating to the active substance. Before such studies are performed, the applicant shall take into account the information from Sections 5, 6 and 7. **U.K.**

Studies undertaken shall permit characterisation of metabolites, breakdown or reaction products as being significant or not, and reflect the nature and extent of the effects judged likely to arise.

4. In the case of certain study types, the use of a representative plant protection product instead of the active substance as manufactured may be more appropriate, for example testing of non-target arthropods, bees, earthworm reproduction, soil micro-flora and non-target terrestrial plants. In the case of certain plant protection product types (for example encapsulated suspension) testing with the plant protection product is more appropriate to testing with active substance when these organisms will be exposed to the plant protection product itself. For plant protection products where the active substance is always intended to be used together with a safener and/or synergist and/or in conjunction with other active substances, plant protection products containing these additional substances shall be used.
5. The potential impact of the active substance on biodiversity and the ecosystem, including potential indirect effects via alteration of the food web, shall be considered.
6. For those guidelines which allow for the study to be designed to determine an effective concentration ( $EC_x$ ), the study shall be conducted to determine an  $EC_{10}$ ,  $EC_{20}$  and  $EC_{50}$ , when required, along with corresponding 95 % confidence intervals. If an  $EC_x$  approach is used, a no observed effect concentration (NOEC) shall still be determined. **U.K.**

Existing acceptable studies that have been designed to generate a NOEC shall not be repeated. An assessment of the statistical power of the NOEC derived from those studies shall be carried out.

7. All of the aquatic toxicity data shall be used when developing a proposal for environmental quality standards (Annual Average EQS, AA-EQS; Maximum Acceptable Concentration EQS, MAC-EQS). The methodology for derivation of these endpoints is outlined in the 'Technical Guidance for Deriving Environmental Quality Standards'<sup>(14)</sup> for the Water Framework Directive 2000/60/EC of the European Parliament and of the Council<sup>(15)</sup>.



---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) [View outstanding changes](#)

---

8. In order to facilitate the assessment of the significance of test results obtained, including the estimation of intrinsic toxicity and the factors affecting toxicity, the same strain (or recorded origin) of each relevant species shall, where possible, be used in the various toxicity tests specified.
9. Higher tier studies shall be designed and data analysed using suitable statistical methods. Full details of the statistical methods shall be reported. Where appropriate and necessary, higher tier studies shall be supported by chemical analysis to verify exposure has occurred at an appropriate level.
10. Pending the validation and adoption of new studies and of a new risk assessment scheme, existing protocols shall be used to address the acute and chronic risk to bees, including those on colony survival and development, and the identification and measurement of relevant sub-lethal effects in the risk assessment.

#### 8.1. **Effects on birds and other terrestrial vertebrates** U.K.

For all avian and mammalian feeding studies, average achieved dose shall be reported, including where possible the dose in mg substance/kg body weight. Where dosing via the diet is utilised, the active substance shall be distributed uniformly in the diet.

##### 8.1.1. *Effects on birds* U.K.

##### 8.1.1.1. *Acute oral toxicity to birds* U.K.

The acute oral toxicity of the active substance to birds shall be determined.  
*Circumstances in which required*

The effects of the active substance on birds shall be investigated except where the substance is included in plant protection products used, for example, in enclosed spaces and wound healing treatments where birds will experience neither direct nor secondary exposure.

##### *Test conditions*

A study shall be provided establishing the acute oral toxicity (LD<sub>50</sub>) of the active substance. Where available, the study shall be performed with a quail species (Japanese quail (*Coturnix coturnix japonica*) or Bobwhite quail (*Colinus virginianus*)), since regurgitation is rare in these species. The study shall provide, where possible, LD<sub>50</sub> values. The lethal threshold dose, time courses of response and recovery, the LD<sub>10</sub> and LD<sub>20</sub> shall be reported together with the no observed effect level (NOEL) and gross pathological findings. Where LD<sub>10</sub> and LD<sub>20</sub> cannot be estimated, an explanation shall be provided. Study design shall be optimised for the achievement of an accurate LD<sub>50</sub>.

The highest dose used in tests shall not exceed 2 000 mg substance/kg body weight, however, depending on the expected exposure levels in the field following the intended use of the compound, higher doses may be required.

##### 8.1.1.2. *Short-term dietary toxicity to birds* U.K.

A study shall be provided establishing the short-term dietary toxicity. LC<sub>50</sub> values, lowest lethal concentration (LLC), where possible, NOEC values, time courses of response and recovery and pathological findings shall be reported in such study. LC<sub>50</sub> and NOEC values shall be converted to daily dietary dose (LD<sub>50</sub>) expressed in mg substance/kg bw/day and NOEL expressed in mg substance/kg bw/day.

##### *Circumstances in which required*

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

A study on the dietary (five-day) toxicity of the active substance to birds shall only be required where the mode of action or results from mammalian studies indicate a potential for the dietary LD<sub>50</sub> measured by the short-term dietary toxicity study to be lower than the LD<sub>50</sub> based on an acute oral study. The short-term dietary toxicity test shall not be conducted for any other purpose than to determine intrinsic toxicity through dietary exposure, unless a justification of the need to do so is supplied.

*Test conditions*

The test species shall be the same as tested under point 8.1.1.1.

8.1.1.3. *Sub-chronic and reproductive toxicity to birds* U.K.

A study shall be provided establishing the sub-chronic and reproductive toxicity of the substance to birds. The EC<sub>10</sub> and EC<sub>20</sub> shall be reported. Where they cannot be estimated, an explanation shall be provided together with the NOEC expressed in mg substance/kg bw/day.

*Circumstances in which required*

The sub-chronic and reproductive toxicity of the active substance to birds shall be investigated, unless the applicant shows that exposure of adults, or exposure of nest sites during the breeding season is unlikely to occur. Such a justification shall be supported by information showing that no exposure or delayed effects will occur during the breeding season.

*Test conditions*

The study shall be conducted on the same species as tested under point 8.1.1.1.

8.1.2. *Effects on terrestrial vertebrates other than birds* U.K.

The following information shall be derived from the mammalian toxicological assessment based on the studies referred to in Section 5.

8.1.2.1. *Acute oral toxicity to mammals* U.K.

The acute oral toxicity of the active substance to mammals shall be determined and the LD<sub>50</sub> expressed mg substance/kg bw/day.

*Circumstances in which required*

The effects of the active substance on mammals shall be investigated except when the substance is included in plant protection products used, for example, in enclosed spaces and wound healing treatments where mammals will experience neither direct nor secondary exposure.

8.1.2.2. *Long-term and reproductive toxicity to mammals* U.K.

*Circumstances in which required*

The reproductive toxicity of the active substance to mammals shall be investigated, unless a justification is provided by the applicant showing that exposure of adults, during the breeding season is unlikely to occur. Such a justification shall be supported by information showing that no exposure or delayed effects will occur during the breeding season.

The most sensitive ecotoxicologically relevant mammalian long-term toxicological endpoint (NOAEL) expressed as mg substance/kg bw/day shall be reported. The EC<sub>10</sub> and EC<sub>20</sub> shall be reported together with the NOEC expressed in mg substance/kg bw/day. Where EC<sub>10</sub> and EC<sub>20</sub> cannot be estimated an explanation shall be provided.

8.1.3. *Active substance bioconcentration in prey of birds and mammals* U.K.

For active substances with a log Pow > 3, an assessment of the risk posed by bioconcentration of the substance in the prey of birds and mammals shall be provided.

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

#### 8.1.4. *Effects on terrestrial vertebrate wildlife (birds, mammals, reptiles and amphibians)* U.K.

Available and relevant data, including data from the open literature for the active substance of concern, regarding the potential effects to birds, mammals, reptiles and amphibians (see point 8.2.3) shall be presented and taken into account in the risk assessment.

#### 8.1.5. *Endocrine disrupting properties* U.K.

Consideration shall be given to whether the active substance is a potential endocrine disruptor according to Union or internationally agreed guidelines. This may be done in consulting the mammalian toxicology section (see Section 5). In addition, other available information on toxicity profile and mode of action shall be taken into account. If as a result of this assessment, the active substance is identified as a potential endocrine disruptor, the type and conditions of the study to be performed shall be discussed with the national competent authorities.

### 8.2. **Effects on aquatic organisms** U.K.

Reports of the tests referred to in points 8.2.1, 8.2.4 and 8.2.6 shall be submitted for every active substance and supported with analytical data on concentrations of the substance in the test media.

When aquatic toxicity studies are conducted with a poorly soluble substance, limit concentrations lower than 100 mg substance/L may be acceptable, however precipitation of the substance in the test medium shall be avoided and a solubiliser, auxiliary solvent or dispersing agent shall be used when appropriate. Testing using the plant protection product may be required by the national competent authorities if no biological effects occur at the solubility limit of the active substance.

Toxicity endpoints (such as LC<sub>50</sub>, EC<sub>10</sub>, EC<sub>20</sub>, EC<sub>50</sub> and NOEC) shall be calculated on the basis of nominal or mean/initial measured concentrations.

#### 8.2.1. *Acute toxicity to fish* U.K.

A study shall be provided on the acute toxicity to fish (LC<sub>50</sub>) and details of observed effects.  
*Circumstances in which required*

A test on rainbow trout (*Oncorhynchus mykiss*) shall be carried out.  
*Test conditions*

The acute toxicity of the active substance to fish shall be determined. In order to minimise fish testing, a threshold approach to acute toxicity testing on fish shall be considered. An acute toxicity fish limit test shall be conducted at 100 mg substance/L or at an appropriate concentration selected from aquatic endpoints (points 8.2.4, 8.2.6 or 8.2.7) following consideration of the threshold exposure. When mortality is detected in the fish limit test an acute fish dose-response toxicity study shall be required to determine an LC<sub>50</sub> for use in the risk assessment conducted in accordance with the relevant risk quotient analysis (see point 2 of the introduction of this Section).

#### 8.2.2. *Long-term and chronic toxicity to fish* U.K. *Circumstances in which required*

A long-term or chronic toxicity study on fish shall be provided for all active substances where exposure of surface water is likely and the substance is deemed to be stable in water, that is to say there is less than 90 % loss of the original substance over 24 hours via hydrolysis (see point

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

7.2.1.1). A fish early life stage study shall be provided in these circumstances. However, if a fish full life cycle study is provided an early life stage study shall not be required.

#### 8.2.2.1. *Fish early life stage toxicity test* U.K.

A fish early life stage toxicity test shall determine effects on development, growth and behaviour, and details of observed effects on fish early life stages. The EC<sub>10</sub> and EC<sub>20</sub> shall be reported together with the NOEC. Where EC<sub>10</sub> and EC<sub>20</sub> cannot be estimated, an explanation shall be provided.

#### 8.2.2.2. *Fish full life cycle test* U.K.

A fish full life cycle test shall provide information on the effects on reproduction of the parental and the viability of the filial generation. The EC<sub>10</sub> and EC<sub>20</sub> shall be reported together with the NOEC.

For active substances that are not considered as potential endocrine disruptors, a fish full life cycle test may be required depending upon the persistence and bioaccumulative potential of the substance.

For active substances that fulfil the screening criteria on either of the fish screening assays, or for which there are other indications of endocrine disruption (see point 8.2.3), appropriate additional endpoints shall be included in the test and discussed with the national competent authorities.

#### *Test conditions*

Studies shall be designed to reflect concerns identified through lower tier testing, mammalian and bird toxicology studies and other information. The exposure regime shall be selected accordingly, taking account of the rates of application proposed.

#### 8.2.2.3. *Bioconcentration in fish* U.K.

The test on bioconcentration in fish shall provide the steady-state bioconcentration factors, uptake rate constants and depuration rate constants, incomplete excretion, metabolites formed in fish and, if available, information on organ-specific accumulation.

All data shall be provided with confidence limits for each test substance. Bioconcentration factors shall be expressed as a function of both total wet weight and of the lipid content of the fish.

Data provided under point 6.2.5 shall be considered, where relevant, in addressing this point.

#### *Circumstances in which required*

The bioconcentration of the substance, shall be assessed where:

- the log Pow is greater than 3 (see point 2.7) or there are other indications of bioconcentration, and
- the substance is considered stable, that is to say there is less than 90 % loss of the original substance over 24 hours via hydrolysis (see point 7.2.1.1).

#### 8.2.3. *Endocrine disrupting properties* U.K.

Consideration shall be given to whether the active substance is a potential endocrine disruptor in aquatic non-target organisms according to Union or internationally agreed guidelines. In addition, other available information on toxicity profile and mode of action shall be taken into account. If as a result of this assessment, the active substance is identified as a potential endocrine disruptor, the type and conditions of the studies to be performed shall be discussed with the national competent authorities.

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

#### 8.2.4. Acute toxicity to aquatic invertebrates **U.K.** Circumstances in which required

The acute toxicity shall be determined for a *Daphnia* species (preferably *Daphnia magna*). For active substances with an insecticidal mode of action or which show insecticidal activity a second species shall be tested, for example Chironomid larvae or Mysid shrimps (*Americamysis bahia*).

##### 8.2.4.1. Acute toxicity to *Daphnia magna* **U.K.**

A test shall be provided on the 24- and 48-hour acute toxicity of the active substance to *Daphnia magna*, expressed as the median effective concentration (EC<sub>50</sub>) for immobilisation, and where possible, the highest concentration causing no immobilisation.

###### *Test conditions*

Concentrations up to 100 mg substance/L shall be tested. A limit test at 100 mg substance/L may be performed where the results of a range finding test indicate that no effects are to be expected.

##### 8.2.4.2. Acute toxicity to an additional aquatic invertebrate species **U.K.**

A test shall be provided on the 24- and 48-hour acute toxicity of the active substance to an additional aquatic invertebrate species, expressed as the median effective concentration (EC<sub>50</sub>) for immobilisation, and where possible, the highest concentration causing no immobilisation.

###### *Test conditions*

The conditions as set out in point 8.2.4.1 shall apply.

#### 8.2.5. Long-term and chronic toxicity to aquatic invertebrates **U.K.** Circumstances in which required

A long-term or chronic toxicity study on aquatic invertebrates shall be provided for all active substances where exposure of surface water is likely and the substance is deemed to be stable in water, that is to say there is less than 90 % loss of the original substance over 24 hours via hydrolysis (see point 7.2.1.1).

A chronic toxicity study shall be submitted on one aquatic invertebrate species. If acute toxicity tests have been conducted on two aquatic invertebrate species the acute endpoints shall be taken into account (see point 8.2.4) in order to determine the appropriate species to be tested in the chronic toxicity study.

If the active substance is an insect growth regulator, an additional study on chronic toxicity shall be carried out using relevant non-crustacean species such as *Chironomus* spp.

##### 8.2.5.1. Reproductive and development toxicity to *Daphnia magna* **U.K.**

The aim of the test on reproductive and development toxicity to *Daphnia magna* shall be to measure adverse effects such as immobilisation and loss of reproductive capacity and to provide details of observed effects. The EC<sub>10</sub>, and EC<sub>20</sub> shall be reported together with the NOEC. Where EC<sub>10</sub> and EC<sub>20</sub> cannot be estimated, an explanation shall be provided.

##### 8.2.5.2. Reproductive and development toxicity to an additional aquatic invertebrate species **U.K.**

The test on reproductive and development toxicity to an additional aquatic invertebrate species shall measure adverse effects such as immobilisation and loss of reproductive capacity and provide details of observed effects. The EC<sub>10</sub>, and EC<sub>20</sub> shall be reported together with the NOEC. Where EC<sub>10</sub> and EC<sub>20</sub> cannot be estimated, an explanation shall be provided.

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

#### 8.2.5.3. *Development and emergence in *Chironomus riparius** U.K.

The active substance shall be applied to the water overlying sediment and effects on survival and development of *Chironomus riparius*, including effects on emergence of adults, shall be measured to provide endpoints for those substances considered to interfere with insect moulting hormones or that have other effects on insect growth and development. The EC<sub>10</sub> and EC<sub>20</sub> shall be reported together with the NOEC.

##### *Test conditions*

Concentrations of active substance in the overlying water and the sediment shall be measured to establish an EC<sub>10</sub>, EC<sub>20</sub> and a NOEC. The active substance shall be measured often enough to allow the calculation of test endpoints based on nominal as well as time-weighted average concentrations.

#### 8.2.5.4. *Sediment dwelling organisms* U.K.

When accumulation of an active substance in aquatic sediment is indicated or predicted by environmental fate studies, the impact on a sediment-dwelling organism shall be assessed. The chronic risk to *Chironomus riparius* or *Lumbriculus* spp. shall be determined. An appropriate alternative test species may be used where a recognised guideline is available. The active substance shall be applied to either the water or the sediment phase of a water/sediment system and the test shall take account of the major route of exposure. The key endpoint from the study shall be presented in terms of mg substance/kg dry sediment and mg substance/L water and the EC<sub>10</sub> and EC<sub>20</sub> shall be reported together with the NOEC.

##### *Test conditions*

Concentrations of active substance in the overlying water and the sediment shall be measured to establish an EC<sub>10</sub>, EC<sub>20</sub> and a NOEC.

#### 8.2.6. *Effects on algal growth* U.K.

##### *Circumstances in which required*

Testing shall be carried out on one green alga (such as *Pseudokirchneriella subcapitata*, synonym *Selenastrum capricornutum*).

For active substances that exhibit herbicidal activity a test on a second species from a different taxonomic group shall be performed such as a diatom, for example *Navicula pelliculosa*.

The EC<sub>10</sub>, EC<sub>20</sub>, EC<sub>50</sub> and corresponding NOEC values shall be provided.

##### 8.2.6.1. *Effects on growth of green algae* U.K.

A test shall be provided establishing EC<sub>10</sub>, EC<sub>20</sub>, EC<sub>50</sub> for green algae and corresponding NOEC values for algal growth rate and yield, based on measurements of biomass or surrogate measurement variables.

##### *Test conditions*

Concentrations up to 100 mg substance/L shall be tested. A limit test at 100 mg substance/L may be performed when results of a range-finding test indicate that no effects are to be expected at lower concentrations.

##### 8.2.6.2. *Effects on growth of an additional algal species* U.K.

A test shall be provided establishing EC<sub>10</sub>, EC<sub>20</sub>, EC<sub>50</sub> for an additional algal species and corresponding NOEC values for algal growth rate and yield, based on measurements of biomass (or surrogate measurement variables).

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

### *Test conditions*

The test conditions as set out in point 8.2.6.1 shall apply.

#### 8.2.7. *Effects on aquatic macrophytes* U.K.

A test shall be provided establishing EC<sub>10</sub>, EC<sub>20</sub>, EC<sub>50</sub> and corresponding NOEC values for *Lemna* species growth rate and yield, based on measurements of number of fronds and at least one additional measurement variable (dry weight, fresh weight or frond area).

For other species of aquatic macrophytes, a test shall provide sufficient information to evaluate impact on aquatic plants and provide EC<sub>10</sub>, EC<sub>20</sub>, EC<sub>50</sub> and corresponding NOEC values based on measurement of appropriate biomass parameters.

#### *Circumstances in which required*

A laboratory test with *Lemna* species shall be performed for herbicides and plant growth regulators and for substances where there is evidence from information submitted under point 8.6 of Part A of this Annex or point 10.6 of Part A of the Annex to Regulation (EU) No 284/2013 that the test substance has herbicidal activity. Additional testing may be required by the national competent authorities on other macrophyte species depending on the mode of action of the substance, or if clear indications of higher toxicity are apparent to dicotyledonous (for example auxin inhibitor, broad leaf herbicides) or other monocotyledonous (for example grass herbicides) plant species from efficacy or terrestrial non-target plants tests (see point 8.6 of Part A of this Annex and point 10.6 of Part A of the Annex to Regulation (EU) No 284/2013).

Additional aquatic macrophyte species tests may be undertaken on a dicotyledonous species, such as *Myriophyllum spicatum*, *Myriophyllum aquaticum* or a monocotyledonous species, such as aquatic grass *Glyceria maxima*, as appropriate. The need to perform such studies shall be discussed with the national competent authorities.

#### *Test conditions*

Concentrations up to 100 mg substance/L shall be tested. A limit test at 100 mg substance/L may be performed when results of a range-finding test indicate that no effects are to be expected.

#### 8.2.8. *Further testing on aquatic organisms* U.K.

Further studies on aquatic organisms may be conducted to refine the identified risk and shall provide sufficient information and data to evaluate potential impact on aquatic organisms under field conditions.

Studies undertaken may take the form of additional species testing, modified exposure testing, microcosm or mesocosm studies.

#### *Circumstances in which required*

The need to perform such studies shall be discussed with the national competent authorities.

#### *Test conditions*

The type and conditions of the study to be performed shall be discussed with the national competent authorities.

#### 8.3. **Effect on arthropods** U.K.

##### 8.3.1. *Effects on bees* U.K.

Effects on bees shall be assessed and the risk evaluated, including the risk deriving from residues of the active substance or its metabolites in nectar, pollen and water, including guttation. Reports of the tests referred to in points 8.3.1.1, 8.3.1.2 and 8.3.1.3 shall be submitted, except where plant

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

protection products containing the active substance are for exclusive use in situations where bees are not likely to be exposed such as:

- (a) food storage in enclosed spaces;
- (b) non-systemic preparations for application to soil, except granules;
- (c) non-systemic dipping treatments for transplanted crops and bulbs;
- (d) wound sealing and healing treatments;
- (e) non systemic rodenticidal baits;
- (f) use in greenhouses without bees as pollinators.

For seed treatments the risk from drift of dust during drilling of the treated seed shall be taken into account. As regards granules and slug pellets the risk from drift of dust during application shall be taken into account. If an active substance is systemic and to be used on seeds, bulbs, roots, applied directly to soil, irrigation water, or applied directly to or into the plant, for example by spraying or stem injection, the risk to bees foraging those plants shall be assessed, including the risk deriving from residues of the plant protection product in nectar, pollen and water, including guttation.

Where bees are likely to be exposed, testing by both acute (oral and contact) and chronic toxicity, including sub-lethal effects, shall be conducted.

Where exposure of bees to residues in nectar, pollen or water resulting from systemic properties of the active substance may occur and where the acute oral toxicity is  $< 100 \mu\text{g}/\text{bee}$  or a considerable toxicity for larvae occurs, residues concentrations in these matrices shall be provided and the risk assessment shall be based on a comparison of the relevant endpoint with those residue concentrations. If this comparison indicates that an exposure to toxic levels cannot be excluded, effects shall be investigated with higher tier tests.

#### 8.3.1.1. Acute toxicity to bees **U.K.**

Where bees are likely to be exposed, testing for acute oral and contact toxicity shall be performed.

##### 8.3.1.1.1. Acute oral toxicity **U.K.**

A test for acute oral toxicity shall be provided establishing the acute  $\text{LD}_{50}$  values together with the NOEC. Sub-lethal effects, if observed, shall be reported.

Test conditions

The test shall be conducted with the active substance. Results shall be presented in terms of  $\mu\text{g}$  active substance/bee.

##### 8.3.1.1.2. Acute contact toxicity **U.K.**

A test for acute contact toxicity shall be provided establishing the acute  $\text{LD}_{50}$  values together with the NOEC. Sub-lethal effects, if observed, shall be reported.

Test conditions

The test shall be conducted with the active substance. Results shall be presented in terms of  $\mu\text{g}$  active substance/bee.

#### 8.3.1.2. Chronic toxicity to bees **U.K.**



---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

A test for chronic toxicity to bees shall be provided establishing the chronic oral EC<sub>10</sub>, EC<sub>20</sub>, EC<sub>50</sub> together with the NOEC. Where the chronic oral EC<sub>10</sub>, EC<sub>20</sub>, EC<sub>50</sub> cannot be estimated, an explanation shall be provided. Sub-lethal effects, if observed, shall be reported.

*Circumstances in which required*

The test shall be carried out where bees are likely to be exposed.

*Test conditions*

The test shall be conducted with the active substance. Results shall be presented in terms of µg active substance/bee.

#### 8.3.1.3. *Effects on honeybee development and other honeybee life stages* U.K.

A bee brood study shall be conducted to determine effects on honeybee development and brood activity. The bee brood study shall provide sufficient information to evaluate possible risks from the active substance on honeybee larvae.

The test shall provide the EC<sub>10</sub>, EC<sub>20</sub> and EC<sub>50</sub> for adult bees, where possible, and larvae together with the NOEC. Where EC<sub>10</sub>, EC<sub>20</sub>, EC<sub>50</sub> cannot be estimated, an explanation shall be provided. Sub-lethal effects, if observed, shall be reported.

*Circumstances in which required*

The test shall be carried out for active substances for which sub-lethal effects on growth or development cannot be excluded, unless the applicant shows that it is not possible that honeybee brood will be exposed to the active substance.

#### 8.3.1.4. *Sub-lethal effects* U.K.

Tests investigating sub-lethal effects, such as behavioural and reproductive effects, on bees and, where applicable, on colonies may be required.

#### 8.3.2. *Effects on non-target arthropods other than bees* U.K.

*Circumstances in which required*

Effects on non-target terrestrial arthropods shall be investigated for all active substances except where plant protection products containing the active substance are for exclusive use in situations where non-target arthropods are not exposed such as:

- food storage in enclosed spaces that preclude exposure,
- wound sealing and healing treatments,
- enclosed spaces with rodenticidal baits.

Two indicator species, the cereal aphid parasitoid *Aphidius rhopalosiphi* (Hymenoptera: Braconidae) and the predatory mite *Typhlodromus pyri* (Acari: Phytoseiidae) shall always be tested. Initial testing shall be performed using glass plates and mortality (and reproduction effects if assessed) shall be reported. Testing shall determine a rate-response relationship and LR<sub>50</sub><sup>(16)</sup>, ER<sub>50</sub><sup>(17)</sup> and NOEC endpoints shall be reported for assessment of the risk to these species in accordance with the relevant risk quotient analysis. If adverse effects can be clearly predicted from these studies then testing using higher tier studies may be required (see point 10.3 of Part A of the Annex to the Regulation (EU) No 284/2013 for further details).

With active substances suspected of having a special mode of action (such as insect growth regulators, insect feeding inhibitors) additional tests involving sensitive life stages, special routes of uptake or other modifications, may be required by the national competent authorities. The rationale for the choice of test species used shall be provided.

#### 8.3.2.1. *Effects on *Aphidius rhopalosiphi** U.K.

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

A test shall provide sufficient information to evaluate the toxicity in terms of LR<sub>50</sub> and NOEC of the active substance to *Aphidius rhopalosiphi*.

*Test conditions*

Initial testing shall be performed using glass plates.

#### 8.3.2.2. *Effects on Typhlodromus pyri* U.K.

A test shall provide sufficient information to evaluate the toxicity in terms of LR<sub>50</sub> and NOEC of the active substance to *Typhlodromus pyri*.

*Test conditions*

Initial testing shall be performed using glass plates.

### 8.4. **Effects on non-target soil meso- and macrofauna** U.K.

#### 8.4.1. *Earthworm — sub-lethal effects* U.K.

A test shall provide information on the effects on growth, reproduction and behaviour of the earthworm.

*Circumstances in which required*

Sub-lethal effects on earthworms shall be investigated where the active substance can contaminate soil.

*Test conditions*

Testing shall determine a dose-response relationship and the EC<sub>10</sub>, EC<sub>20</sub> and NOEC shall enable the risk assessment to be conducted in accordance with the appropriate risk quotient analysis, taking into account likely exposure, the organic carbon content (f<sub>oc</sub>) of the test medium and the lipophilic properties (K<sub>ow</sub>) of the test substance. The test substance shall be incorporated into the soil to obtain a homogenous soil concentration. Testing with soil metabolites may be avoided if there is analytical evidence to indicate that the metabolite is present at an adequate concentration and duration in the study conducted with the parent active substance.

#### 8.4.2. *Effects on non-target soil meso- and macrofauna (other than earthworms)* U.K.

*Circumstances in which required*

Effects on soil organisms, other than earthworms, shall be investigated for all test substances, except in situations where soil organisms are not exposed such as:

- (a) food storage in enclosed spaces that preclude exposure;
- (b) wound sealing and healing treatments;
- (c) enclosed spaces with rodenticidal baits.

For plant protection products applied as a foliar spray data on *Folsomia candida* and *Hypoaspis aculeifer* may be required by the national competent authorities. If data are available on both *Aphidius rhopalosiphi* and *Typhlodromus pyri* these may be used in an initial risk assessment. If concern is raised with either species tested under point 8.3.2, data on both *Folsomia candida* and *Hypoaspis aculeifer* shall be provided.

If data on *Aphidius rhopalosiphi* and *Typhlodromus pyri* are not available, then the data set out in point 8.4.2.1 shall be provided.

For plant protection products applied directly to soil as soil treatments either as a spray or as a solid formulation, testing shall be carried out on both on *Folsomia candida* and *Hypoaspis aculeifer* (see point 8.4.2.1).

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

#### 8.4.2.1. *Species level testing* U.K.

A test shall provide sufficient information to perform an assessment of the toxicity of the active substance to the soil invertebrate indicator species *Folsomia candida* and *Hypoaspis aculeifer*.  
Test conditions

Testing shall determine a dose-response relationship and the EC<sub>10</sub>, EC<sub>20</sub> and NOEC shall enable the risk assessment to be conducted in accordance with the appropriate risk quotient analysis, taking into account likely exposure, the organic carbon content (f<sub>oc</sub>) of the test medium and the lipophilic properties (K<sub>ow</sub>) of the test substance. The test substance shall be incorporated into the soil to obtain a homogenous soil concentration. Testing with soil metabolites may be avoided if there is analytical evidence to indicate that the metabolite is present at an adequate concentration and duration in the study conducted with the parent active substance.

#### 8.5. **Effects on soil nitrogen transformation** U.K.

A test shall provide sufficient data to evaluate the impact of active substances on soil microbial activity, in terms of nitrogen transformation.

*Circumstances in which required*

The test shall be carried out where plant protection products containing the active substance are applied to soil or can contaminate soil under practical conditions of use. In the case of active substances intended for use in plant protection products for soil sterilisation, the studies shall be designed to measure rates of recovery following treatment.

*Test conditions*

Soils used shall be freshly sampled agricultural soils. The sites from which soil is taken shall not have been treated during the previous two years with any substance that could substantially alter the diversity and levels of microbial populations present, other than in a transitory manner.

#### 8.6. **Effects on terrestrial non-target higher plants** U.K.

##### 8.6.1. *Summary of screening data* U.K.

The information provided shall be sufficient to permit the evaluation of effects of the active substance on non-target plants.

*Circumstances in which required*

Screening data shall establish whether test substances exhibit herbicidal or plant growth regulatory activity. The data shall include testing from at least six plant species from six different families including both mono- and dicotyledons. The tested concentrations and rates shall be equal or higher than the maximum recommended application rate and at a rate either to simulate use pattern under field conditions, with testing conducted after the final treatment, or at a rate applied directly that takes in to account the accumulation of residues following multiple applications of the plant protection product. If screening studies do not cover the specified range of species or the necessary concentrations and rates, tests as set out in point 8.6.2 shall be carried out.

For assessment of active substances with herbicidal or plant growth regulatory activity screening data shall not be used. Point 8.6.2 shall apply.

*Test conditions*

A summary of available data from tests used to assess biological activity and dose range finding studies, whether positive or negative, which may provide information with respect to possible impact on other non-target flora, shall be provided, together with an assessment as to the potential impact on non-target plant species.

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

These data shall be supplemented by further information, in summary form, on the observed effects on plants during the course of field testing, namely efficacy, residues, environmental fate and ecotoxicological field studies.

#### 8.6.2. *Testing on non-target plants* U.K.

A test shall provide the ER<sub>50</sub> values of the active substance to non-target plants.

##### *Circumstances in which required*

For active substances that exhibit herbicidal or plant growth regulator activity, vegetative vigour and seedling emergence concentration/response tests shall be provided for at least six species representing families for which herbicidal/plant growth regulatory action has been found. Where, from the mode of action, it can be clearly established that either seedling emergence or vegetative vigour is effected, only the relevant study shall be conducted.

Data are not required, where exposure is negligible, for example in the case of rodenticides, active substances used for wound protection or seed treatment, or in the case of active substances used on stored products or in glasshouses where exposure is precluded.

##### *Test conditions*

Dose-response tests on a selection of 6 to 10 monocotyledon and dicotyledon plant species representing as many taxonomic groups as possible shall be provided.

#### 8.7. **Effects on other terrestrial organisms (flora and fauna)** U.K.

Any available data on the effects of the product on other terrestrial organisms shall be submitted.

#### 8.8. **Effects on biological methods for sewage treatment** U.K.

A test shall provide an indication as to the potential of the active substance on biological sewage treatment systems.

##### *Circumstances in which required*

Effects on biological methods for sewage treatment shall be reported where the use of plant protection products containing the active substance can give rise to adverse effects on sewage treatment plants.

#### 8.9. **Monitoring data** U.K.

Available monitoring data concerning adverse effects of the active substance to non-target organisms shall be reported.

### SECTION 9 U.K.

#### *Literature data*

A summary of all relevant data from the scientific peer reviewed open literature on the active substance, metabolites and breakdown or reaction products and plant protection products containing the active substance shall be submitted.

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

## SECTION 10 U.K.

### Classification and labelling

Proposals for the classification and labelling of the active substance in accordance with Regulation (EC) No 1272/2008 shall be submitted and justified, including:

- pictograms,
- signal words,
- hazard statements, and
- precautionary statements.

## PART B U.K.

### MICRO-ORGANISMS INCLUDING VIRUSES

#### Introduction

- (i) Active substances are defined in Article 2(2) of Regulation (EC) No 1107/2009 and include chemical substances and micro-organisms including viruses. U.K.

This Part provides data requirements for active substances consisting of micro-organisms, including viruses.

The term ‘micro-organism’ as defined in Article 3 of Regulation (EC) No 1107/2009 applies to, but is not limited to, bacteria, fungi, protozoa, viruses and viroids.

- (ii) For all micro-organisms that are subject to application all available relevant knowledge and information in literature should be provided. U.K.

The most important and informative information is obtained by the characterisation and identification of a micro-organism. Such information is found in Sections 1 to 3 (identity, biological properties and further information) which form the basis for an assessment of human health and environmental effects.

Newly generated data from conventional toxicological and/or pathological experiments on laboratory animals are normally required unless the applicant can justify, on the basis of the previous information, that the use of the micro-organism, under the proposed conditions of use, does not have any harmful effects on human and animal health or on groundwater or any unacceptable influence on the environment.

- (iii) Pending the acceptance of specific guidelines at international level, the information required shall be generated using available test guidelines accepted by the competent authority (e.g. USEPA guideline<sup>(18)</sup>); where appropriate, test guidelines as described in Part A of this Annex should be adapted in such a way that they are appropriate for micro-organisms. Testing shall include viable and, if appropriate, non-viable micro-organisms, and a blank control.
- (iv) Where testing is done, a detailed description (specification) of the material used and its impurities, in accordance with point 1.4, must be provided. The material used shall be of that specification that will be used in the manufacture of preparations to be authorised. U.K.

Where studies are conducted using micro-organisms produced in the laboratory or in a pilot plant production system, the studies must be repeated using micro-organisms as manufactured,

---

*Changes to legislation:* There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

unless it can be demonstrated that the test material used is essentially the same for the purposes of the testing and assessment.

- (v) Where the micro-organism has been genetically modified, a copy of the evaluation of the data concerning the assessment of risk to the environment, as stated in Article 48 to Regulation (EC) No 1107/2009, has to be submitted.
- (vi) Where relevant, data shall be analysed using appropriate statistical methods. Full details of the statistical analysis shall be reported (e.g. all point estimates shall be given with confidence intervals, exact p-values should be given rather than stating significant/non significant).
- (vii) In the case of studies in which dosing extends over a period, dosing shall preferably be done using a single batch of the micro-organism, if stability permits. **U.K.**

If the studies are not performed using a single batch of the micro-organism, the similarity of the different batches has to be stated.

Whenever a study implies the use of different doses, the relationship between dose and adverse effect must be reported.

- (viii) If the plant protection action is known to be due to the residual effect of a toxin/metabolite or if significant residues of toxins/metabolites are to be expected not related to the effect of the active substance, a dossier for the toxin/metabolite has to be submitted in accordance with the requirements of Part A of this Annex,.

## 1. IDENTITY OF THE MICRO-ORGANISM **U.K.**

The identification together with the characterisation of the micro-organism provides the most important information and is a key point for decision-making.

### 1.1. Applicant **U.K.**

The name and address of the applicant must be provided, as must the name, position, telephone and fax number of the appropriate person to contact.

Where, in addition, the applicant has an office, agent or representative in the Member State to which the application for approval is submitted, and if different, in the rapporteur Member State appointed by the Commission, the name and address of the local office, agent or representative must be provided, as must the name, position, telephone and fax number of the appropriate person to contact.

### 1.2. Producer **U.K.**

The name and address of the producer or producers of the micro-organism must be provided as must the name and address of each plant in which the micro-organism is produced. A contact point (preferably a central contact point, to include name, telephone and fax number) must be provided, with a view to providing updating information and responding to queries arising, regarding production technology, processes and the quality of product (including where relevant, individual batches). Where, following approval of the micro-organism, there are changes in the location or number of producers, the information required must again be notified to the Commission and the Member States.

### 1.3. Name and species description, strain characterisation **U.K.**

- (i) The micro-organism should be deposited at an internationally recognised culture collection and given an accession number and these details must be submitted.

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

- (ii) Each micro-organism that is subject to the application shall be identified and named at the species level. The scientific name and taxonomic grouping, i.e. family, genus, species, strain, serotype, pathovar or any other denomination relevant to the micro-organism, must be stated. **U.K.**

It must be indicated whether the micro-organism:

- is indigenous or non-indigenous at the species level to the intended area of application,
- is a wild type,
- is a spontaneous or induced mutant,
- has been modified, using techniques described in Part 2 of Annex IA and in Annex IB to Directive 2001/18/EC<sup>(19)</sup> of the European Parliament and of the Council.

In the latter two cases, all known differences between the modified micro-organism and the parent wild strain must be provided.

- (iii) Best available technology should be used to identify and characterise the micro-organism at the strain level. The appropriate test procedures and criteria used for identification (e.g. morphology, biochemistry, serology, molecular identification) must be provided.
- (iv) Common name or alternative and superseded names and code names used during the development, if any, must be provided.
- (v) Relationships to known pathogens shall be indicated.

#### 1.4. **Specification of the material used for manufacturing of formulated products** **U.K.**

##### 1.4.1. *Content of the micro-organism* **U.K.**

The minimum and maximum content of the micro-organism in the material used for manufacturing of formulated products, must be reported. The content shall be expressed in appropriate terms, such as number of active units per volume or weight or any other manner that is relevant to the micro-organism.

Where the information provided relates to a pilot plant production system, the information required must again be provided to the Commission and the Member States once industrial scale production methods and procedures have stabilised, if production changes result in a changed specification of purity.

##### 1.4.2. *Identity and content of impurities, additives, contaminating micro-organisms* **U.K.**

It is desirable to have a plant protection product without contaminants (including contaminating micro-organisms), if possible. The level and nature of acceptable contaminants shall be judged from a risk assessment point of view, by the competent authority.

If possible and appropriate, the identity and maximum content of all contaminating micro-organisms, expressed in the appropriate unit, must be reported. The information on identity must be provided where possible as outlined in point 1.3 of Part B of this Annex.

Relevant metabolites (i.e. if expected to be of concern to human health and/or the environment) known to be formed by the micro-organism shall be identified and characterised at different states or growth stages of the micro-organism (see point (viii) of this introduction).

Where relevant detailed information on all components such as condensates, culture medium, etc. must be provided.

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

In the case of chemical impurities that are relevant for human health and/or the environment, the identity and maximum content, expressed in appropriate terms, must be provided.

In the case of additives, the identity and content in g/kg must be provided.

The information on identity of chemical substances such as additives must be provided as outlined in point 1.10 of Part A of this Annex.

#### 1.4.3. *Analytical profile of batches* U.K.

Where relevant, the same data as outlined in point 1.11 of Part A of this Annex have to be reported, using the appropriate units.

## 2. BIOLOGICAL PROPERTIES OF THE MICRO-ORGANISM U.K.

### 2.1. **History of the micro-organism and its uses. Natural occurrence and geographical distribution** U.K.

Familiarity, interpreted as the availability of relevant knowledge of the micro-organism, shall be presented.

#### 2.1.1. *Historical background* U.K.

The historical background of the micro-organism and its use (tests/research projects or commercial use) must be provided.

#### 2.1.2. *Origin and natural occurrence* U.K.

The geographical region and the place in the ecosystem (e.g. host plant, host animal, or soil from which the micro-organism was isolated) must be stated. The method of isolation of the micro-organism shall be reported. The natural occurrence of the micro-organism in the relevant environment shall be given if possible at strain level.

In the case of a mutant, or a genetically modified micro-organism, detailed information should be provided on its production and isolation and on the means by which it can be clearly distinguished from the parent wild strain.

### 2.2. **Information on target organism(s)** U.K.

#### 2.2.1. *Description of the target organism(s)* U.K.

Where relevant, details of harmful organisms against which protection is afforded, must be provided.

#### 2.2.2. *Mode of action* U.K.

The principal mode of action shall be indicated. In connection with the mode of action it shall also be stated if the micro-organism produces a toxin with a residual effect on the target organism. In that case, the mode of action of this toxin shall be described.

If relevant, information on the site of infection and mode of entry into the target organism and its susceptible stages shall be given. The results of any experimental studies must be reported.

It shall be stated by which way an uptake of the micro-organism, or its metabolites (especially toxins) may occur (e.g. contact, stomach, inhalation). It must also be stated whether or not the micro-organism or its metabolites are translocated in plants and, where relevant, how this translocation takes place.



---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) [View outstanding changes](#)

---

In case of pathogenic effect on the target organism, infective dose (the dose needed to cause infection with the intended effect on a target species) and transmissibility (possibility of spread of the micro-organism in the target population, but also from one target species to another (target) species) after application under the proposed condition of use shall be indicated.

### 2.3. **Host specificity range and effects on species other than the target harmful organism** U.K.

Any available information on the effects on non-target organisms within the area to which the micro-organism may spread shall be given. The occurrence of non-target organisms being either closely related to the target species or being especially exposed shall be indicated.

Any experience of the toxic effect of the active substance or its metabolic products on humans or animals, of whether the organism is capable of colonising or invading humans or animals (including immunosuppressed individuals) and whether it is pathogenic shall be stated. Any experience of whether the active substance or its products may irritate skin, eyes or respiratory organs of humans or animals and whether it is allergenic in contact with skin or when inhaled shall be stated.

### 2.4. **Development stages/life cycle of the micro-organism** U.K.

Information on the life cycle of the micro-organism, described symbiosis, parasitism, competitors, predators, etc., including host organisms, as well as vectors for viruses, must be presented.

The generation time and the type of reproduction of the micro-organism must be stated.

Information on the occurrence of resting stages and their survival time, their virulence and infection potential must be provided.

The potential of the micro-organism to produce metabolites, including toxins that are of concern for human health and/or the environment, in its different development stages after the release, must be indicated.

### 2.5. **Infectiveness, dispersal and colonisation ability** U.K.

The persistence of the micro-organism and information on its life cycle under the typical environmental conditions of use must be indicated. In addition, any particular sensitivity of the micro-organism to certain compartments of the environment (e.g. UV light, soil, water) must be stated.

The environmental requirements (temperature, pH, humidity, nutrition requirements, etc.) for survival, reproduction, colonisation, damage (including human tissues) and effectiveness of the micro-organism must be stated. The presence of specific virulence factors shall be indicated.

The temperature range at which the micro-organism grows must be determined, including minimum, maximum and optimum temperatures. This information is of particular value as a trigger for studies of effects on human health (Section 5).

The possible effect of factors such as temperature, UV light, pH, and the presence of certain substances on the stability of relevant toxins must also be stated.

Information on possible dispersal routes of the micro-organism (via air as dust particles or aerosols, with host organisms as vectors, etc.), under typical environmental conditions relevant to the use, must be provided.

### 2.6. **Relationships to known plant or animal or human pathogens** U.K.

---

*Changes to legislation:* There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

The possible existence of one or more species of the genus of the active and/or, where relevant, contaminating micro-organisms known to be pathogenic to humans, animals, crops or other non-target species and the type of disease caused by them shall be indicated. It shall be stated whether it is possible, and if so, by which means to clearly distinguish the active micro-organism from the pathogenic species.

#### 2.7. Genetic stability and factors affecting it **U.K.**

Where appropriate, information on genetic stability (e.g. mutation rate of traits related to the mode of action or uptake of exogenous genetic material) under the environmental conditions of proposed use must be provided.

Information must also be provided on the micro-organism's capacity to transfer genetic material to other organisms as well as its capacity to being pathogenic for plants, animals or man. If the micro-organism carries relevant additional genetic elements, the stability of the encoded traits shall be indicated.

#### 2.8. Information on the production of metabolites (especially toxins) **U.K.**

If other strains belonging to the same microbial species as the strain subject to the application are known to produce metabolites (especially toxins) with unacceptable effects on human health and/or the environment during or after application, the nature and structure of this substance, its presence inside or outside the cell and its stability, its mode of action (including external and internal factors of the micro-organism necessary to action) as well as its effect on humans, animals or other non-target species shall be provided.

The conditions under which the micro-organism produces the metabolite(s) (especially toxin(s)) must be described.

Any available information on the mechanism by which the micro-organisms regulate the production of the(se) metabolite(s) shall be provided.

Any available information on the influence of the produced metabolites on the micro-organism's mode of action shall be provided.

#### 2.9. Antibiotics and other anti-microbial agents **U.K.**

Many micro-organisms produce some antibiotic substances. Interference with the use of antibiotics in human or veterinary medicine must be avoided at any stage of the development of a microbial plant protection product.

Information on the micro-organism's resistance or sensitivity to antibiotics or other anti-microbial agents must be provided, in particular the stability of the genes coding for antibiotic resistance, unless it can be justified that the micro-organism has no harmful effects on human or animal health, or that it can not transfer its resistance to antibiotics or other anti-microbial agents.

### 3. FURTHER INFORMATION ON THE MICRO-ORGANISM **U.K.** **Introduction**

- (i) The information provided must describe the intended purposes for which preparations containing the micro-organism are used, or are to be used and the dose and manner of their use or proposed use.
- (ii) The information provided must specify the normal methods and precautions to be followed in the handling, storage and transport of the micro-organism.

---

*Changes to legislation: There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes*

---

- (iii) The studies, data and information submitted, must demonstrate the suitability of measures proposed for use in emergency situations.
- (iv) The information and data referred to are required for each micro-organism, except where otherwise specified.

### 3.1. **Function** U.K.

The biological function must be specified from among the following:

- control of bacteria,
- control of fungi,
- control of insects,
- control of mites,
- control of molluscs,
- control of nematodes,
- control of weeds,
- other (must be specified).

### 3.2. **Field of use envisaged** U.K.

The field(s) of use, existing and proposed, for preparations containing the micro-organism must be specified from among the following:

- field use, such as agriculture, horticulture, forestry, and viticulture,
- protected crops (e.g. in greenhouses),
- amenity,
- weed control on non-cultivated areas,
- home gardening,
- house plants,
- stored products,
- other (specify).

### 3.3. **Crops or products protected or treated** U.K.

Details of existing and intended use in terms of crops, groups of crops, plants, or plant products protected, must be provided.

### 3.4. **Method of production and quality control** U.K.

Full information on how the micro-organism is produced in bulk must be provided.

Both production method/process and product must be subject to a continuous quality control by the applicant. In particular, the occurrence of spontaneous changing of major characteristics of the micro-organism and of the absence/presence of significant contaminants shall be monitored. The quality assurance criteria for the production shall be submitted.

The techniques used to ensure a uniform product, and the assay methods for its standardisation, maintenance and purity of the micro-organism must be described and specified (e.g. HACCP).

### 3.5. **Information on the occurrence or possible occurrence of the development of resistance of the target organism(s)** U.K.

Available information on the possible occurrence of the development of resistance or cross-resistance of the target organism(s) must be provided. Where possible, appropriate management strategies shall be described.

---

*Changes to legislation: There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes*

---

### 3.6. **Methods to prevent loss of virulence of seed stock of the micro-organism** U.K.

Methods to prevent loss of virulence of starting cultures shall be provided.

In addition, any method, if available, that could prevent the micro-organism from losing its effects on the target species must be described.

### 3.7. **Recommended methods and precautions concerning handling, storage, transport or fire** U.K.

A safety data sheet pursuant to Article 31 of Regulation (EC) No 1907/2006 must be provided for each micro-organism.

### 3.8. **Procedures for destruction or decontamination** U.K.

In many cases the preferred or sole means of safe disposal of micro-organisms, contaminated materials, or contaminated packaging, is through controlled incineration in a licensed incinerator.

Methods to dispose safely of the micro-organism or, where necessary, to kill it prior to disposal, and methods to dispose of contaminated packaging and contaminated materials, must be fully described. Data must be provided for such methods to establish their effectiveness and safety.

### 3.9. **Measures in case of an accident** U.K.

Information on procedures for rendering the micro-organism harmless in the environment (e.g. water or soil) in case of an accident must be provided.

## 4. ANALYTICAL METHODS U.K.

### Introduction

The provisions of this Section only cover analytical methods required for post-registration control and monitoring purposes.

Post-approval monitoring might be considered for all areas of risk assessment. This is particularly the case when (strains of) micro-organisms that are non-indigenous to the intended area of application are considered for approval. For analytical methods used for generation of data as required in this Regulation or for other purposes the applicant has to provide a justification for the method used; where necessary separate guidance will be developed for such methods on the basis of the same requirements as defined for methods for post-registration control and monitoring purposes.

Descriptions of methods must be provided and include details of equipment, materials and conditions used. The applicability of any internationally recognised method must be reported.

As far as practicable these methods must employ the simplest approach, involve the minimum cost, and require commonly available equipment.

Data on specificity, linearity, accuracy and repeatability, as defined in points 4.1 and 4.2 of Part A of this Annex, are also required for methods used to analyse micro-organisms and their residues.

For this Section the following applies:

<b>Impurities, metabolites, relevant metabolites, residues</b>	As defined in Regulation (EC) No 1107/2009
--	--

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

<b>Relevant impurities</b>	Impurities, as defined above, that are of concern for human or animal health and/or the environment
----------------------------	---

On request the following samples must be provided:

- (i) samples of the micro-organism as manufactured;
- (ii) analytical standards of relevant metabolites (especially toxins) and all other components included in the residue definition;
- (iii) if available, samples of reference substances for the relevant impurities.

#### 4.1. **Methods for the analysis of the micro-organism as manufactured** U.K.

- Methods for the identification of the micro-organism.
- Methods for providing information on possible variability of seed stock/active micro-organism.
- Methods to differentiate a mutant of the micro-organism from the parent wild strain.
- Methods for the establishment of purity of seed stock from which batches are produced and methods to control that purity.
- Methods to determine the content of the micro-organism in the manufactured material used for the production of formulated products and methods to show that contaminating micro-organisms are controlled to an acceptable level.
- Methods for the determination of relevant impurities in the manufactured material.
- Methods to control the absence and to quantify (with appropriate limits of determination) the possible presence of any human and mammalian pathogens.
- Methods to determine storage stability, shelf-life of the micro-organism, if appropriate.

#### 4.2. **Methods to determine and quantify residues (viable or non-viable)** U.K.

of:

- the active micro-organism(s),
- relevant metabolites (especially toxins),

on and/or in crop, in foodstuffs and feeding stuffs, in animal and human body tissues and fluids, in soil, in water (including drinking water, ground water and surface water) and in air where relevant.

Analytical methods for amount or activity of proteinaceous products shall also be included, e.g. by testing exponential cultures and culture supernatants in an animal cell bioassay.

## 5. **EFFECTS ON HUMAN HEALTH** U.K.

### **Introduction**

- (i) Available information based on the properties of the micro-organism and corresponding organisms (Sections 1, 2 and 3), including health and medical reports may be sufficient for a decision whether the micro-organism would cause health effects (infectious/pathogenic/toxic) in humans or not.
- (ii) The information provided, taken together with that provided for one or more preparations containing the micro-organism, must be sufficient to permit an evaluation to be made as to the risks for man, directly and/or indirectly associated with the handling and use of plant protection products containing the micro-organism, and the risk for man handling treated products, and the risk for man arising from residual traces

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

- or contaminants remaining in food and water. In addition, the information provided must be sufficient to: **U.K.**
- permit a decision to be made as to whether, or not, the micro-organism can be approved,
  - specify appropriate conditions or restrictions to be associated with any approval,
  - specify risk and safety phrases (once introduced) for the protection of man, animals and the environment to be included on packaging (containers),
  - identify relevant first aid measures as well as appropriate diagnostic and therapeutic measures to be followed in the event of infection or another adverse effect in man.
- (iii) All effects found during investigations shall be reported. Investigations which may be necessary in order to evaluate the probable mechanism involved, and to assess the significance of these effects, must also be performed.
- (iv) For all studies actual achieved dose in colony forming units per kg body weight (cfu/kg), as well as in other appropriate units, must be reported.
- (v) Evaluation of the micro-organism shall be carried out in a tier-wise manner.

The first tier (Tier I) includes available basic information and basic studies, which have to be performed for all micro-organisms. Expert judgment will be necessary to decide about the appropriate test programme on a case-by-case basis. Newly generated data from conventional toxicological and/or pathological experiments on laboratory animals are normally required unless the applicant can justify, on the basis of the previous information, that the use of the micro-organism, under the proposed conditions of use, does not have any harmful effects on human and animal health. Pending the acceptance of specific guidelines at international level, the information required shall be generated using available test guidelines (e.g. USEPA OPPTS Guidelines).

Tier II studies must be conducted if tests under Tier I have shown adverse health effects. The type of study to be performed depends on the effects observed in the Tier I studies. Before performing such studies, the applicant shall seek agreement of the competent authorities on the type of study to be performed.

#### *TIER I*

##### 5.1. **Basic information** **U.K.**

Basic information is required about the potential of the micro-organism to cause adverse effects such as ability to colonise, to cause damage and to produce toxins and other relevant metabolites.

##### 5.1.1. *Medical data* **U.K.**

Where available, and without prejudice to the provisions of Article 10 of Directive 98/24/EC, practical data and information relevant to the recognition of the symptoms of infection or pathogenicity and on the effectiveness of first aid and therapeutic measures have to be submitted. Where relevant, the effectiveness of potential antagonists, shall be investigated and reported. Where relevant, methods to kill or render the micro-organism uninfected must be indicated (see point 3.8).

Data and information relevant to the effects of human exposure, where available and of the necessary quality, are of particular value, in confirming the validity of extrapolations made and conclusions reached with respect to target organs, virulence, and the reversibility of adverse effects. Such data can be generated following accidental or occupational exposure.

##### 5.1.2. *Medical surveillance on manufacturing plant personnel* **U.K.**

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) [View outstanding changes](#)

---

Available reports of occupational health surveillance programmes, supported with detailed information on the design of the programme and on exposure to the micro-organism must be submitted. Such reports should, where feasible, include data relevant to the mechanism of action of the micro-organism. These reports shall, where available, include data from persons exposed in manufacturing plants or after application of the micro-organism (e.g. in efficacy trials).

Special attention shall be devoted to those whose susceptibility may be affected, e.g. pre-existing disease, medication, compromised immunity, pregnancy or breast feeding.

#### 5.1.3. *Sensitisation/allergenicity observations, if appropriate* U.K.

Available information on the sensitisation and allergenic response of workers, including workers in manufacturing plants, agricultural and research workers and others exposed to the micro-organism must be provided, and include, where relevant, details of any incidences of hypersensitivity and chronic sensitisation. The information provided shall include details of frequency, level and duration of exposure, symptoms observed and other relevant clinical observation. Information shall be given about whether workers have been subjected to any allergy tests or interviewed about allergenic symptoms.

#### 5.1.4. *Direct observation, e.g. clinical cases* U.K.

Available reports from the open literature on the micro-organism or closely related members of the taxonomic group (relating to clinical cases), where they are from reference journals or official reports, must be submitted together with reports of any follow-up studies undertaken. Such reports are of particular value and shall contain complete descriptions of the nature, level and duration of exposure, as well as the clinical symptoms observed, first aid and therapeutic measures applied and measurements and observations made. Summary and abstract information is of limited value.

If there are animal studies performed, reports relating to clinical cases can be of particular value in confirming the validity of interpretations from animal data to man and in identifying unexpected adverse effects which are specific to humans.

### 5.2. **Basic studies** U.K.

In order to make it possible to correctly interpret the obtained results, it is of greatest importance that the suggested test methods are relevant regarding species sensitivity, administration route, etc., and relevant from a biological and toxicological point of view. The way of administration of the test micro-organism depends on the main exposure routes to humans.

To evaluate medium- and long-term effects after acute, sub-acute or semi-chronic exposure to micro-organisms, it is necessary to use the options provided in the OECD guidelines, to extend the studies concerned with a recovery period (after which full macroscopic and microscopic pathology is to be performed, including an exploration for micro-organisms in the tissues and organs). This facilitates the interpretation of certain effects and provides the possibility to recognise infectiveness and/or pathogenicity, which in turn helps taking decisions on other issues such as the necessity to perform long-term studies (carcinogenicity etc., see point 5.3), and whether or not to perform residue studies (see point 6.2).

#### 5.2.1. *Sensitisation*<sup>(20)</sup> U.K.

##### *Aim of the test*

The test will provide sufficient information to assess the potential of the micro-organism to provoke sensitisation reactions by inhalation as well as with dermal exposure. A maximised test has to be performed.

*Circumstances in which required*<sup>(21)</sup>

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

Information on sensitisation must be reported.

#### 5.2.2. Acute toxicity, pathogenicity and infectiveness **U.K.**

The studies, data and information to be provided and evaluated must be sufficient to permit the identification of effects following a single exposure to the micro-organism, and in particular to establish, or indicate:

- the toxicity, pathogenicity and infectiveness of the micro-organism,
- the time course and characteristics of the effects with full details of behavioural changes and possible gross pathological findings at post-mortem,
- where possible mode of toxic action,
- the relative hazards associated with the different routes of exposure, and
- blood analyses throughout the studies in order to evaluate the clearance of the micro-organism.

Acute toxic/pathogenic effects may be accompanied by infectiveness and/or more long-term effects which cannot be observed immediately. With a view to health evaluation, it is therefore necessary to carry out studies on the ability to infect in connection with oral intake, inhalation and intraperitoneal/subcutaneous injection by test mammals.

During the acute toxicity, pathogenicity and infectiveness studies, an estimation of the micro-organism and/or the active toxin clearance in the organs deemed to be relevant for microbial examination (e.g. liver, kidneys, spleen, lungs, brain, blood and site of administration) must be performed.

The observations to be made shall reflect expert scientific judgement and may include the micro-organism numeration in all the tissues likely to be affected (e.g. showing lesions) and in the main organs: kidneys, brain, liver, lungs, spleen, bladder, blood, lymphatic ganglia, gastrointestinal tract, thymus gland and lesions at the inoculation site in the dead or moribund animals and at interim and final sacrifice.

The information generated through acute toxicity, pathogenicity and infectiveness testing is of particular value in assessing hazards likely to arise in accident situations and consumer risks due to exposure to possible residues.

##### 5.2.2.1. Acute oral toxicity, pathogenicity and infectiveness **U.K.** *Circumstances in which required*

The acute oral toxicity, pathogenicity and infectiveness of the micro-organism must be reported.

##### 5.2.2.2. Acute inhalation toxicity, pathogenicity and infectiveness **U.K.** *Circumstances in which required*

The inhalation toxicity<sup>(22)</sup>, pathogenicity and infectiveness of the micro-organism must be reported.

##### 5.2.2.3. Intraperitoneal/subcutaneous single dose **U.K.**

The intraperitoneal/subcutaneous test is considered a highly sensitive assay to elicit in particular infectiveness.

##### *Circumstances in which required*

The intraperitoneal injection is always required for all micro-organisms, however, expert judgement may be exercised to evaluate whether subcutaneous injection is preferred instead of intraperitoneal injection if the maximum temperature for growth and multiplication is lower than 37 °C.



---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

### 5.2.3. Genotoxicity testing **U.K.**

#### *Circumstances in which required*

If the micro-organism produces exotoxins in accordance with point 2.8, then these toxins and any other relevant metabolites in the culture medium must also be tested for genotoxicity. Such tests on toxins and metabolites shall be performed using the purified chemical if possible.

If basic studies do not indicate that toxic metabolites are formed, studies on the micro-organism itself shall be considered depending on expert judgement on the relevance and validity of the basic data. In the case of a virus the risk of insertional mutagenesis in mammal cells or the risk of carcinogenicity has to be discussed.

#### *Aim of the test*

These studies are of value in:

- the prediction of genotoxic potential,
- the early identification of genotoxic carcinogens,
- the elucidation of the mechanism of action of some carcinogens.

It is important that a flexible approach is adopted, with selection of further tests being dependent upon interpretation of results at each stage.

#### *Test conditions*<sup>(23)</sup>

Genotoxicity of cellular micro-organisms will be studied after breaking of the cells, wherever possible. Justification should be provided on the method of sample preparation used.

Genotoxicity of viruses shall be studied on infectious isolates.

### 5.2.3.1. *In vitro studies* **U.K.**

#### *Circumstances in which required*

Results of *in vitro* mutagenicity tests (bacterial assay for gene mutation, test for clastogenicity in mammalian cells and test for gene mutation in mammalian cells) must be provided.

### 5.2.4. Cell culture study **U.K.**

This information must be reported for intracellular replicating micro-organisms, such as viruses, viroids or specific bacteria and protozoa, unless the information from Sections 1, 2 and 3 clearly demonstrates that the micro-organism does not replicate in warm-blooded organisms. A cell culture study shall be performed in human cell or tissue cultures of different organs. Selection can be based on expected target organs after infection. If human cell or tissue cultures of specific organs are not available, other mammal cell and tissue cultures can be used. For viruses, the ability to interact with the human genome is a key consideration.

### 5.2.5. Information on short-term toxicity and pathogenicity **U.K.**

#### *Aim of the test*

Short-term toxicity studies must be designed to provide information as to the amount of the micro-organism that can be tolerated without toxic effects under the conditions of the study. Such studies provide useful data on the risks for those handling and using preparations containing the micro-organism. In particular, short-term studies provide an essential insight into possible cumulative actions of the micro-organism, and the risks to workers who may be intensively exposed. In addition short-term studies provide information useful in the design of chronic toxicity studies.

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

The studies, data and information to be provided and evaluated, must be sufficient to permit the identification of effects following repeated exposure to the micro-organism, and in particular to further establish, or indicate:

- the relationship between dose and adverse effects,
- toxicity of the micro-organism including where necessary the NOAEL for toxins,
- target organs, where relevant,
- the time course and characteristics of the effects with full details of behavioural changes and possible gross pathological findings at post-mortem,
- specific toxic effects and pathological changes produced,
- where relevant the persistence and reversibility of certain toxic effects observed, following discontinuation of dosing,
- where possible, the mode of toxic action, and
- the relative hazard associated with the different routes of exposure.

During the short-term toxicity study, an estimation of the micro-organism clearance in the main organs must be performed.

Investigations shall be included for pathogenicity and infectiveness end points.

*Circumstances in which required*

The short-term toxicity (minimum 28 days) of the micro-organism must be reported.

The choice of test species has to be justified. The choice of study length depends on acute toxicity and clearance data.

Expert judgement is required to decide what route of administration is preferable.

#### 5.2.5.1. *Health effects after repeated inhalatory exposure* U.K.

Information on the health effects after repeated inhalatory exposure is considered necessary, particularly for the risk assessment of the occupational setting. Repeated exposure might influence the clearance capacity (e.g. resistance) of the host (human). Furthermore, for proper risk assessment the toxicity after repeated exposure to contaminants, growth medium, co-formulants and the micro-organism needs to be addressed. It should be kept in mind that the co-formulants in the plant protection product can influence the toxicity and infectiveness of a micro-organism.

*Circumstances in which required*

Information on the short-term infectiveness, pathogenicity and toxicity (respiratory route) of a micro-organism is required, unless the information already provided is sufficient to assess human health effects. This can be the case if it is demonstrated that the test material has no inhalable fraction and/or repeated exposure is not expected.

#### 5.2.6. *Proposed treatment: first aid measures, medical treatment* U.K.

The first aid measures to be used in the event of infection and in the event of contamination of eyes must be provided.

Therapeutic regimes for use in the event of ingestion or contamination of eyes and skin must be described in full. Information based on practical experience, where it exists and is available, in other cases on theoretical grounds, as to the effectiveness of alternative treatment regimes, where relevant, must be provided.

Information on resistance to antibiotics must be provided.

(END OF TIER I)

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

## TIER II

### 5.3. Specific toxicity, pathogenicity and infectiveness studies U.K.

In certain cases, it can be necessary to carry out supplementary studies to further clarify the adverse human effects.

In particular, if results from earlier studies indicate that the micro-organism may cause long-term health effects, studies on chronic toxicity, pathogenicity and infectiveness, carcinogenicity and reproductive toxicity must be carried out. Furthermore, where a toxin is produced, kinetic studies must be performed.

Studies required must be designed on an individual basis, in the light of the particular parameters to be investigated and the objectives to be achieved. Before performing such studies, the applicant shall seek agreement of the competent authorities on the type of study to be performed.

### 5.4. *In vivo* studies in somatic cells U.K.

#### *Circumstances in which required*

If all the results of the *in vitro* studies are negative further testing must be done with consideration of other relevant information available. The test can be an *in vivo* study or an *in vitro* study using a different metabolising system from that/those previously used.

If the *in vitro* cytogenetic test is positive, an *in vivo* test using somatic cells (metaphase analysis in rodent bone marrow or micronucleus test in rodents) must be conducted.

If either of the *in vitro* gene mutation tests is positive, an *in vivo* test to investigate unscheduled DNA synthesis or a mouse spot test must be conducted.

### 5.5. Genotoxicity — *In vivo* studies in germ cells U.K.

#### *Aim of the test and test conditions*

See point 5.4 of part A.

#### *Circumstances in which required*

When any result of an *in vivo* study in somatic cells is positive, *in vivo* testing for germ cell effects may be justified. The necessity for conducting these tests will have to be considered on a case-by-case basis, taking into account other relevant information available including use and expected exposure. Suitable tests would need to examine interaction with DNA (such as the dominant lethal assay), to look at the potential for inherited effects and possibly make a quantitative assessment of heritable effects. It is recognised that in view of their complexity, the use of quantitative studies would require strong justification.

(END OF TIER II)

### 5.6. Summary of mammalian toxicity, pathogenicity and infectiveness and overall evaluation U.K.

A summary of all data and information provided under points 5.1 through 5.5, must be submitted, and include a detailed and critical assessment of those data in the context of relevant evaluative and decision making criteria and guidelines, with particular reference to the risks for man and animals that may or do arise, and the extent, quality and reliability of the data base.

It must be explained whether exposure of animals or humans has any implications for vaccination or serological monitoring.

## 6. RESIDUES IN OR ON TREATED PRODUCTS, FOOD AND FEED U.K.

### Introduction

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

- (i) The information provided, taken together with that for one or more preparations containing the micro-organism, must be sufficient to permit an evaluation to be made as to the risk for man and/or animals, arising from exposure to the micro-organism and its residual traces and metabolites (toxins) remaining in or on plants or plant products.
- (ii) In addition, the information provided must be sufficient to: **U.K.**
  - permit a decision to be made as to whether or not the micro-organism can be approved,
  - specify appropriate conditions or restrictions to be associated with any approval
  - where relevant, set maximum residue levels, preharvest intervals to protect consumers and waiting periods, to protect workers handling the treated crops and products.
- (iii) For the evaluation of risk arising from residues, experimental data on levels of exposure to the residue may not be required where it can be justified, that the micro-organism and its metabolites are not hazardous to humans in the concentrations that could occur as a result of authorised use. This justification can be based on open literature, on practical experience and on information submitted in Sections 1, 2 and 3 and Section 5.

**6.1. Persistence and likelihood of multiplication in or on crops, feedingstuffs or foodstuffs** **U.K.**

A substantiated estimation of persistence/competitiveness of the micro-organism and relevant secondary metabolites (especially toxins) in or on the crop under the environmental conditions prevailing at and after the intended use, taking into account in particular the information provided in Section 2, has to be delivered.

Moreover, the application shall state to which extent and on which basis it is considered that the micro-organism can (or cannot) multiply in or on the plant or plant product or during processing of raw products.

**6.2. Further information required** **U.K.**

Consumers may be exposed to micro-organisms for a considerable time as a result of the consumption of treated food commodities; potential effects on the consumers must, therefore, be derived from chronic or semi-chronic studies, so that a toxicological end point, such as the ADI, can be established for risk management.

**6.2.1. Non-viable residues** **U.K.**

A non viable micro-organism is a micro-organism that is not capable of replication or of transferring genetic material.

If relevant quantities of the micro-organism or of produced metabolites, especially toxins, have been found to be persistent in points 2.4 and 2.5, full experimental residue data as provided for in Section 6 of Part A of this Annex is required, if concentrations of the micro-organism and/or its toxins in or on the treated foodstuffs or feedingstuffs are expected to occur in concentrations higher than under natural conditions or in a different phenotypic state.

In accordance with Regulation (EC) No 1107/2009, the conclusion concerning the difference between natural concentrations and an elevated concentration due to treatment with the micro-organism, is to be based on experimentally obtained data, and not on extrapolations or calculations using models.

Before performing such studies, the applicant shall seek agreement of the competent authorities on the type of study to be performed.

---

*Changes to legislation:* There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

### 6.2.2. Viable residues **U.K.**

If the information submitted in accordance with point 6.1 suggests persistence of relevant amounts of the micro-organism in or on treated products, food or feed, possible effects on humans and/or animals must be investigated, unless it can be justified from Section 5, that the micro-organism and its metabolites and/or degradation products are not hazardous to humans in the concentrations and of the nature that could occur as a result of authorised use.

In accordance with Regulation (EC) No 1107/2009, the conclusion concerning the difference between natural concentrations and an elevated concentration due to treatment with the micro-organism, is to be based on experimentally obtained data, and not on extrapolations or calculations using models.

The persistence of viable residues needs special attention if infectiveness or pathogenicity to mammals has been found in points 2.3 and 2.5 or in Section 5 and/or if any other information suggests a hazard to consumers and/or workers. In this case the competent authorities may require studies similar to those provided for in Part A.

Before performing such studies, the applicant shall seek agreement of the competent authorities on the type of study to be performed.

### 6.3. Summary and evaluation of residue behaviour resulting from data submitted under points 6.1 and 6.2 **U.K.**

## 7. FATE AND BEHAVIOUR IN THE ENVIRONMENT **U.K.**

### Introduction

- (i) Information on the origin, the properties, and the survival of the micro-organism and its residual metabolites as well as its intended use form the basis for an assessment of environmental fate and behaviour. **U.K.**

Experimental data are normally required unless it can be justified that an assessment of its fate and behaviour in the environment can be performed with the information already available. This justification can be based on open literature, on practical experience and on information submitted in Sections 1 to 6. The function of the micro-organism in environmental processes is of particular interest.

- (ii) The information provided, taken together with other relevant information, and that for one or more preparations containing the micro-organism, must be sufficient to permit an assessment of its fate and behaviour as well as that of its residual traces and toxins, where they are of significance for human health and/or the environment.
- (iii) In particular, the information provided shall be sufficient to: **U.K.**
- decide whether, or not, the micro-organism can be approved,
  - specify appropriate conditions or restrictions to be associated with any approval,
  - specify the pictograms (once introduced), signal words, and relevant hazard and precautionary statements for the protection of the environment, which are to be included on packaging (containers),
  - predict the distribution, fate, and behaviour in the environment of the micro-organism and its metabolites as well as the time courses involved,
  - identify measures necessary to minimise contamination of the environment and impact on non-target species.
- (iv) Any relevant metabolites (i.e. of concern for human health and/or the environment) formed by the test organism under any relevant environmental conditions shall

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

be characterised. If relevant metabolites are present in or produced by the micro-organism, data as outlined under Section 7 of Part A of this Annex may be required, if all of the following conditions are met: **U.K.**

- the relevant metabolite is stable outside the micro-organism, see point 2.8, and
  - a toxic effect of the relevant metabolite is independent of the presence of the micro-organism, and
  - the relevant metabolite is expected to occur in the environment in concentrations considerably higher than under natural conditions.
- (v) Available information on the relationship with naturally occurring wild type relatives shall be taken into account.
- (vi) Before performing studies as referred to below, the applicant shall seek agreement of the competent authorities on whether studies need to be performed and, if so, the type of study to be conducted. The information from the other Sections has, also, to be taken into account.

#### 7.1. Persistence and multiplication **U.K.**

Where relevant, appropriate information on the persistence and multiplication of the micro-organism, in all environmental compartments has to be given, unless it can be justified that exposure of the particular environmental compartment to the micro-organism is unlikely to occur. Special attention shall be given to

- competitiveness under the environmental conditions prevailing at and after the intended use, and
- population dynamics in seasonally or regionally extreme climates (particularly hot summer, cold winter and rainfall) and to agricultural practices applied after intended use.

Estimated levels of the specified micro-organism in a time course after use of the product under the proposed conditions of use shall be given.

##### 7.1.1. Soil **U.K.**

Information on viability/population dynamics shall be reported in several cultivated and uncultivated soils representative of soils typical of the various EU regions where use exists or is anticipated. The provisions on choice of soil and its collection and handling, as referred to in the introduction of point 7.1 of Part A, have to be followed. If the test organism is to be used in association with other media, e.g. rockwool, this must be included in the test range.

##### 7.1.2. Water **U.K.**

Information should be reported on viability/population dynamics in natural sediment/water systems under both dark and illuminated conditions.

##### 7.1.3. Air **U.K.**

In case of particular concerns for operator, worker or bystander exposure, information on the concentrations in air might be necessary.

#### 7.2. Mobility **U.K.**

The possible spread of the micro-organism and its degradation products in relevant environmental compartments has to be evaluated, unless it can be justified that exposure of the particular environmental compartments to the micro-organism is unlikely to occur. In this context, the intended use (e.g. field or greenhouse, application to soil or to crops), life cycle

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

stages, including occurrence of vectors, persistence and the ability of the organism to colonise adjacent habitats are of particular interest.

The spread, the persistence and probable transport ranges need special attention if toxicity, infectiveness or pathogenicity has been reported or if any other information suggests possible hazard to humans, animals or to the environment. In this case the competent authorities may require studies similar to those provided for in Part A. Before performing such studies, the applicant shall seek agreement of the competent authorities on the type of study to be performed.

## 8. EFFECTS ON NON-TARGET ORGANISMS **U.K.**

### Introduction

- (i) The information on identity, biological properties and further information in Sections 1, 2, 3 and 7 is central to the assessment of impact on non-target species. Additional useful information may be found on fate and behaviour in the environment in Section 7 and on residue levels in plants in Section 6 which, together with information on the nature of the preparation and its manner of use, defines the nature and extent of potential exposure. The information submitted in accordance with Section 5 will provide essential information as to effects to mammals and the mechanisms involved. **U.K.**

Experimental data are normally required, unless it can be justified that an assessment of effects on non-target organisms can be performed with the information already available.

- (ii) The choice of the appropriate non-target organisms for testing of environmental effects shall be based on the identity of the micro-organism (including the host specificity, mode of action and ecology of the organism). From such knowledge it would be possible to choose the appropriate test-organisms, such as organisms closely related to the target organism.
- (iii) The information provided, taken together with that for one or more preparations containing the micro-organism, must be sufficient to permit an assessment of the impact on non-target species (flora and fauna), likely to be at risk from exposure to the micro-organism, where they are of environmental significance. Impact can result from single, prolonged or repeated exposure and can be reversible or irreversible.
- (iv) In particular, the information provided for the micro-organism, together with other relevant information, and that provided for one or more preparations containing it, shall be sufficient to: **U.K.**
- decide whether, or not, the micro-organism can be approved,
  - specify appropriate conditions or restrictions to be associated with any approval,
  - permit an evaluation of short- and long-term risks for non-target species — populations, communities, and processes — as appropriate,
  - classify the micro-organism as to biological hazard,
  - specify the precautions necessary for the protection of non-target species, and
  - specify the pictograms (once introduced), signal words, and relevant hazard and precautionary statements for the protection of the environment, to be mentioned on packaging (containers).
- (v) There is a need to report all potentially adverse effects found during routine investigations on environmental effects, to undertake and report, where required by the competent authorities, such additional studies which may be necessary to investigate the probable mechanisms involved and to assess the significance of these effects. All

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

---

available biological data and information which are relevant to the assessment of the ecology profile of the micro-organism must be reported.

- (vi) For all studies, average achieved dose in cfu/kg body weight as well as in other appropriate units must be reported.
- (vii) It may be necessary to conduct separate studies for relevant metabolites (especially toxins), where these products can constitute a relevant risk to non-target organisms and where their effects cannot be evaluated by the available results relating to the micro-organism. Before such studies are performed, the applicant shall seek agreement of the competent authorities on whether such studies need to be performed and, if so, the type of study to be conducted. The information from Sections 5, 6 and 7 has to be taken into account.
- (viii) In order to facilitate the assessment of the significance of test results obtained, the same strain (or recorded origin) of each relevant species shall, where possible, be used in the various tests specified.
- (ix) Tests must be performed unless it can be justified that the non-target organism will not be exposed to the micro-organism. If it is justified that the micro-organism does not cause toxic effects or is not pathogenic or infective to vertebrates or plants, only reaction to appropriate non-target organisms must be investigated.

#### 8.1. **Effects on birds** U.K.

##### *Aim of the test*

Information on toxicity, infectiveness and pathogenicity to birds must be reported.

#### 8.2. **Effects on aquatic organisms** U.K.

##### *Aim of the test*

Information on toxicity, infectiveness and pathogenicity to aquatic organisms must be reported.

##### 8.2.1. *Effects on fish* U.K.

###### *Aim of the test*

Information on toxicity, infectiveness and pathogenicity to fish must be reported.

##### 8.2.2. *Effects on freshwater invertebrates* U.K.

###### *Aim of the test*

Information on toxicity, infectiveness and pathogenicity to freshwater invertebrates must be reported.

##### 8.2.3. *Effects on algae growth* U.K.

###### *Aim of the test*

Information on effects on algal growth, growth rate and capacity to recover must be reported.

##### 8.2.4. *Effects on plants other than algae* U.K.

###### *Aim of the test*

Information on effects on plants other than algae must be reported.

#### 8.3. **Effects on bees** U.K.

##### *Aim of the test*

Information on toxicity, infectiveness and pathogenicity to bees must be reported.



---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) [View outstanding changes](#)

---

#### 8.4. **Effects on arthropods other than bees** U.K.

##### *Aim of the test*

Information on toxicity, infectiveness and pathogenicity to arthropods other than bees must be reported. The selection of the test species should be related to the potential use of the plant protection products (e.g. foliar or soil application). Special attention should be given to organisms used for biological control and organisms playing an important role in integrated pest management.

#### 8.5. **Effects on earthworms** U.K.

##### *Aim of the test*

Information on toxicity, infectiveness and pathogenicity to earthworms must be reported.

#### 8.6. **Effects on non-target soil micro-organisms** U.K.

Impact on relevant non-target micro-organisms and on their predators (e.g. protozoa for bacterial inoculants) shall be reported. Expert judgement is required to decide whether additional studies are necessary. Such decision will take into consideration the available information in this Section and other Sections, in particular data on the specificity of the micro-organism, and the expected exposure. Useful information may also be available from the observations carried out in efficacy testing. Special attention shall be given to organisms used in integrated crop management (ICM).

#### 8.7. **Additional studies** U.K.

The additional studies might include further acute studies on additional species or processes (such as sewage systems) or higher tier studies such as chronic, sub-lethal or reproductive studies on selected non-target organisms.

Before performing such studies, the applicant shall seek agreement of the competent authorities on the type of study to be performed.

### 9. **SUMMARY AND EVALUATION OF ENVIRONMENTAL IMPACT** U.K.

A summary and evaluation of all data relevant to the environmental impact, shall be carried out in accordance with the guidance given by the competent authorities of the Member States concerning the format of such summaries and evaluations. It shall include a detailed and critical assessment of those data in the context of relevant evaluative and decision making criteria and guidelines, with particular reference to the risks for the environment and non-target species that may or do arise, and the extent, quality and reliability of the data base. In particular the following issues shall be addressed:

- distribution and fate in the environment, and the time courses involved,
- identification of non-target species and populations at risk, and the extent of their potential exposure,
- identification of precautions necessary to avoid or minimise contamination of the environment, and for the protection of non-target species.

---

**Changes to legislation:** There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) [View outstanding changes](#)

---

- (1) [OL L 276, 20.10.2010, p. 33.](#)
- (2) [OJ L 353, 31.12.2008, p. 1.](#)
- (3) [OJ L 70, 16.3.2005, p. 1.](#)
- (4) [OJ L 50, 20.2.2004, p. 44.](#)
- (5) See page 85 of his Official Journal.
- (6) United Nations New York and Geneva (2009) Publication ISBN 978-92-1-139135-0.
- (7) [OJ L 396, 30.12.2006, p. 1.](#)
- (8) [OJ L 365, 31.12.1994, p. 34.](#)
- (9) aAOEL, abbreviation for 'Acute AOEL'.
- (10) LD<sub>50</sub>, abbreviation for 'Lethal Dose, 50 %', that is to say the dose required to kill half the members of a tested population after a specified test duration.
- (11) [OJ L 131, 5.5.1998, p. 11.](#)
- (12) mg/kg bw/day = mg active substance / kg body weight of the concerned species / day.
- (13) Safety intervals refer in this Section to pre-harvest intervals (PHIs), withholding periods or storage periods in the case of post-harvest treatments.
- (14) European Communities (2011) Publication ISBN: 978-92-79-16228-2.
- (15) [OJ L 327, 22.12.2000, p. 1.](#)
- (16) LR<sub>50</sub>, abbreviation for 'Lethal Rate, 50 %', that is to say the application rate required to kill half the members of a tested population after a specified test duration.
- (17) ER<sub>50</sub>, abbreviation for 'Effect Rate, 50 %', that is to say the application rate required to cause an effect on half the members of a tested population after a specified test duration.
- (18) USEPA Microbial Pesticide Test Guidelines, OPPTS Series 885, February 1996.
- (19) [OJ L 106, 17.4.2001, p. 1.](#)
- (20) The available methods for testing dermal sensitisation are not suitable for testing micro-organisms. Sensitisation by inhalation is most probably a greater problem compared with dermal exposure to micro-organisms but so far, there are no validated test methods. Development of these kinds of methods is therefore of great importance. Until then, all micro-organisms should be regarded as potential sensitisers. This approach also takes into consideration immuno-compromised or other sensitive individuals in the population (e.g. pregnant women, new-born children or elderly).
- (21) As a consequence of the absence of proper test methods all micro-organisms will be labelled as potential sensitisers, unless the applicant wants to demonstrate the non-sensitising potential by submitting data. Therefore, this data requirement should be regarded as not obligatory but optional, on a provisional base.
- (22) An inhalation study may be replaced by an intratracheal study.
- (23) As the present test methods are designed to be performed on soluble chemicals, it is necessary that the methods are developed so as to become relevant for micro-organisms.

**Changes to legislation:**

There are outstanding changes not yet made to Commission Regulation (EU) No 283/2013. Any changes that have already been made to the legislation appear in the content and are referenced with annotations.

[View outstanding changes](#)

**Changes and effects yet to be applied to :**

- Annex Pt. A Section 1 point 1.4.1 inserted by S.I. 2019/720 Sch. 2 para. 176(2)(b)
- Annex word omitted by S.I. 2019/556 reg. 21(5)(a)(i)
- Annex Pt. A point 6.10.1 word omitted by S.I. 2019/556 reg. 21(5)(b)(x)
- Annex Pt. A point 7.1.4.3 word omitted by S.I. 2019/556 reg. 21(5)(b)(xiii)
- Annex Pt. A point 7.2.2.4 word omitted by S.I. 2019/556 reg. 21(5)(b)(xiii)
- Annex Pt. A point 7.2.3 word omitted by S.I. 2019/556 reg. 21(5)(b)(xiii)
- Annex Pt. A point 7.3.2 word omitted by S.I. 2019/556 reg. 21(5)(b)(xiii)
- Annex Pt. A point 8.1.5 word omitted by S.I. 2019/556 reg. 21(5)(b)(xv)(bb)
- Annex Pt. A point 8.2 word omitted by S.I. 2019/556 reg. 21(5)(b)(xvi)
- Annex Pt. A point 8.2.2.2 word omitted by S.I. 2019/556 reg. 21(5)(b)(xvi)
- Annex Pt. A point 8.2.3 word omitted by S.I. 2019/556 reg. 21(5)(b)(xvii)(bb)
- Annex Pt. A point 8.2.7 word omitted by S.I. 2019/556 reg. 21(5)(b)(xviii)
- Annex Pt. A point 8.2.8 word omitted by S.I. 2019/556 reg. 21(5)(b)(xviii)
- Annex Pt. A point 8.3.2 word omitted by S.I. 2019/556 reg. 21(5)(b)(xviii)
- Annex Pt. A point 8.4.2 word omitted by S.I. 2019/556 reg. 21(5)(b)(xviii)
- Annex Pt. A point 5.8.3 word substituted by S.I. 2019/556 reg. 21(5)(b)(v)
- Annex Pt. A point 6.5.3 word substituted by S.I. 2019/556 reg. 21(5)(b)(viii)
- Annex Pt. A point 8.1.5 word substituted by S.I. 2019/556 reg. 21(5)(b)(xv)(aa)
- Annex Pt. A point 8.2.3 word substituted by S.I. 2019/556 reg. 21(5)(b)(xvii)(aa)
- Annex Pt. A Section 1 point 1.4 word substituted by S.I. 2019/720 Sch. 2 para. 176(2)(a)(ii)
- Annex words inserted by S.I. 2019/556 reg. 21(5)(a)(v)
- Annex Pt. A point 5.9 words inserted by S.I. 2019/556 reg. 21(5)(b)(vi)
- Annex Pt. B point 5.1.1 words inserted by S.I. 2019/556 reg. 21(5)(c)(iii)
- Annex words omitted by S.I. 2019/556 reg. 21(5)(a)(iv)
- Annex words omitted by S.I. 2019/556 reg. 21(5)(a)(vii)
- Annex Pt. A point 1.5 words omitted by S.I. 2019/556 reg. 21(5)(b)(ii)
- Annex Pt. A point 6.3 words omitted by S.I. 2019/556 reg. 21(5)(b)(vii)(bb)
- Annex Pt. A point 6.3 words omitted by S.I. 2019/556 reg. 21(5)(b)(vii)(cc)
- Annex Pt. A point 6.3 words omitted by S.I. 2019/556 reg. 21(5)(b)(vii)(dd)
- Annex Pt. A point 6.3 words omitted by S.I. 2019/556 reg. 21(5)(b)(vii)(ff)
- Annex Pt. A point 7.1.2.2.2 words omitted by S.I. 2019/556 reg. 21(5)(b)(xii)(aa)
- Annex Pt. A point 7.1.3.2 words omitted by S.I. 2019/556 reg. 21(5)(b)(xii)(aa)
- Annex Pt. A point 7.1.2.2.2 words omitted by S.I. 2019/556 reg. 21(5)(b)(xii)(bb)
- Annex Pt. A point 7.1.3.2 words omitted by S.I. 2019/556 reg. 21(5)(b)(xii)(bb)
- Annex Pt. B point 7.1.1 words omitted by S.I. 2019/556 reg. 21(5)(c)(iv)
- Annex words substituted by S.I. 2019/556 reg. 21(5)(a)(ii)
- Annex words substituted by S.I. 2019/556 reg. 21(5)(a)(iii)
- Annex words substituted by S.I. 2019/556 reg. 21(5)(a)(vi)
- Annex Pt. A point 1.2 words substituted by S.I. 2019/556 reg. 21(5)(b)(i)
- Annex Pt. A point 3.9 words substituted by S.I. 2019/556 reg. 21(5)(b)(iii)
- Annex Pt. A point 4.2 words substituted by S.I. 2019/556 reg. 21(5)(b)(iv)
- Annex Pt. A point 6.6.2 words substituted by S.I. 2019/556 reg. 21(5)(b)(ix)(aa)
- Annex Pt. A point 6.6.2 words substituted by S.I. 2019/556 reg. 21(5)(b)(ix)(bb)
- Annex Pt. A point 6.6.2 words substituted by S.I. 2019/556 reg. 21(5)(b)(ix)(cc)
- Annex Pt. A point 6.3 words substituted by S.I. 2019/556 reg. 21(5)(b)(vii)(aa)
- Annex Pt. A point 6.3 words substituted by S.I. 2019/556 reg. 21(5)(b)(vii)(ee)
- Annex Pt. A point 7.1 words substituted by S.I. 2019/556 reg. 21(5)(b)(xi)

- Annex Pt. B point 1.1 words substituted by [S.I. 2019/556 reg. 21\(5\)\(c\)\(i\)](#) (This amendment not applied to legislation.gov.uk. Reg. 21(5)(c)(i) substituted immediately before IP completion day by [S.I. 2020/1376, regs. 1\(4\), 3\(17\)\(b\)](#))
- Annex Pt. B point 1.2 words substituted by [S.I. 2019/556 reg. 21\(5\)\(c\)\(ii\)](#)
- Annex Pt. B point 1.4.1 words substituted by [S.I. 2019/556 reg. 21\(5\)\(c\)\(ii\)](#)
- Annex Pt. B point 8.6 words substituted by [S.I. 2019/556 reg. 21\(5\)\(c\)\(v\)](#)
- Annex Pt. A Section 1 point 1.4 words substituted by [S.I. 2019/720 Sch. 2 para. 176\(2\)\(a\)\(i\)](#)
- Annex Pt. B point 1.1 words substituted by [S.I. 2019/556, reg. 21\(5\)\(c\)\(i\)](#) (as substituted) by [S.I. 2020/1376 reg. 3\(17\)\(b\)](#)
- Annex Pt. A point 6.6.2 words substituted in earlier amending provision [S.I. 2019/556, reg. 21\(5\)\(b\)\(ix\)\(aa\)](#) by [S.I. 2020/1376 reg. 3\(17\)\(a\)\(ii\)](#)
- Annex Pt. A point 6.6.2 words substituted in earlier amending provision [S.I. 2019/556, reg. 21\(5\)\(b\)\(ix\)\(bb\)](#) by [S.I. 2020/1376 reg. 3\(17\)\(a\)\(ii\)](#)
- Annex Pt. A point 6.3 words substituted in earlier amending provision [S.I. 2019/556, reg. 21\(5\)\(b\)\(vii\)\(ee\)](#) by [S.I. 2020/1376 reg. 3\(17\)\(a\)\(i\)](#)
- Annex Pt. A point 7.1 words substituted in earlier amending provision [S.I. 2019/556, reg. 21\(5\)\(b\)\(xi\)](#) by [S.I. 2020/1376 reg. 3\(17\)\(a\)\(iii\)\(aa\)](#)
- Annex Pt. A point 7.1 words substituted in earlier amending provision [S.I. 2019/556, reg. 21\(5\)\(b\)\(xi\)](#) by [S.I. 2020/1376 reg. 3\(17\)\(a\)\(iii\)\(bb\)](#)

#### **Changes and effects yet to be applied to the whole legislation item and associated provisions**

- Signature words omitted by [S.I. 2019/556 reg. 21\(4\)](#)
- Annex Pt. A s. 8 word omitted by [S.I. 2019/556 reg. 21\(5\)\(b\)\(xiv\)](#)
- Annex Pt. A s. 1 point 1.4 word substituted in earlier amending provision [S.I. 2019/720, Sch. 2 para. 176\(2\)\(a\)\(i\)](#) by [S.I. 2020/1567 Sch. 2 para. 61](#)
- Annex Pt. A s. 1 point 1.4.1 word substituted in earlier amending provision [S.I. 2019/720, Sch. 2 para. 176\(2\)\(b\)](#) by [S.I. 2020/1567 Sch. 2 para. 61](#)
- Annex Pt. B s. 9 words omitted by [S.I. 2019/556 reg. 21\(5\)\(c\)\(vi\)](#)
- Art. 1(1) Art. 1 renumbered as Art. 1(1) by [S.I. 2019/556 reg. 21\(2\)\(a\)](#)
- Art. 1(2) inserted by [S.I. 2019/556 reg. 21\(2\)\(b\)](#)